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GENERAL INTRODUCTION
Worldwide the incidence and burden of heart valve disease is increasing due to aging 
of the world population and the problem of rheumatic cardiac disease in developing 
countries and in parts of the population in the developed world.1 Between 2007 
and 2050 the world population will increase from 6.5 to 9.1 billion inhabitants.1 
Furthermore, the annual number of patients requiring heart valve replacement 
is estimated to triple from approximately 290,000 in 2003, to over 850,000 by 
2050.2
In the Netherlands cardiovascular disease is the leading cause of death. According 
to the annual report of the Dutch Heart Association, 308.828 patients required 
admission due to cardiovascular disease in the Netherlands in 2004 of which 7286 
patients were admitted due to rheumatic heart disease or valve disease (2.4%). 
Subsequently, 1449 patients died of heart valve disease (3.2%).3 Furthermore, 
approximately 3000 patients require valve replacement due to aortic valve disease 
per year in the Netherlands.4
SPECIFIC VALVE LESIONS
Functionally, aortic valve disease can be subdivided in aortic stenosis, aortic valve 
regurgitation and the combination of these two.
Aortic valve stenosis
Aortic valve stenosis in adults is most commonly caused by calcifi cation of a 
normal trileafl et valve or a bicuspid valve (congenital abnormality).5 Calcifi c disease 
develops at the base of the cusps progressing to the leafl ets, causing a reduction in 
leafl et motion and effective valve area without commissural fusion. Although less 
common in the developed countries, aortic valve stenosis can also be caused by 
rheumatic fever. This is characterized by diffuse fi brosis in the leafl ets of a tricuspid 
valve with fusion of one or two of the commisures.6 Calcifi cation may be present.
Aortic stenosis can be graded as follows: Mild (aortic valve area more than 1.5 cm2, 
mean aortic gradient less than 25 mm Hg, or jet velocity less than 3.0 m per second), 
moderate (area 1.0 to 1.5 cm2, mean gradient 25 to 40 mm Hg, or jet velocity 3.0 to 
4.0 m per second) or severe (area less than 1.0 cm2, mean gradient greater than 40 
mm Hg, or jet velocity greater than 4.0 m per second).5
Natural history 
Aortic stenosis in adults can be asymptomatic for long periods of time, although 
this period can vary widely among individuals.7 Eventually, symptoms of angina 
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pectoris, heart failure, and syncope will develop and when symptoms are present, 
the average survival is 2 to 3 years with an increased risk of sudden death.5 Thus, 
the development of symptoms marks a critical point in the natural history of aortic 
stenosis. Aortic stenosis progresses more rapidly in patients in whom it is caused 
by the degenerative calcifi c process than in patients in whom stenosis is caused by 
rheumatic fever or has a congenital origin. However, the rate of progression of 
aortic stenosis and development of symptoms varies widely per patient. For this 
reason regular clinical follow-up is advised for all patients with asymptomatic mild 
or moderate aortic stenosis.5
Treatment options
There is no medical treatment to delay the progression of aortic stenosis. Underlying 
conditions such as systemic hypertension should be medically treated in asymptomatic 
patients, and antibiotic prophylaxis is indicated in patients with aortic stenosis for 
prevention of infective endocarditis and in patients with aortic stenosis caused by 
rheumatic fever for preventing recurrent episodes. For patients with aortic stenosis 
who have developed symptoms there is yet no proper medical treatment and surgery 
is indicated as early as possible.5, 7
According to the ACC/AHA guidelines for the management of patients with valvular 
heart disease,5 aortic valve replacement is indicated for symptomatic patients with 
severe aortic stenosis (Class I, level of evidence B) and for patients with severe 
aortic stenosis undergoing coronary artery bypass graft surgery (CABG; Class 
I, level of evidence C). It is also indicated for patients with severe aortic stenosis 
undergoing surgery on the aorta or other heart valves (Class I, level of evidence 
C) and is recommended for patients with severe aortic stenosis and left ventricular 
systolic dysfunction (ejection fraction less than 0.50; Class I, level of evidence C). 
Furthermore, aortic valve replacement is reasonable for patients with moderate 
aortic stenosis undergoing CABG or surgery on the aorta or other heart valves (Class 
IIa, level of evidence B). If the patient is asymptomatic with severe aortic stenosis 
and has a high likelihood of progression, an abnormal response to exercise or the 
patient has mild aortic stenosis with signs of rapid progression and requires CABG; 
aortic valve replacement may be considered (Class IIB, level of evidence C).
Finally, aortic valve replacement may be considered for asymptomatic patients with 
extremely severe aortic stenosis when the patient’s expected operative mortality is 
1.0% or less.
Loes bw.indd   14 31-10-2007   14:40:32
General Introduction
15
Aortic valve regurgitation
Aortic valve regurgitation may have several causes.5, 7 These causes comprise congenital 
abnormalities, rheumatic disease, infective endocarditis, and systemic hypertension, 
dissection of the ascending aorta, myxomatous degeneration or perforation of the 
valve cusps after balloonvalvulotomy or surgical commisurotomy.
Natural history
Aortic valve regurgitation may develop acutely or gradually as a chronic condition. 
Some of the above mentioned conditions, in particular infective endocarditis, 
dissection of the ascending aorta or unsuccessful balloonvalvulotomy or surgical 
commisurotomy for congenital aortic stenosis can cause acute aortic regurgitation. 
Acute severe aortic regurgitation can result in a sudden increase of left ventricular 
fi lling pressures and reduction in cardiac output causing cardiogenic shock or 
pulmonary oedema with poor prognosis.7 
However, the majority of above mentioned conditions cause slowly progressive 
chronic aortic regurgitation.5 Patients with chronic aortic valve regurgitation 
remain asymptomatic for a long time throughout a compensated phase, which 
is characterized by recruitment of preload reserve and compensatory ventricular 
hypertrophy allowing the left ventricle to maintain a normal ejection fraction despite 
an increased afterload. Severe aortic regurgitation develops when the compensatory 
phase can not be maintained and the preload reserve may be exhausted resulting 
in a further increase in afterload with a reduction in ejection fraction causing left 
ventricular systolic dysfunction. Dyspnoea, angina and heart failure may be present 
at that time.5
The natural history of aortic regurgitation depends primarily on its severity.8 After 
onset of symptoms in acute severe aortic regurgitation, 1-year survival is only 
10-30%.6 Mild or moderate chronic aortic regurgitation may hardly affect daily 
activity or reduce life expectancy. The progression rate to the development of 
symptoms with or without left ventricular dysfunction is 4.3% per year according 
to the ACC/AHA guidelines.5
Treatment options
Medical treatment consists of vasodilating agents to improve forward stroke 
volume and reduce regurgitant volume. Medical treatment is indicated in patients 
with severe aortic regurgitation who have symptoms or left ventricular dysfunction 
when surgery is not an option due to additional cardiac or non-cardiac factors.5 
Furthermore, in patients with severe heart failure and severe left ventricular 
dysfunction awaiting aortic valve replacement, vasodilators can be used to optimize 
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haemodynamic performance of these patients.7 Asymptomatic patients in the 
compensated phase with normal left ventricular function may also benefi t from 
vasodilators. Vasodilator therapy is not recommended for asymptomatic patients 
with mild or moderate aortic regurgitation and a normal left ventricular function in 
absence of systemic hypertension because of the excellent outcome of these patients 
without medical treatment.5
The majority of patients with severe aortic regurgitation require aortic valve 
surgery, mostly replacement.5, 7 Aortic valve replacement is indicated especially in 
symptomatic patients with severe aortic regurgitation regardless of left ventricular 
systolic function (Class I, level of evidence B), in asymptomatic patients with chronic 
severe aortic regurgitation and left ventricular systolic dysfunction (ejection fraction 
0.50 or less) at rest (Class I, level of evidence B), or in patients with chronic severe 
aortic regurgitation while undergoing CABG or surgery on the aorta or other heart 
valves (Class I, level of evidence C). 
Aortic valve replacement is reasonable for asymptomatic patients with severe aortic 
regurgitation with normal left ventricular systolic function (ejection fraction greater 
than 0.50) but with severe left ventricular dilatation (Class IIa, level of evidence B). 
Finally, aortic valve replacement may be considered in patients with moderate aortic 
regurgitation while undergoing CABG or surgery on the ascending aorta (Class IIb, 
level of evidence C) or in asymptomatic patients with severe aortic regurgitation 
with normal left ventricular systolic function at rest (ejection fraction greater than 
0.50), with left ventricular dilatation, when there is evidence of progressive left 
ventricular dilatation, declining exercise tolerance, or abnormal haemodynamic 
responses to exercise (Class IIb, level of evidence C) .
Combined aortic valve stenosis and aortic valve regurgitation
In patients with combined aortic stenosis and aortic regurgitation and in some 
patients with aortic valve regurgitation with aortic stenosis, the predominant lesion 
causes the symptoms and form the basis of management.5, 7 In combined aortic 
valve disease, 1 lesion usually predominates over the other. Unlike the management 
of a severe single valve lesion, fi rm guidelines for mixed aortic valve disease are 
diffi cult to establish. The most obvious approach is to surgically correct disease that 
produces more than mild symptoms. In an aortic stenosis-dominant aortic valve 
disease operation is required in the presence of even mild symptoms. In regurgitant 
dominant lesions, surgery can be delayed until symptoms develop or asymptomatic 
left ventricular dysfunction becomes evident.5 
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VALVE SUBSTITUTE OPTIONS
Although aortic valve repair may be an option in severe heart valve disease,9 a 
large number of valves are not suitable for repair and therefore require replacement. 
Aortic valve replacement has signifi cantly improved the life expectancy of patients 
with severe aortic valve disease receiving optimum medical therapy if possible. 
Nowadays, different aortic valve substitutes are available with each specifi c 
advantages and disadvantages.
A recent development concerns the percutaneous and transapical valve replacement 
techniques using biological valve substitutes. However at present, these techniques 
are only applied in the elderly.
Biological prostheses
Biological prostheses (or xenografts or heterografts) are the most commonly used 
prostheses for aortic valve replacement in current practice.5 Figure 1 displays 
examples of biological prostheses. They can be divided in stented and stentless 
biological prostheses. Stented biological prostheses are made of animal tissue, for 
example porcine valve tissue or bovine pericardial tissue. Main advantages are 
the low thrombogenicity, no requirement of anticoagulation treatment, relatively 
standard implantation technique with a standard reoperation risk and are readily 
availability. Important disadvantages of these valves are their limited durability and 
its deteriorating haemodynamic performance. 
Stentless biological prostheses are a newer generation biological prostheses. They 
are composed of bovine pericardium or porcine aortic valves with a smaller amount 
of cloth for stabilization, sewing or tissue ingrowth and are supposed to have a 
better haemodynamic performance compared to the stented biological prostheses. 
However, long-term results on durability are not yet available. Advantages of a 
stentless biological valve are the lower degree of stenosis because of absence of 
the stent and lower transvalvular gradients that presumably should improve long-
term survival and these valve substitutes are readily available. Disadvantages are 
the incomplete long-term results and complexity of implantation compared with 
stented biological prostheses.
The ACC/AHA guidelines recommend that the biological prostheses preferably 
should be implanted in patients older than 65 years. The rate of structural failure 
of biological prostheses is age-dependent, higher in younger patients. In patients 
younger than 40 years almost half of these valve substitutes degenerates within 10 
years.5 For patients older than 65 years this failure rate is less than 10% at 15 years 
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after operation and furthermore a survival benefi t is shown for patients receiving 
a bioprosthesis. Furthermore, there is an increased risk of bleeding in this group. 
Patients younger than 65 years and requiring aortic valve replacement who do not 
wish to use anticoagulation treatment are also eligible for aortic valve replacement 
with a biological prosthesis.5
Mechanical prostheses
Mechanical valves were for the fi rst time used as valve substitutes in the 1960’s by 
Harken.10 Since then, they have become widely used valve substitutes in aortic valve 
replacement. Most currently used mechanical valve prostheses are bileafl et valves. 
See fi gure 2 for examples. Unileafl et and ball valves are less commonly used because 
their design is being regarded as not optimal, because of the greater extension of the 
valve construction above the annulus, the increased embolization risk, and they are 
associated with greater noise compared to bileafl et valves.11 The main advantage 
of mechanical valves is their life-long durability and these valve prosthesis are 
readily and easy to implant.12 Main disadvantage of mechanical prostheses is the 
high thrombogenicity requiring life-long anticoagulation. This results in increased 
risk of bleeding and risk of thrombo-embolism despite anticoagulation therapy. 
Furthermore, for women who are in the childbearing age the mechanical prosthesis 
has several potential disadvantages, including not only an increased maternal 
mortality risk during pregnancy (1-4%) mainly due to valve thrombosis, but also an 
increased risk of embryopathy due to side effects of oral anticoagulant drugs.13 When 
anticoagulation treatment is necessary during pregnancy, the ACC/AHA guidelines5 
give no specifi c recommendations although frequent monitoring of women during 
pregnancy is indicated. Warfarin crosses the placenta and is contraindicated because 
it is associated with an increase in spontaneous abortions, stillbirths and prematurity.5 
Furthermore, it is associated with embryopathy during the fi rst trimester and central 
Figure 1. a. pericardial bovine biological prosthesis, b. stented porcine biological prosthesis, 
c. stentless porcine biological prosthesis
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nervous system abnormalities after exposure during any trimester. Unfractionated 
heparin does not pass the placenta and is not teratogenic but the risks of maternal 
valve thrombo-embolic complications and maternal death are highly increased 
during the fi rst trimester. Low-weighted-molecular-heparin seems to have a low 
risk of bleeding complications, does not pass the placental barrier and is relatively 
safe for the foetus, however evidence for this meeting the treatment goals is not 
adequately available. 5
Allografts
Since the introduction into clinical practice in 1962, allografts (or homografts) have 
become established in clinical practice. Although by far not as common as mechanical 
prostheses and biological prostheses, allografts are used in approximately 4% of 
valve replacements.
The allograft was fi rstly implanted in the aortic valve position by Donald Ross 
in 1962.14 Over time the surgical implantation technique used changed from the 
subcoronary technique to the root replacement technique. The use of the root 
replacement technique seemed to be associated with less structural or technical 
failure compared with the subcoronary implantation technique.15 Allografts can be 
implanted in two ways: as a subcoronary implant or as a complete aortic root, 
both technically more demanding compared with implantation of stented valve 
prostheses. When using the subcoronary technique, only the allograft cusps and hinge 
points of the aortic segment were implanted in the immediately adjacent aortic wall, 
leaving the coronary arteries untouched. The root replacement technique requires 
reimplantation of the coronary arteries but leaves the geometry of the aortic valve 
and root unchanged. Especially in patients with endocarditis, the root replacement 
technique offers the advantage of allowing excision of all infected tissue with 
       
Figure 2. a. Starr-Edwards ball- in-cage prosthesis, b. Medtronic Hall unileafl et valve, 
c. St. Jude Medical® bileafl et mechanical valve
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subsequent replacement by the allograft. The advantages of allografts are superior 
haemodynamics and the low thrombogenicity making anticoagulation treatment 
unnecessary. Disadvantages are its limited availability, the surgical expertise that is 
required for insertion and the limited durability. Due to the non-viable character of 
the allograft, these valve substitutes are subject to calcifi cation, inevitably resulting in 
reoperation later in life.15, 16 An age-dependent mode of structural failure compared 
to stented biological prosthesis is observed.16, 17 
Autografts
The autograft procedure was introduced by Donald Ross in 1967.18 Ross initially 
used the scalloped subcoronary implantation technique to insert the pulmonary 
valve into the left ventricular outfl ow tract with encouraging results.19 It became 
a worldwide-accepted procedure for aortic valve replacement despite the need for 
specifi c surgical expertise to perform this double valve operation on both the aortic 
and pulmonary valve. Although initially the Ross operation was employed using the 
subcoronary implantation technique, over the years most centers shifted towards 
the root replacement technique, nowadays the most commonly used implantation 
technique. The root replacement technique appeared to be easier to apply and was 
associated with a decreased incidence of early and late failure compared to the 
other techniques.20, 21 However, there are centers that successfully and exclusively 
employ the subcoronary implantation technique.22 Potential advantages are the use 
of the patient’s own living valve with favourable haemodynamic characteristics, 
low risk of endocarditis risk, low rate of thrombo-embolic events and avoidance of 
anticoagulant treatment. The alleged claim of growth potential of the autograft valve 
in children became a matter of discussion as dilatation may play a role in diameter 
increase as well. 23, 24 The autograft is the only living valve substitute providing long-
term viability of most or all components of the valve.18, 25 However, the autograft 
procedure is a technically demanding operation that requires replacement of both 
Figure 3: Cryopreserved aortic allograft with aortic arch
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Figure 4: Schematic overview of the pulmonary autograft procedure (Ross operation)
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the aortic and the pulmonary valve. Also, both the autograft in aortic position and 
the valve substitute in the right ventricular outfl ow tract may develop structural 
failure over time. Therefore, the durability of the autograft procedure depends on 
the lifetime of both valve substitutes.
YOUNG ADULT PATIENTS WHO REQUIRE AORTIC VALVE REPLACEMENT
Since the fi rst heart valve replacement in 1960, prognosis of patients with aortic 
valve disease has improved dramatically.10 However, in particular young adult 
patients, who have to undergo aortic valve replacement, have an impaired survival 
compared to the age-matched general population. Nevertheless, young adult patients 
still have a relatively long life ahead, and complications associated with the different 
prosthetic valve substitutes need careful consideration. 
The ideal valve substitute does not exist. This ideal valve substitute would be easy 
to implant, would have a life-long durability, would have low thrombogenicity, no 
need to use medication, be resistant to endocarditis with few or no complications 
on the early and long-term.11 
Concerning the available valve substitutes, over the past decades multiple studies 
have reported on the outcome of aortic valve replacement with the different 
prosthesis types.11,26,27
Mechanical prostheses are a good option in young adult patients since they are 
durable and designed to outlive the patient. However, due to their thrombogenicity 
they require lifelong anticoagulation that carries an increased risk of bleeding. 
Especially for young adult patients who live an active lifestyle and young women who 
want to become pregnant, the use of anticoagulation may result in an unfavorable 
outcome. 
Biological valve substitutes like the porcine and bovine biological prostheses do not 
require anticoagulation. On the downside, all biological prostheses have a limited 
durability, and in young adult patients this implies that a considerable proportion 
of patients will need a reoperation during the remainder of life. This has led to a 
recommendation that a biological prosthesis should be used for older patients (> 
65 years).5 Some centers have started to use stentless biological prostheses in adult 
patients younger than 65 years in the past decade, anticipating that the durability 
of these valve substitutes may have improved compared to older biological valve 
substitutes, and that their haemodynamic profi le is superior to that of stented 
biological prostheses, both important potential advantages in particular for young 
adult patients who lead an active life.5 
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Allografts can offer young adult patients to live an active life without the limitations 
of anticoagulation necessary after aortic valve replacement with a mechanical 
prosthesis. Furthermore, their haemodynamic profi le is compared with mechanical 
prostheses and biological prostheses. Besides the absence of anticoagulation use, 
allografts are a good valve substitute in active endocarditis to reconstruct of the 
anatomy of the aortic valve and adjacent structures, to have a low risk of both 
prosthetic valve endocarditis and of thrombo-embolic events.28
Autografts are the only living valve substitute available and have a proper 
haemodynamic adaptation, no anticoagulation treatment is necessary, patients 
can live an active lifestyle and patient survival could to be superior compared with 
survival of patients with other valve substitutes.19, 29 These characteristics may be 
especially important for young adult patients.
Prognosis after aortic valve replacement depends on multiple factors that are 
associated with the patient and the type of prosthesis used. Given the number and 
complexity of these factors that affect outcome after aortic valve replacement, 
balanced and objective selection of the preferred valve substitute for the individual 
patient remains diffi cult. In particular in young adult patients, who have a 
relatively long life expectancy, optimal valve selection is important to ascertain a 
minimal burden of prosthetic valve disease. The 2006 AHA/ACC Guidelines for 
the Management of Patients with Valvular Heart Disease5 do not provide specifi c 
instructions for valve selection in young adult patients, just general guidelines:
“Although the Ross operation, homograft, heterograft, and valve repair each offer an 
attractive alternative to a mechanical valve for those with relative contraindication to 
Warfarin therapy for anticoagulation (e.g., athletes or women desiring pregnancy), 
in the absence of long-term results, it is not believed that the indications for surgery 
with the Ross operation, heterograft, or homograft differ from those for mechanical 
valve replacement at this time”.
This statement shows that the choice of an aortic valve prosthesis is a complex one 
that needs to be tailored to the individual patient. With the current knowledge on 
outcome of patients after aortic valve replacement with different types of prosthesis, 
no specifi c recommendations can be given. This is especially true for the subset of 
young adult patients, in whom only a limited amount of evidence on outcome is yet 
available.
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AIM OF THE THESIS 
The focus of this thesis is on prognosis of young adult patients after aortic valve 
replacement with the different available valve substitutes. By studying different 
cohorts of young adult patients who underwent aortic valve replacement with 
different valve substitutes, it is attempted to gain further insight into the factors 
that determine outcome and provide more specifi c and evidence-based guidelines 
for prosthetic valve selection.
To achieve this, the following research questions were proposed:
What are the most important factors predicting outcome after aortic valve 1. 
replacement in young adult patients who underwent aortic valve replacement?
What are the results with allograft aortic valve and root replacement?2. 
Are there specifi c young adult patient populations potentially benefi ting from 3. 
the autograft or the allograft as a valve substitute?
Is the autograft still the favorable option in young adult patients?4. 
What determines outcome of reoperative root replacement in patients who 5. 
underwent previous aortic root surgery?
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SHORT ABSTRACT
The optimal prosthesis choice in young adults requiring aortic valve replacement 
(AVR) remains controversial. We studied whether implanted prosthesis type is an 
important determinant of outcome after AVR in 414 young adults (age 16-55) who 
underwent 438 AVRs between 1991 and 2001, using 204 mechanical prostheses, 
3 bioprostheses, 150 allografts and 81 autografts. We evaluated peri-operative 
characteristics, early and late mortality, occurrence of valve-related events and 
predictors of adverse outcome and prosthesis selection. Prosthesis type was not a 
predictor of late mortality. Important predictors of increased late mortality were 
prior aortic valve surgery, impaired left ventricular function, concomitant mitral 
valve surgery and older patient age. 
In conclusion, survival after AVR in young adults in this series is mainly determined 
by patient factors and not by prosthesis type. 
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ABSTRACT
Background and aim of the study
The optimal prosthesis choice in young adults requiring aortic valve replacement 
(AVR) remains controversial. We studied whether implanted prosthesis type is an 
important determinant of outcome after AVR in young adults.
Methods
Between 1991 and 2001 414 young adults (age 16-55) underwent 438 consecutive 
AVRs using 204 mechanical prostheses (MP), 3 bioprostheses (BP), 150 allografts 
(AL) and 81 autografts (AU). We evaluated peri-operative characteristics, early and 
late mortality, occurrence of valve-related events and predictors of adverse outcome 
and prosthesis selection.
Results
Mean age was 41±11 years; for MP 45, for BP 50, for AL 39, for AU 31 years. MP 
selection was associated with: older age, impaired left ventricular function (LVF) 
and concomitant mitral valve surgery (concMVS); AL selection: ascending aortic 
aneurysm, active endocarditis; Marfan’s disease; AU selection: younger age, prior 
balloonvalvuloplasty and isolated valve disease.
Hospital mortality was 2.3% (N=10). During follow-up (97% complete) 30 patients 
died. Ten-year survival was better for AU (96%±2%) compared to MP (84%±4%) 
and AL (92%±2%). Prosthesis type was not predictive of late mortality. Predictors 
of increased late mortality were prior aortic valve surgery, impaired LVF, concMVS 
and older patient age. 
Ten-year freedom from bleeding and thrombo-embolism was 89%±3% for MP 
versus 94%±3% for AL and 99%±1% for AU (p=0.054). Ten-year freedom from 
reoperation was 95%±2% for MP versus 79%±5% for AL and 87%±5% for AU 
(p=0.003). 
Conclusions
Survival after AVR in young adults in Rotterdam is mainly determined by patient 
factors and not by prosthesis type. A randomized controlled trial is necessary 
whether valve prosthesis type indeed plays a crucial role in improving survival in 
young adult patients.
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Introduction
For patients who require aortic valve replacement, the two valve substitutes available 
are mechanical prosthesis and tissue valves (bioprosthesis, allograft and autograft). 
All valve types have their specifi c advantages and disadvantages. Mechanical 
prostheses are designed to last a lifetime but require lifelong anticoagulation therapy 
due to their increased thrombogenicity. Even though anticoagulation therapy is 
relatively safe, it does increase the risk of bleeding complications. Tissue valves 
require no anticoagulation therapy and their hemodynamic performance is more 
favorable. However tissue valves have a limited durability and therefore the patient 
may require a reoperation later in life. 
Over the past decades multiple studies have reported on the outcome of aortic valve 
replacement with the different prosthesis types.[1,2,3] This has led to a recommendation 
that a bioprosthesis should be used for older patients (> 65 years). [2] Yet the optimal 
prosthesis choice for young adults remains controversial. Although mechanical 
prostheses provide a durable solution in these patients who have a relatively long 
life ahead of them, tissue valves do not require anticoagulation and their superior 
haemodynamic performance may result in a better patient survival. [4,5,6] We studied 
outcome of patients aged 16 to 55 years who underwent aortic valve replacement at 
our institution between 1991 and 2001 to assess whether implanted prosthesis type 
is an important predictor of outcome after aortic valve replacement in young adult 
patients or whether outcome is related to patient factors.
Material and Methods
Patients
Between 1991 and 2001 414 consecutive patients aged 16 to 55 years underwent 
aortic valve replacement at Erasmus University Medical Center in Rotterdam, The 
Netherlands. These patients underwent a total of 438 aortic valve replacements: 204 
mechanical prostheses (MP) were implanted, consisting of 199 St. Jude prostheses, 
4 ATS prostheses and one Björk Shiley prosthesis. Three stented bioprostheses (BP), 
all Carpentier-Edwards Perimount prostheses, were implanted, 150 allografts (AL) 
and 81 autografts (AU). Because of the limited number of bioprostheses implanted, 
they were excluded from further analyses. All operations were performed on 
cardiopulmonary bypass with moderate hypothermia. Crystalloid cardioplegia and 
topical cooling were used for myocardial protection and in some cases circulatory 
arrest was needed.
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For patients who received a mechanical prosthesis information on patient 
characteristics, perioperative details and follow-up was reported according the 
guidelines for reporting morbidity and mortality after cardiac valvular operations7 
and was collected retrospectively from hospital records, correspondence with 
treating physicians and through the civil registry. For patients who received allografts 
and autografts this information was obtained from our ongoing prospective cohort 
study.8,9 All information was entered into a relational database (Microsoft Access 
W2000) and cross-checked for completeness and correctness.
Mortality and Follow Up
Early mortality and morbidity were registered and the causes of death were 
documented. Hospital mortality was defi ned as death of the patient within any time 
interval after operation if the patient was not discharged from the hospital. Thirty-
day mortality was defi ned as mortality within 30 days after surgery regardless of the 
patient’s geographical location.7 
Statistical analysis
The collected information was analyzed using SPSS 12.1 for Windows (SPSS, 
Chicago, Ill). Continuous variables are displayed as mean ± 1 SD, discrete variables 
as proportions, unless stated otherwise. Means were compared using the independent 
sample T-test or ANOVA. Proportions were compared using the chi-square test. Using 
univariate logistic regression predictors of prosthesis selection were determined. 
Potential risk factors for increased early mortality were determined using univariate 
logistic regression analysis. The Kaplan-Meier method was used to analyze freedom 
from valve related events, reoperation and late mortality. Univariate and multivariate 
Cox proportional hazard regression analysis was done to determine predictors of 
late death (death > 30 days postoperative), reoperation and valve-related events. 
Results
Patient characteristics are listed in Table 1 and perioperative details in Table 2. 
Seventy-one percent of the patients were male; this did not differ between the valve 
types. Aortic stenosis was more common in the mechanical and autograft recipients, 
while aortic regurgitation was most common in the allograft recipients.
Two hundred and four mechanical prosthesis were implanted. Factors that were 
associated with mechanical prosthesis implantation were older patient age (1.1; 95% 
CI 1.07-1.12; p<0.001), impaired left ventricular function (1.5; 95% CI 1.2-1.9; 
p=0.002) and need for concomitant mitral valve surgery (3.4; 95% CI 1.7-6.8; p= 
0.001).
Loes bw.indd   31 31-10-2007   14:40:35
Chapter 2
32
A total of 150 allografts were implanted. Factors that were associated with allograft 
implantation were NYHA class > III (2.4; 95% CI 1.2-4.6; p=0.009), the presence 
of an aneurysm of the ascending aorta (2.4; 95% CI 1.4-4.2; p=0.002), active 
endocarditis (6.7; 2.9-15.3; p<0.001) and Marfan’s disease (n=19) (5.8; 95% CI 
2.1-16.5; p=0.001). 
The 81 patients who received an autograft were younger compared to the other valve 
types (1.1; 95% CI 1.09-1.15; p<0.001), had more often prior balloon valvuloplasty 
(10.8; 95% CI 3.6-32.0; p<0.0001) and had more often isolated aortic valve disease 
(7.9; 95% CI 1.9-33.0; p=0.005).
Table 1. Preoperative patient characteristics
All
(n=438)
Mechanical
(n=204)
Allograft
(n=150)
Autograft
(n=81)
Biological
(n=3)
Males (%) 71% (n=313) 73% (n=149) 73% (n=110) 63% (n=51) 100% (n=3)
Age 
(years, mean, range)
41 (16-55) 45 (18-55) 39 (16-54) 31 (16-52) 50 (43-54)
Creatinin 
(μmol/l, mean, range)
92 (27-1152) 93 (27-1152) 99 (39-900) 73 (38-121) 87 (66-110)
Sinus rhythm 93% 90% (n=184) 94% (n=141) 99% (n=80) 100% (n=3)
NYHA class
I-II
III-IV
V
62% (n=270)
37% (n=164)
1% (n=4)
58% (n=118)
42% (n=86)
-
59% (n=88)
38% (n=58)
3% (n=4)
78% (n=63)
22% (n=18)
-
33% (n=1)
67% (n=2)
-
Normal LVF$ 69% 63% (n=129) 75% (n=112) 72% (n=59) 100% (n=3)
Diagnosis1 
AR†
AS†
AS+AR
45% (n=199)
28% (n=121)
27% (n=117)
41% (n=83)
32% (n=65)
27% (n=55)
58% (n=87)
19% (n=28)
23% (n=35)
36% (n=29)
32% (n=26)
32% (n=26)
-
67% (n=2)
33% (n=1)
Etiology
Congenital*
Prosthesis/valve repair
Degenerative
Endocarditis
Aneurysm/dissection
Rheumatic
Other
38% (n=170)
19% (n=82)
12% (n=52)
10% (n=42)
9% (n=37)
10% (n=44)
3% (n=11)
34% (n=69)
21% (n=42)
18% (n=37)
5% (n=11)
7% (n=14)
12% (n=24)
3% (n=7)
35% (n=53)
16% (n=24)
8% (n=12)
18% (n=27)
15% (n=22)
7% (n=10)
1% (n=2)
56% (n=45)
20% (n=16)
4% (n=3)
5% (n=4)
1% (n=1)
12% (n=10)
2% (n=2)
100% (n=3)
-
-
-
-
-
-
Previous valve surgery 25% (n=110) 26% (n=53) 21% (n=32) 31% (n=25) -
Emergent procedure 6% (n=28) 5% (n=10) 12% (n=18) - -
Preoperative
ventilatory support
2% (n=9) 1% (n=2) 5% (n=7) - -
1One patient had a Bjork-Shiley type mechanical valve and underwent prophylactic replacement
*P<0.01 autograft vs mechanical prosthesis and allografts
† P<0.001 allograft vs mechanical prosthesis and autografts
$ P<0.02 mechanical prosthesis vs allografts and autografts
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Hospital morbidity and mortality
Rethoracotomy was necessary in 76 patients (17%). Main causes were bleeding 
(n=51, 67%) and tamponade (n=22, 29%). The number of rethoracotomies for 
bleeding or tamponade decreased signifi cantly in more recent years (p=0.02). 
One patient required a rethoracotomy due to a rhythm disorder and one due to 
pericarditis constrictiva. Two patients had a deep sternal wound infection requiring 
reintervention (<1%). Eight patients had a stroke postoperatively (2%).
Ten patients died in hospital (overall hospital mortality 2.3%); 4 mechanical 
prosthesis patients, 4 allograft patients and 2 autograft patients. Details on the 
hospital deaths are shown in Table 3.
No signifi cant difference in hospital mortality was observed between the different 
valve types. Of these deaths, 4 were patients who underwent elective surgery. For 
these elective patients causes of death were as follows: One elective patient underwent 
a triple valve operation with implantation of an allograft and died of right and left 
ventricular failure 4 days after operation. The second patient had Turner syndrome, 
received a mechanical prosthesis and died of a myocardial infarction 6 days after 
Table 2. Peri-operative details 
All
(n=438)
Mechanical
(n=204)
Allograft
(n=150)
Autograft
(n=81)
Biological
(n=3)
Cross-clamp time (min) 123 
(23-650)
106
 (38-650)
132 
(23-326)
149
 (90-238)
115 
(84-155)
CPB time (min) 179 
(64-1125*)
158 
(64-1125)
190 
(95-485)
214 
(114-685)
159 
(113-244)
Circulatory arrest (min) 35 (1-269*) 42 (1-269) 33 (5-99) 22 (5-64) -
Concomitant procedures#
Other valve surgery1
CABG
CABG +other valve surgery
Other2
13%
12%
<1%
20%
21%
17%
1%
14%
9%
9%
-
32%
<1%
4%
-
9%
-
66%
-
-
Complications
Bleeding/Tamponade
Sternal wound infection
Pacemaker
CVA/TIA
17%
<1%
1%
2%
16%
<1%
1%
1%
16%
-
<1%
5%
21%
<1%
-
-
-
-
-
-
Early mortality 10 (2.3%) 4 (2.0%) 4 (2.7%) 2 (2.4%) 0 (0%)
* The CPB time of 1125 min concerned one extreme case. This patient had a familiar connective tissue disorder with 
diffi culty performing the anastomoses in the fragile tissue. The circulatory arrest was intermittently applied.
# Not exclusive categories
1 Other valve surgery includes mitral valve surgery, tricuspid valve surgery and pulmonary valve surgery
2 Other concomitant procedures includes closure of an atrial/ventricular septum defect, surgery on ascending and/or 
aortic arch and enucleation of a subvalvular membrane 
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operation. The third elective patient received an allograft and died suddenly 11 days 
postoperatively. Finally, one elective patient also with Turner syndrome and extreme 
left ventricular hypertrophy, received an autograft, required 13 days after the in 
initial operation a reoperation due to bleeding of lesions in the ascending aorta and 
died during reoperation of severely depressed left ventricular function.
Univariate logistic regression analysis identifi ed female gender, prior combined aortic 
and mitral valve surgery, active endocarditis, impaired renal function, an abnormal 
cardiac rhythm pre-operative, NYHA class IV and urgent surgery as potential risk 
factors for hospital mortality.
Survival
Mean follow-up for the entire study population was 6.8 years (SD 3.3 years; range 
0-12.9 years). Total follow-up comprised 2977 patient years. For mechanical 
prosthesis allografts and autografts mean follow-up duration was 6.2 yrs (SD 3.2; 
range 0-12.8 yrs, 1268 patient years), 7.2 yrs (SD 3.6; range 0-12.9 yrs, 1086 patient 
Table 3. Hospital deaths (n=10). Number of patients (n=415) 
Sex Age Type 
operation
Valve type
in situ
preoperative
Indication for surgery Valve type
in situ
postoperative
Cause of deathTime
 after 
operation 
(days)
F 24 Elective Native valve Aortic stenosis Autograft Heart failure 13
F 40 Urgent Native valve Aortic stenosis Autograft Heart failure 0
F 42 Emergency Homograft Abscess/remains 
endocarditis
St Jude 
21 mm
CVA 27
F 48 Elective Native valve Bicuspid valve, 
aortic stenosis
St Jude 
21 mm
Myocardial 
Infarction 
6
F 50 Elective Native valve Rheumatic aortic 
regurgitation and 
stenosis
Homograft 
21 mm
Tamponade 11
F 53 Elective St Jude Aortic
regurgitation
Homograft 
22 mm
Heart failure 4
M 46 Emergency Native valve Active endocarditis Homograft 
21 mm
Intracranial 
hemorrhage
8
M 47 Emergency Native valve Bicuspid valve,
aortic stenosis
St Jude 
29 mm
Heart failure 15
M 51 Urgent Native valve Active 
endocarditis
Homograft 
23 mm
Heart failure 0
M 54 Emergency Native valve Aneurysm ascending 
aorta, aortic 
regurgitation
Björk Shiley 25 
mm 
Myocardial 
Infarction
0
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years) and 7.7 yrs (SD 2.6; range 0-12.9 yrs, 622 patient years), respectively and 
was signifi cantly different between the three groups (p=0.001).
The end point of the study follow-up was set on 1 January 2004. Follow-up was 
97% complete to this date. Thirty patients died during follow-up: 20 mechanical 
prosthesis patients, 9 allograft patients and 1 autograft patient. Causes of death 
during follow-up are described below by valve type.
Three patients who received a mechanical prosthesis died after a massive brain 
hemorrhage, 2 patients died after a stroke, 6 patients died suddenly, 1 patient died 
due to arrhythmia, 1 died after a myocardial infarction, 1 due to progressive heart 
failure, 2 because of renal failure, 2 died of cancer and 2 patients died of unknown 
causes.
Three allograft patients died because of aortic valve endocarditis, 2 patients died 
suddenly, 2 patients died due to heart failure, 1 patient died after a reoperation 
due to an aneurysm of the ascending aorta and 1 patient died after a myocardial 
infarction. The autograft patient died of a myocardial infarction 2 months after 
reoperation for structural valve deterioration and implantation of a mechanical 
prosthesis.
Overall ten-year survival was 89.5% ± 1.8%. Ten-year survival was 84.2%±3.8% 
for the mechanical prosthesis group compared to 91.8%±2.3% for the allograft 
group and 96.2%±2.1% for the autograft group (Log-rank test p=0.08; Figure 1).
Table 4 shows the results of the univariate and the multivariate Cox regression 
analysis to identify factors that may affect late mortality. In the univariate model 
mechanical prosthesis (p=0.03) and autograft (p=0.05) were signifi cant potential 
predictors of late mortality, yet failed to show a signifi cant effect on late mortality 
in the multivariate model.
Valve related events
Table 5 displays the occurrence of valve related events by valve types. Twelve patients 
had a thromboembolic event (0.40%/ patient year, none lethal), of whom six had a 
mechanical valve. Thirteen patients had a major bleeding during follow-up and one 
patient had two bleeding episodes (0.47%/ patient year, 6 lethal). Two patients with 
mechanical prosthesis had valve thrombosis (0.16%/ patient year; none lethal) of 
which one had two incidents of valve thrombosis.
Prosthetic valve endocarditis occurred in 13 patients (0.44%/patient year). Of these 
patients 7 were treated with antibiotics, 5 required an aortic valve replacement 
and one patient with an allograft had a valve-sparing operation with removal 
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of vegetations off the cusps. There were 3 deaths resulting from prosthetic valve 
endocarditis. These patients died before surgical treatment could take place.
Paravalvular leakage occurred in 7 patients, all requiring reoperation (0.24%/
patient year) and structural failure happened to 33 patients (1.1%/patient year). 
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Figure 1. Cumulative survival after aortic valve replacement by implanted valve type
Table 4. Risk factors for late mortality
Risk factors
Univariate analysis model
HR 95% C.I. P-value 
Multivariate analysis model
HR 95% C.I. P-value
Pre-operative impaired renal 
function#
Pre-operative left ventricular 
function
Concomitant mitral valve surgery
Prior aortic valve surgery
Age*
Prosthesis type
- Mechanical prosthesis
- Allograft
- Autograft (reference group)
1.003 (1.002-1.005) <0.001
5.6 (2.6-12.2) <0.001
3.6 (1.6-8.1) 0.002
3.0 (1.4-6.1) 0.003
1.04 (1.004-1.09) 0.03
8.8 (1.2-65.4) 0.03
4.8 (0.6-38.0) 0.14
1.0
1.004 (1.002-1.006) <0.001
5.1 (2.2-11.6) <0.001
3.0 (1.3-7.1) 0.01
3.7 (1.7-7.7) 0.001
1.02 (0.98-1.1) 0.41
0.9 (0.03-1.9) 0.85
0.2 (0.4-2.1) 0.18
1.0
HR = hazard ratio, with 95% confi dence intervals
#Renal function was analyzed as a continuous variable. The HR represents the increase in risk per additional grade 
of creatinin
*Age was analyzed as a continuous variable. The HR represents the increase in risk per additional year of age. 
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Overall ten-year freedom from thromboembolic events (TE), valve thrombosis and 
bleeding was 92.7% ± 1.7%. For mechanical prosthesis ten years freedom from TE 
and bleeding was 89.1% ± 3.3% and worse compared to allografts or autografts 
93.5% ± 2.6% and 98.7% ± 1.3% respectively (Log Rank test p=0.054).
Overall 10-year freedom from endocarditis was 96.8% ± 1.0%. For patients with 
a mechanical prosthesis the ten-year freedom from endocarditis was 97.4%±1.2, 
for the allograft patients 96.5%±1.5% and for the autograft patients 96.7%±2.4% 
(Log Rank test p=0.73).
Reoperation 
A total of 42 patients underwent 44 aortic valve reoperations, see table 5. Of these 
25 had an allograft, 10 a mechanical valve patients and 9 an autograft. Two patients 
underwent a re-reoperation within 30 days of the reoperation. In one patient this 
Table 5. Late valve-related events
Type valve-related 
event
Number valve- 
related events
N= 80
Occurrence rate
(% per patient year)
Reoperation
N=44
Valve related
deaths 
N=8
SVD
Mech
Allo
Auto
-
22
9
-
2.0
1.4
-
21
9
-
0
0
NSVD
Mech
Allo
Auto
4
3
-
0.32
0.28
-
4
3
-
0
0
-
Endocarditis
Mech
Allo
Auto
6
6
1
0.47
0.55
0.16
4
1
-
0
3
0
TE
Mech
Allo
Auto
6
4
2
0.47
0.37
0.32
-
-
-
2
0
0
Bleeding
Mech
Allo
Auto
11
3
-
0.87
0.28
-
-
-
-
3
0
-
Valve thrombosis
Mech
Allo
Auto
3
-
-
0.24
-
-
2
-
-
0
-
-
SVD= structural valve deterioration, NSVD= non-structural valve deterioration, TE= Thrombo-embolic event. 
Mech = mechanical prosthesis, allo = allograft, auto = autograft
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was due to prosthetic valve endocarditis and in the second patient due to patient-
prosthesis mismatch. 
Freedom from reoperation at 10 years was for the entire study population 
87.4%±2.1%. 
Freedom from reoperation for the mechanical prosthesis, allograft and autograft 
at 10 years was 94.8%±1.9%, 78.8% ±4.5% and 87.0%± 4.5% respectively. See 
also Figure 2. Patients receiving a mechanical prosthesis had a signifi cantly better 
freedom from reoperation compared to allograft patients (p=0.003). No signifi cant 
difference was found between mechanical prosthesis patients and the autograft 
patients (p=0.11), or between the allograft and autograft patients (p=0.21).
Comments
Prosthetic valve selection
When choosing a prosthetic aortic valve type for young adult patients who have 
a relatively long life expectancy, the increased hazard of thrombo-embolism and 
bleeding associated with the use of mechanical valves is weighed against the 
increased hazard of structural failure when using tissue valves. For women who 
are pregnant the mechanical prosthesis has several disadvantages, including not 
only an increased mortality risk during pregnancy (1-4%), mainly due to valve 
thrombosis but also an increased risk of embryopathy with oral anticoagulants.10 
In addition, hemodynamic profi le, availability, and resistance to endocarditis of the 
prosthetic valve type may play an important role, next to patient preference. The 
AHA/ACC guidelines for the management of patients with valvular heart disease 
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only provide major criteria for valve selection in patients who require aortic valve 
replacement.11 Valve selection particularly in young adult patients is left more or less 
completely at the discretion of the treating physician. It is obvious from our study 
that the patient profi le is an important predictor of valve selection. Patients who 
receive a mechanical valve are older, more often have an impaired left ventricular 
function and more frequently need concomitant mitral valve surgery compared to 
allograft and autograft recipients. Patients, who receive allograft valve replacement 
more often present acutely, have a worse preoperative NYHA class, aortic root 
pathology, active endocarditis or Marfan’s disease. Finally, patients who undergo 
autograft aortic valve replacement are usually younger, present with isolated aortic 
valve disease, and are more frequently previously treated by balloon valvuloplasty 
implying that congenital heart disease is involved. 
Whether prosthetic valve selection also affects patient survival is still unclear. 
Several authors hypothesize that the use of stentless biological prostheses may be 
associated with better patient survival through faster regression of left ventricular 
hypertrophy and superior hemodynamics.12,13 The present study aimed to elucidate 
whether prosthetic valve selection is an important predictor of outcome in young 
adult patients or whether outcome is mainly related to patient factors. Although 
selection of aortic valve prosthesis is predictive of the type of valve-related events 
that occur over time, in our study it is not an independent predictor of mortality 
in the fi rst decade after the operation. This is in contradiction to a recent update of 
the randomized controlled trial of patients who underwent aortic valve replacement 
with either an autograft or allograft valve (Yacoub et al.; abstract presented at AHA 
Scientifi c sessions November 15, 2005); in this trial there was a survival advantage 
of patients who were randomized to autograft aortic valve replacement. However, 
several other (non-randomized) studies did not detect a patient survival difference 
between different implanted valve types.2,3,14
Survival after aortic valve replacement
Survival in the fi rst decade after operation appears good in our young adult patient, 
but compared to mortality of the age-matched general Dutch population (10-year 
survival of approximately 97%), allograft and mechanical valve patients have a 
considerable excess mortality (84% and 92% at 10 years respectively). Survival of 
the autograft patients is comparable to the general population (96% at 10 years). 
This seems to be in contradiction with other reports of aortic valve replacement in 
young adults that showed no signifi cant difference in survival between patients with 
mechanical and bioprostheses regarding long-term survival.2,15 However, after we 
Loes bw.indd   39 31-10-2007   14:40:37
Chapter 2
40
employed multivariable Cox regression analysis, the type of implanted prosthesis 
was no longer predictive of survival. 
Survival in the fi rst decade after operation appears to be mainly determined by 
patient-related factors. Two of these factors (pre-operative impaired left ventricular 
function and the need for concomitant mitral valve surgery) were also predictive of 
mechanical prosthetic valve selection, and explain why mechanical valve patients have 
a higher mortality rate compared to patients who received allografts or autografts. 
In other studies patient-related factors like patient age, sex, diabetes mellitus and 
NYHA class IV3 and concomitant CABG and preoperative left ventricular grade2 
were identifi ed as determinants of survival in young adults. 
The burden of prosthetic valve disease
The occurrence of valve related complications in our study population is comparable 
with other reports. Although structural failure was absent in mechanical prosthesis, 
the risk of reoperation –although low- was not absent. In the present study 5.2% 
of the mechanical prostheses were replaced after 10 years. Khan et al reported 
a freedom from reoperation for mechanical valves 98.7% at 10 years3 and Ruel 
et al 94.6% at 10 years.2 Also, bleeding and thrombo-embolic events were quite 
common (0.87%/patient year and 0.47%/patient year, respectively) but better than 
reported by other authors.3,16 Khan et al3 report a rate of valve thrombosis of 0.30% 
compared to 0.24% in our series.
An important advantage of the allograft is that it can be tailored to reconstruct 
specifi c endocarditis lesions and is therefore the most suitable option for surgical 
treatment of an infected aortic root. The allograft is durable against endocarditis, 
which makes it an excellent valve substitute in those patients who present with 
active endocarditis.15 This is refl ected by the low occurrence rates of allograft 
endocarditis in our series (0.55%/patient year). Unfortunately, the longevity of the 
allograft is disappointing especially in younger patients. This phenomenon has been 
reported previously8,19 and although immune-mediated processes are hypothesized 
to underlie the increased failure rates observed in younger patients 20 this still needs 
to be clinically confi rmed. 
Autografts in our series have low thromboembolic event rate (0.32%/pt yr), no 
anticoagulation was used, no bleeding events occurred, have an excellent survival 
pattern and the patient can live a close to normal life. On the down side, the 
autograft procedure is a complex double valve operation whereby a healthy valve is 
replaced. A possible reoperation of the autograft and/or the valve substitute used to 
reconstruct the right ventricular outfl ow tract is complex. Thus far in our experience 
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the durability of the autograft procedure has been acceptable on the median term 
and after correction for patient age between autograft and allograft patients in our 
series, the autograft performs better than the allograft. However in the last few 
years several reports tempered the initial enthusiasm for the autograft procedure 
due to relatively high failure rates of autografts. In our series 9 autografts (11%) 
required reoperation in the study period which is comparable to other studies. 17,18
Study limitations
This is a single center cohort study. The valve choice for this particular patient 
cohort may very well be different at other centers with possible other results of the 
infl uence of valve prosthesis choice on outcome after aortic valve replacement. Our 
results give an insight in our experience with the different aortic valve prosthesis 
types, but cannot be generalized to all young adults who undergo aortic valve 
replacement in Europe. A prospective randomized multicenter study would be the 
only way to answer the question whether there may be a survival advantage with a 
particular prosthesis in young adult patients.
It is expected that the complications related to the limited durability of the allograft 
and autograft valve types will increase in the second decade after the operation. 
This may result in an increased morbidity and mortality rate in the longer term. It 
is not yet possible to derive any conclusions from our study (maximum follow-up 
of 12.9 years) regarding the effect that valve type may have on survival beyond 10 
years postoperative.
Finally, the autograft and allograft cohort were monitored in a prospective manner, 
while a retrospective study of the mechanical valve recipients was performed. This 
may have resulted in underreporting of valve-related complications in the mechanical 
valve cohort and an underestimation of the true burden of anticoagulation 
therapy.
Conclusions
In conclusion, in our center patient survival after aortic valve replacement in young 
adults is mainly determined by patient characteristics and not by prosthesis type. 
A randomized controlled trial is necessary to answer the question whether valve 
prosthesis type indeed plays a crucial role in improving survival in young adult 
patients, or whether other measures like optimizing the timing of surgery and 
medical therapy to provide improved myocardial protection are the key to a longer 
life expectancy. 
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ALLOGRAFTS FOR AORTIC VALVE 
OR ROOT REPLACEMENT: 
INSIGHTS FROM AN 18-YEAR 
SINGLE CENTER PROSPECTIVE 
FOLLOW-UP STUDY
Allografts for aortic valve or root replacement: insights from an 18-year single-center 
prospective follow-up study. Takkenberg JJM, Klieverik LMA, Bekkers JA, Kappetein AP, 
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ABSTRACT
Objectives
Whether allografts are the biological valve of choice for AVR in nonelderly patients 
remains a topic of debate. In this light we analyzed our ongoing prospective allograft 
AVR cohort and compared allograft durability with other biological aortic valve 
substitutes.
Methods
Between 4/1987 and 10/2005, 336 patients underwent 346 allograft AVRs (95 
subcoronary, 251 root replacement). Patient and perioperative characteristics, 
cumulative survival, freedom from reoperation and valve-related events were 
analysed. Using microsimulation, for adult patients age-matched actual freedom 
from allograft reoperation was compared to porcine and pericardial bioprostheses.
Results
Mean age was 45 years (range 1 month-83 yrs), 72% were males. Etiology was 
mainly endocarditis 32% (active 22%), congenital 31%, degenerative 9%, and 
aneurysm/dissection 12%. 27% underwent prior cardiac surgery. Hospital mortality 
was 5.5% (N=19). During follow-up (mean 7.4 yrs, max 18.5 yrs, 98% complete) 
54 patients died, there were 57 valve-related reoperations (3 early technical, 11 non-
structural, 39 structural valve deterioration (SVD), 4 endocarditis), 5 CVAs, 1 fatal 
bleeding, 8 endocarditis. Twelve-year cumulative survival was 71% (SE 3), freedom 
from reoperation for SVD 77% (SE 4); younger patient age was associated with 
increased SVD rates. Actual risk of allograft reoperation was comparable to porcine 
and pericardial bioprostheses in a simulated age-matched population.
Conclusions
The use of allografts for AVR is associated with low occurrence rates of most 
valve-related events but over time the risk of SVD increases, comparable to stented 
xenografts. It remains in our institute the preferred valve substitute only for patients 
with active aortic root endocarditis and for patients in whom anticoagulation should 
be avoided.
Keywords: aortic valve replacement, allografts, prognosis, reoperation
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Introduction
There is not yet a perfect aortic valve prosthesis. In particular in non-elderly patients 
who have an active lifestyle and a relatively long life expectancy it can be hard to 
select the preferred aortic valve substitute. Choosing the optimal prosthesis requires 
careful weighing of the pros and cons of mechanical and biological valve substitutes 
for each individual patient, taking into account multiple interrelated factors like the 
expected lifespan of the patient, the willingness to take warfarin (and accept the 
associated risks) versus risking a possible reoperation for structural valve failure, 
major contraindications against warfarin therapy, and patient preference[1]. 
In our own institution we started using allografts for aortic valve replacement in the 
late 80’s, assuming that their durability would be better compared to xenografts, 
their hemodynamic profi le superior to mechanical prostheses and xenografts, and 
because they offer (in particular young adult) patients the option to live life to the 
full without the limitations and threats of anticoagulation that would be required 
after implantation of a mechanical prosthesis. We systematically and carefully follow 
patients over time and are now able to make statements about valve performance 
and patient outcome well into the second decade after operation.
The aim of this study is to assess whether allografts are indeed the biological valve 
substitute of choice in non-elderly patients. This is done by describing the clinical 
results of aortic valve and root replacement with allografts in our centre’s prospective 
cohort study, and comparing the performance of allografts with stented porcine and 
pericardial bioprostheses in a simulated age-matched population.
Materials and methods
Between April 1987 and October 2005, 336 consecutive patients underwent 346 
allograft aortic valve replacement or aortic root replacement procedures at Erasmus 
University Medical Center. All patients who receive an allograft in our center are 
enrolled in our ongoing prospective follow-up study[2-4]. Institutional Review 
Board approval was obtained for this prospective follow-up study; the Institutional 
Review Board waived informed consent. Preoperative patient characteristics are 
displayed in Table 1.
Operation
Surgical procedures were performed on cardiopulmonary bypass with moderate 
hypothermia. Crystalloid cardioplegia and topical cooling were used for myocardial 
protection. Deep hypothermia and circulatory arrest were used in 35 patients 
with ascending aorta or arch pathology. Early in our experience the subcoronary 
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technique was used, while since 1998 the root replacement technique has become 
the technique of choice (Figure 1).
Table 1. Preoperative patient characteristics
All patients
N=346
SC technique
N=95
Root replacement
N=251
Mean age 
(years (SD; range)) 45 (16;0.06-83) 45 (15;14-83) 44(16; 0.06-75)
Male/female ratio 248/98 67/28 181/70
Creatinin
(μmol/L,N=322,(SD;range))
103 (86;22-930) 113 (106; 48-930) 99 (76; 22-900)*
Prior cardiac surgery 27% (N=94) 20% (N=19) 30% (N=75)
Hypertension 15% (N=51) 15% (N=14) 15% (N=37)
Ischemic Heart Disease 9% (N=31) 12% (N=11) 8% (N=20)
Marfan 5% (N=18) - 7% (N=18)#
Diabetes Mellitus 4% (N=13) 4% (N=4) 4% (N=9)
Diagnosis
Aortic valve regurgitation (AR)
Aortic valve stenosis (AS)
AR+AS
No AR and/or AS
59% (N=203)
20% (N=67)
16% (N=61)
4% (N=15)
58% (N=55)
26% (N=25)
16% (N=15)
-
60% (N=148)#
17% (N=42)
18% (N=46)
6% (N=15)
Etiology
Endocarditis 
 Active
Congenital (incl. bicuspid)
Other (mainly prosthetic valve)
Degenerative
Aneurysm
Rheumatic
Dissection
32% (N=102)
 N=76
31% (N=106)
10% (N=33)
9% (N=32)
7% (N=25)
6% (N=21)
5% (N=18)
33% (N=31)
N=13
32% (N=30)
9% (N=9)
12% (N=11)
-
15% (N=14)
-
32% (N=80)#
N=63#
30% (N=76)
10% (N=24)
8% (N=21)
10% (N=25)
3% (N=7)
 7% (N=18)
Sinus rhythm 92% (N=318) 91% (N=86) 92% (N=232)
Systolic LVF (N=343)
Good
Impaired
Moderate/Bad
74% (N=255)
18% (N=63)
7% (N=25)
79% (N=75)
17% (N=16)
4% (N=4)
72% (N=180)
19% (N=47)
8% (N=21)
Preoperative NYHA class
I
II
III
IV/V
26% (N=89)
26% (N=91)
30% (N=103)
18% (N=63)
13% (N=12)
27% (N=26)
48% (N=46)
12% (N=11)
31% (N=77)#
26% (N=65)
23% (N=57)
21% (N=52)
Prior CVA 5% (N=17) 8% (N=8) 4% (N=11)
Ventilation support 6% (N=21) -  8% (N=21)#
Urgent operation (<24 hours) 11% (N=38) 2% (N=2) 14% (N=36)#
LVF = left ventricular function, NYHA = New York Heart Association, CVA = cerebrovascular accident, * statistical 
signifi cant difference between the 2 surgical groups according to the unpaired T-test or Mann-Whitney U-test, # statistical 
signifi cant difference between the 2 surgical groups according to the Fisher Exact test or the Chi-Square test.
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Subcoronary allograft implantation was done in 95 patients[5], initially with 
scalloping of the sinus of Valsalva (N=32) while later on the non-coronary sinus 
was preserved (N=63). Root replacement was performed as a freestanding root with 
reimplantation of the coronary arteries in 251 patients. Characteristics of implanted 
allografts are displayed in Table 2.
Follow-up 
All patients who receive an allograft at ErasmusMC are followed prospectively 
by annual telephone interviews and through visits to their cardiologist. 
Echocardiographic follow-up at ErasmusMC is obtained at 6 months postoperative, 
1 year postoperative and thereafter biennially by means of serial standardized 
echocardiography[3]. Valve-related complications were defi ned according to 
the 1996 guidelines for reporting morbidity and mortality after cardiac valvular 
operations[6]. 
The study database was frozen for analysis on December 1, 2005. Follow-up was 
98% complete: 8 patients were lost to follow-up due to emigration. The mean 
follow-up duration was 7.4 years (range 0-18.5 years), with a total follow-up of 
2545 patient years. 
Statistical methods 
Continuous data are presented as means (standard deviation; range), and comparison 
was done using the unpaired T-test unless the data were not normally distributed 
(Kolmogorov-Smirnov test); in these instances we used the Mann-Whitney U-test 
for comparison. Categorical data are presented as proportions, and comparison 
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Figure 1. Number of allografts implanted with the subcoronary implantation technique and the 
root replacement technique by year of operation.
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was done using the Chi-Square test or the Fisher Exact test where appropriate. 
All tests were 2-sided, with an α-level of 0.05. Univariate logistic regression 
analysis was used to study potential determinants of hospital mortality. Cumulative 
survival and freedom from reoperation or reintervention were analysed using 
the Kaplan-Meier method. The survival of a patient started at the time of aortic 
valve operation and ended at the time of death (event) or at the last follow-up 
(censoring). The analysis of allograft survival started at the time of implantation 
and ended with reoperation (event) or last follow-up or patient death (censoring). 
The Tarone-Ware test was used to compare Kaplan-Meier curves between surgical 
techniques (correcting for the differences in follow-up time between the groups). 
The Cox proportional hazards model was used for univariate and multivariate 
analysis of time-related events. Backwards-stepwise or forward-stepwise selection 
of potential predictors was employed, with criteria for entering variables: P<0.05. 
Table 2. Allograft characteristics
All patients
N=346
SC technique
N=95
Root replacement
N=251
Type allograft
Aortic
Pulmonary
98% (N=340)
2% (N=6)
95% (N=90)
5% (N=5)
99% (N=250)#
1% (N=1)
Size allograft (mm)
Mean (SD; range; N=344)
≤ 24 mm
>24 mm
22.7 (2.0; 14-30)
 84% (N=288)
16% (N=56)
23.3 (2.3; 19-30)
70% (N=64)
30% (N=29)
22.4 (1.9; 14-28)*
89% (N=224)#
11% (N=27)
Type donor (N=340)
Heart beating
Non heart beating
Domino
 48% (N=164)
 33% (N=112)
19% (N=64)
53% (N=47)
15% (N=13)
32% (N=29)
47% (N=117)
39% (N=99) #
14% (N=35) #
Donor age (years N=339)
Mean (SD; range) 40 (13; 8-62) 36 (13; 12-60) 42 (12; 8-62)*
Preservation method
Cryopreserved
Fresh
98% (N=339)
2% (N=7)
94% (N=89)
6% (N=6)
99% (N=250)
<1% (N=1)
Origin
Rotterdam
Barcelona
Berlin
London
Other
84% (N=291)
3% (N=10)
7% (N=25)
3% (N=9)
3% (N=11)
92% (N=87)
-
2% (N=2)
6% (N=6)
-
81% (N=2044% (N=10)
9% (N=23) )#
1% (N=3)
5% (N=11)
Quality code (N=336)
1-2
3-5
38% (N=127)
62% (N=209)
66% (N=59)
33% (N=29)
27% (N=68)#
73% (N=180) )#
* statistical signifi cant difference between the 2 surgical groups according to the unpaired T-test or Mann-Whitney 
U-test, # statistical signifi cant difference between the 2 surgical groups according to the Fisher Exact test or the Chi-
Square test.
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Variables that were tested as potential risk factors for hospital and late mortality 
were: patient age (continuous variable expressed in years), gender, preoperative 
ventilation support, preoperative abnormal cardiac rhythm (any rhythm other that 
sinus rhythm), preoperative renal function (creatinin, continuous variable expressed 
in μmol/L), severe renal disease requiring either dialysis or transplantation, prior 
cardiac surgery, Marfan disease, ischemic heart disease, heart valve disease etiology, 
preoperative hypertension, systolic left ventricular function (good versus impaired/
moderate/bad), prior CVA, preoperative NYHA class, emergency of the procedure, 
operative technique, cardiopulmonary bypass time (continuous variable expressed 
in minutes), and time period of operation (before 1998 versus after 1998). Factors 
that were tested as potential risk factors for reoperation for SVD were: patient 
age (continuous variable expressed in years), gender, severe renal disease requiring 
either dialysis or transplantation, prior cardiac surgery, heart valve disease etiology, 
preoperative hypertension, operative technique, surgical experience (considering the 
fi rst 10 cases of an individual surgeon as inexperienced), allograft characteristics 
(including aortic versus pulmonary allograft, size allograft (continuous variable 
expressed in millimeters), type donor, donor age, donor gender, preservation 
method, quality code), donor-recipient sex mismatch, and time period of operation 
(before 1998 versus after 1998). For all analyses mentioned above SPSS 12.0 
for Windows statistical software (SPSS, Chicago, Ill) was used. Using Egret, the 
incidence of structural valve deterioration requiring reoperation was described 
by a Weibull curve, which is a generalization of the exponential distribution that 
accommodates a changing risk over time[7-9]. An age parameter that was based 
on the observed relationship between patient age and structural valve deterioration 
was added to the Weibull model, allowing for patient age-specifi c calculations for 
structural valve deterioration[10, 11]. The age-specifi c Weibull model was entered 
into a previously developed microsimulation model [12, 13] to allow comparison of 
age-specifi c patient life time risk of reoperation for allografts, and stented porcine 
and pericardial bioprostheses[14]. The details of the parameters that were used for 
the microsimulation calculations of the CE pericardial and CE-SAV bioprostheses 
were previously published[14]. For each patient age group and valve type 10,000 
patient lives were simulated; background mortality of the general US population 
was used.
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Results
Early morbidity and mortality Peri-operative data are displayed for all patients 
and by implantation technique in Table 3. Coronary artery bypass grafting for 
complications related to reimplantation of the coronary arteries was necessary in 
6 root replacement patients, of which 2 subsequently died. In one patient the left 
coronary artery button was too small, causing coronary ostium stenosis. Another 
patient had annular calcifi cations extending up to the right coronary ostium that 
was very thin-layered and ruptured after reimplantation. A third patient had an 
active endocarditis of an aortic bioprosthesis with abscesses, and the oedematous 
right coronary artery button ruptured after reimplantation. Another 2 patients 
experienced right ventricular dysfunction due to kinking of the reimplanted right 
coronary artery. In one patient the coronary artery buttons were very big, probably 
causing malperfusion of both the right and left coronary artery. 
Table 3. Perioperative data
All patients
N=346
SC technique
N=95
Root replacement
N=251
Valve requiring operation
Bicuspid
Tricuspid
Quadriscuspid
Allograft
Prosthesis
35% (N=121)
50% (N=173)
1% (N=2)
3% (N=9)
12% (N=41)
44% (N=42)
47% (N=45)
-
4% (N=4)
4% (N=4)
31% (N=79)#
51% (N=128)
1% (N=2)
2% (N=5)
15% (N=37)#
Concomitant procedures
No
Yes
51% (N=176)
49% (N=170)
68% (N=65)
32% (N=30)
 44% (N=111)#
56% (N=140)
Aortic cross clamp time (min (SD; 
range))
138 (46; 0-357) 132 (30; 79-248) 141 (51; 0-357)
Perfusion time (min (SD)) 195 (76; 79-589) 176 (40; 116-316) 203 (84; 79-589)*
Circulatory arrest (min (SD; 
range)) (N=35)
35 (31; 5-163) - 35 (31; 5-163)
Procedure-related CABG 2% (N=6) - 2% (N=6)
Bleeding requiring reoperation 12% (N=41) 14% (N=13) 11% (N=28)
Permanent pacemaker 4% (N=14) 4% (N=4) 4% (N=10)
Perioperative CVA 3% (N=9) 3% (N=3) 2% (N=6)
Hospital death 5.5% (N=19) 4.2% (N=4) 6.0% (N=15)
LVOT = left ventricular outfl ow tract, CABG = coronary artery bypass grafting, SD = standard deviation, min = 
minutes, CVA = cerebrovascular accident, * statistical signifi cant difference between the 2 surgical groups according 
to the unpaired T-test or Mann-Whitney U-test, # statistical signifi cant difference between the 2 surgical groups 
according to the Fisher Exact test or the Chi-Square test.
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During the procedure 5 patients died, and 14 more patients died during the same 
hospitalization or within 30 days postoperative (hospital mortality 5.5%). The 5 
operative deaths were caused by persistent massive bleeding in 3 patients (1 with 
an active endocarditis with abscesses, 1 with an acute dissection, and 1 patient 
who underwent a reoperation for paravalvular leakage of a Bjork-Shiley mechanical 
valve), left ventricular failure in 1 patient who presented with acute endocarditis 
with fi stula to the left atrium, and fi nally 1 patient with prosthetic aortic valve 
endocarditis with extensive tissue destruction of the left ventricular outfl ow tract and 
proximal ascending aorta with abscesses died during a salvage procedure. Causes 
of death in the 14 patients who died during the same hospitalization or within 30 
days postoperative were registered as cardiac and not valve-related in 10 patients, 2 
patients died of a major intracerebral bleeding, 1 patient of a myocardial infarction 
caused by a kink in the reimplanted right coronary artery, and 1 patient with an 
acute endocarditis as a result of a stroke caused by septic emboli. Potential risk 
factors for increased hospital mortality were older patient age (OR 1.07, 95% CI 
1.03-1.11; p<0.001 (continuous variable expressed in years)), severe renal disease 
(requiring either dialysis or transplantation) (OR 11.2, 95% CI 3.4-37.2; p<0.001), 
longer cardiopulmonary bypass time (OR 1.008, 95% CI 1.004-1.013; p<0.001 
(continuous variable expressed in minutes)), emergent procedure (within 24 hours) 
(OR 4.3, 95% CI 1.5-12.0; p=0.006), abnormal preoperative cardiac rhythm (OR 
2.0, 95% CI 1.2-3.1; p=0.005), preoperative ventilation support (OR 4.9, 95% 
CI 1.5-16.2; p=0.01), NYHA class > II (OR 4.4, 95% CI 1.4-13.5; p=0.01), active 
endocarditis (OR 2.8, 95% CI 1.1-7.2; p=0.04), and preoperative hypertension (OR 
2.9, 95% CI 1.1-8.0; p=0.04).
Late survival 
During follow-up another 54 patients died (2.1%/patient year). Of these patients 
36 died of non-valve-related causes. In 2 patients the cause of death could not be 
retrieved. Causes of valve-related death (N=16) were as follows: 9 patients died 
sudden unexpected and unexplained deaths, 3 patients died due to endocarditis, 2 
patients who had structural allograft valve failure died of heart failure, 1 patient died 
after a CVA, and 1 patient died due to a major bleeding. Overall cumulative survival 
including early survival was 92.7% at 1 year (95% CI 90-96%), 86% at 5 years 
(95% CI 82-90%), and 71% at 12 years postoperative (95% CI 65-77%). In Figure 
2 cumulative survival for patients operated with the subcoronary implantation 
technique and the root replacement technique is displayed separately (Tarone-
Ware test p=0.03). Independent predictors of late mortality were older patient age 
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(HR 1.04, 95% CI 1.02-1.06; p<0.001 (continuous variable expressed in years)), 
preoperative ventilation support (HR 2.5, 95% CI 0.96-6.36; p=0.06), preoperative 
abnormal cardiac rhythm (HR 1.9, 95% CI 1.4-2.8; p<0.001), and the use of the 
root replacement technique (HR 2.2, 95% CI 1.2-2.4; p=0.02).
Reoperation 
Reoperation for allograft related causes was necessary in 57 patients (2.2%/patient 
year). Reason for reoperation was structural valve deterioration in 39 patients. 
Non-structural or technical valve failure required reoperation in 14 patients, and 
persistent endocarditis in 4 patients. The allograft was replaced by a mechanical 
valve in 39 patients, an allograft in 10 patients, an autograft in 4 patients, and a 
stented bioprosthesis in 3 patients. One patient did not require replacement of the 
allograft: a vegetation was removed from the proximal anastomosis of the allograft 
3 weeks after the initial operation for active endocarditis. Reoperative mortality was 
1.7% (N=1). Freedom from reoperation for allograft-related causes was 97% at 1 
year (95% CI 95-99%), 92% at 5 years (95% CI 88-95%), and 72% at 12 years 
(95% CI 64-79%), and worse in the subcoronary compared to root replacement 
technique group (Tarone-Ware test p=0.02).
Structural valve deterioration 
In 39 patients structural valve deterioration caused by degeneration of the allograft 
was the reason for replacement of the allograft (1.5%/patient year). This occurred in 
21 patients in the SC group (1.9%/patient year) and in 18 patients in the ARR group 
(1.3%/patient year). Freedom from reoperation for structural valve deterioration 
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Figure 2. Cumulative survival after subcoronary implantation versus root replacement.
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(N=39) was 97% at 5 years (95% CI 95-99), 77% at 12 years (95% CI 69-85%). 
This did not differ between the subcoronary compared to the root replacement 
technique group (Tarone-Ware test p=ns). Using univariate Cox regression modelling 
the following factors were found to be potential predictors of the occurrence of 
reoperation for SVD: patients who received a same-sex donor valve, valves from 
male donors, the implantation of larger donor valves, and younger patient age 
(continuous variable expressed in years). Combining these 4 factors in a multivariate 
model proved quite tedious since most of them (with the exception of patient age) 
are strongly correlated. Therefore, we changed our model building strategy from 
backward to forward stepwise selection and started by entering the only variable 
that was not strongly correlated, namely patient age. Addition of same-sex donor 
valve to this model revealed that when corrected for patient age, same-sex donor 
valve was no longer a signifi cant predictor of SVD occurrence (HR 1.9, p=0.13) 
and we took it out. Next, addition of donor sex to the model showed that, when 
corrected for patient age, male donor sex remained a signifi cant predictor of SVD 
occurrence (HR 3.2; p=0.03), and we left it in the model. In the last step we added 
allograft diameter (continuous variable expressed in millimetres) to the model and 
found that, when corrected for patient age and donor sex, a larger allograft diameter 
was associated with increased SVD rates (HR 1.16; p=0.05) and male donor sex 
was no longer a signifi cant predictor(HR 2.4; p=0.13). Therefore, in our fi nal model 
independent predictors of structural valve deterioration requiring reoperation were 
younger patient age at the time of operation (HR 0.96; 95% CI 0.94-0.98 (age 
continuous variable expressed in years)), and larger allograft diameter (HR 1.2, 
95% CI 1.06-1.40, diameter continuous variable expressed in millimeters)).
In Figure 3 the observed freedom from reoperation from structural valve deterioration 
and the Weibull function representing the effect of patient age on freedom from 
structural valve deterioration are displayed. For example, for a 45-year-old patient 
median time to reoperation for structural allograft valve deterioration was 16.5 
years. The value of the age-dependent scale (σ) parameter of the Weibull model, 
fi tted to represent allograft SVD was: σ = e 2.0755 + 0.0197 * age. The shape parameter 
(β) was estimated at 2.3856. The results of the Weibull model remained virtually 
unchanged when patients younger that 16 years or older than 65 years at the time 
of operation were excluded from the model.
Comparison with other biological valve types 
Figure 4 shows patient age-specifi c (45-65 years) Weibull estimates of reoperation 
for structural valve deterioration for allografts, Carpentier Edwards pericardial 
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bioprostheses and Carpentier Edwards SAV porcine bioprostheses. Figure 5 shows 
the microsimulation estimates of the ”actual” lifetime risk of structural valve 
deterioration for male patients ages 35 though 65 years receiving either an allograft, 
a stented pericardial valve or a stented porcine bioprosthesis.
Other valve-related complications 
During follow-up there were -besides the fatal CVA that was described above-: 2 
non-fatal CVA’s, 1 RIND and 9 TIA’s. The linearized annual occurrence rate (LOR) 
for thrombo-embolic events was 0.5%/patient year. Besides the 4 lethal bleeding 
complications described above, there was 1 other major non-fatal bleeding during 
follow-up. The LOR for major bleeding was 0.2%/patient year. Besides the 4 
endocarditis complications that required reoperation and the 4 lethal endocarditis 
complications, there was 1 non-fatal endocarditis that was treated with antibiotics. 
The LOR for endocarditis was 0.35%/patient year. No valve thrombosis or 
peripheral embolism was observed.
Discussion
Prosthetic valve selection in non-elderly patients who require aortic valve 
replacement is currently a hot topic of discussion[15, 16]. The new 2006 ACC/AHA 
guidelines for the management of patients with valvular heart disease only provide 
general recommendations for prosthetic valve selection in non-elderly patients, 
stating that “a mechanical prosthesis is reasonable for AVR in patients under 65 
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Figure 3. Observed freedom from reoperation for structural valve deterioration (SVD). 
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operation.
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Figure 4a-d. Weibull estimate of age-specifi c freedom from reoperation for structural valve 
deterioration of allografts versus CE pericardial versus CE-SAV stented bioprostheses for patients 
aged 35 (Figure 4a), 45 (Figure 4b), 55 (Figure 4c) and 65 years (Figure 4d) at the time of operation.
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years who do not have a contraindication to anticoagulation. A bioprosthesis is 
reasonable in patients under 65 years of age who elect to receive this valve for 
lifestyle considerations after detailed discussions of the risks of anticoagulation 
versus the likelihood that a second AVR may be necessary in the future”[1]. It is 
diffi cult to make an educated choice between these 2 completely different kinds 
of complication, and patient preference obviously plays an important role in the 
process. When a decision is made in favour of a biological valve substitute, the 
next question pops up: which one? We hypothesized in the late 80’s that allografts 
would have a superior durability and hemodynamic profi le compared to stented 
bioprostheses in non-elderly patients, but the results presented in this paper show 
that this hypothesis has to be rejected. What insights can be obtained from our 
18-year single center prospective follow-up cohort of allograft patients? Looking 
back, the high expectations we had 18 years ago can only be met in part. The results 
show that although the use of allografts for AVR is associated with low occurrence 
rates of most valve-related events (in particular endocarditis), over time the risk 
of reoperation for structural valve deterioration increases, and is comparable to 
stented xenografts.
Patient survival Patient survival in our allograft cohort was comparable to other 
series that report survival after allograft aortic valve and root replacement[15, 
17-20]. The impaired survival of patients undergoing allograft root replacement 
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Figure 5. Age-specifi c microsimulation-based estimates of actual patient lifetime risk of structural 
valve deterioration requiring reoperation for allografts versus CE pericardial versus CE-SAV stented 
bioprostheses.
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versus the subcoronary implantation technique can be explained by the differences 
in patient profi le (less isolated valve disease, more active endocarditis and complex 
root pathology) between the subcoronary implantation technique and the root 
replacement technique. Survival relative to the general age-matched Dutch 
population is markedly decreased, for example a 45-year-old male in the general 
Dutch population has a 12-year survival of 94%, while after allograft aortic valve 
or root replacement this is only 71%. This decreased relative survival has become 
a well-known phenomenon for patients after aortic valve replacement[21], with 
the exception of patients who undergo a Ross procedure[22, 23]. Whether there is 
patient selection or a true survival advantage in Ross patients, will remain a matter 
of debate until a randomized trial has been conducted. 
Allograft durability This study shows that allograft durability is age-dependent in 
non-elderly patients and comparable to 2 commonly used stented bioprostheses 
in age-matched individuals who undergo aortic valve replacement. Freedom from 
any valve-related reoperation was better using the root replacement technique 
compared to the subcoronary implantation technique. This is in accordance 
with the observations in a recent systematic review of the effect of allograft 
implantation technique on reoperation rate[24]. However, when only reoperation 
for degenerative structural valve deterioration is studied, reoperation rates are 
comparable between the 2 insertion techniques. Younger patient age is associated 
with increased reoperation rates for structural valve deterioration in this cohort, 
an observation that is confi rmed by several other reports[16, 18, 19]. The effect of 
patient age on valve durability is also comparable to CE pericardial and CE-SAV 
stented bioprostheses, suggesting a common pathway of degeneration. This is in 
accordance with a recently published study from Cleveland, Ohio, that demonstrated 
comparable failure rates for allografts and stented bovine pericardial prostheses for 
patients at all adult ages[16]. Our study adds to this the observation that stented 
porcine bioprostheses also have a comparable age-related valve failure occurrence. 
Therefore, we can conclude that durability does not play an important factor in 
choosing either of these 3 valve types.
Patient risk of reoperation Using microsimulation we demonstrated that the actual 
patient lifetime risk of structural valve deterioration requiring reoperation is 
comparable for all three valve types. This risk ranges from approximately 15% for 
a 65-year old patient to almost 70% in a 35-year old patient. These evidence-based 
estimates of actual patient risk of structural valve failure requiring a reoperation 
may provide a useful tool for patient counselling, quantifying the risks associated 
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with each therapeutic option. The demonstration simulation model (freeware) can 
be downloaded from our website (www.cardiothoracicresearch.nl) or requested by 
e-mail.
Reoperative mortality in our series was remarkably low, less than 2%. Although an 
allograft reoperation can be quite complicated, our results illustrate that it can be 
accomplished with a low reoperative mortality risk. Key is to closely monitor the 
patient over time, particularly in the second decade after operation when the risk of 
structural failure increases. This allows for careful planning of the reoperation, and 
avoids emergency reoperative procedures in decompensated patients.
Other valve-related complications Although durability of allografts is comparable 
to the most commonly used stented bioprostheses, the occurrence of other valve-
related complications is quite low. In particular the annual occurrence rate of 
endocarditis is very low in our cohort, given that 22% of patients who received 
an allograft had an active endocarditis preoperatively. Also, thrombo-embolic and 
bleeding event rates are low in comparison to stented bioprostheses. However, this 
observed difference can at least in part be explained by the patient age difference 
between the allograft and stented bioprosthesis studies. 
Changes in policy over time Figure 1 shows that early on in our experience we 
mainly used the subcoronary implantation technique while by the mid-90’s the root 
replacement technique became the gold standard in our clinic for implanting an 
allograft in aortic position. As we reported previously, the subcoronary technique 
has a learning curve and its use resulted in our clinic in several early technical 
failures[4]. With the shift in surgical technique and due to the emerging disappointing 
durability outcomes, a change in patient profi le took place: while early on in our 
series allograft aortic valve or root replacement was done in a broad range of 
patients that required aortic valve replacement, nowadays the main indication for 
the use of allografts is active endocarditis. Given its excellent resistance to infection, 
the allograft is a good solution for patients with active endocarditis, in particular 
when the aortic root is involved. Allograft root replacement can also be considered 
for patients with a (relative) contraindication for anticoagulation and patients with 
aortic root pathology. 
Limitations Our study reports results from a single institution with a large 
proportion of patients with endocarditis and root pathology and may thus not be 
applicable to all patients who require aortic valve replacement. We were unable to 
study allograft mismatch as a potential risk factor for the occurrence of structural 
valve deterioration since we do not systematically measure the recipient annulus 
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at the time of operation. However, in the early postoperative phase only 1 patient 
had a gradient of more than 15 mmHg and therefore allograft mismatch appears 
uncommon in our series. Also, the microsimulation estimates that were used to 
calculate lifetime risks of structural valve deterioration requiring reoperation were 
largely based on pooled estimates of valve related complications from published 
reports. This may have resulted in overestimates or underestimates of complications 
and therefore have infl uenced the calculated lifetime risks. Furthermore, we assumed 
in the microsimulation analyses that all patients with structural valve deterioration 
were reoperated, while in real life this may not be the case.
Conclusions and recommendations The use of allografts for AVR is associated 
with low occurrence rates of most valve-related events but over time the risk of 
SVD increases, comparable to stented xenografts. Lifetime risk of reoperation is 
considerable, especially in younger patients. Careful follow-up of patients and 
early recognition of symptoms and signs of structural valve failure are the key to 
a successful reoperation. The allograft remains in our institute the preferred valve 
substitute only for patients with active aortic root endocarditis and for patients in 
whom anticoagulation should be avoided.
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ABSTRACT
Background 
Surgery for persistent active native aortic valve endocarditis (NVE) remains 
challenging. No fi rm specifi c recommendations are available for use of particular 
valve substitute in active native aortic valve endocarditis surgery. In this regard, 
we analyzed our combined experience with allografts and mechanical prostheses in 
NVE surgery.
Methods
Between 1980 and 2002, 138 patients underwent aortic valve replacement for 
NVE in two centers with 106 allografts(ALLO) and 32 mechanical prostheses(MP). 
Patient and perioperative characteristics, early and late morbidity and mortality 
were analyzed. 
Results
Mean age was 47 years(range 14-76), 81% were males, 34% required emergent 
surgery. Abscesses were more common in ALLO recipients, 38% versus 18% in MP 
recipients. MP patients required more often concomitant mitral valve replacement 
(34% versus 5%) compared with ALLO patients. Hospital mortality was 8%(n=11); 
9% ALLO (n=10), 3% MP (n=1).
During follow-up(mean 8 years, range 0-25 years) 33 patients died; 22 ALLO 
patients(24%) and 11 MP patients(21%). Fifteen-year survival was 59%±6% 
for ALLO patients and 66%±9% for MP patients. Seven patients developed late 
recurrent endocarditis; six ALLO and one MP(p=0.29). 
Overall fi fteen-year freedom from reoperation was 76%±9% for ALLO and 
93%±6% for MP (p=0.02). 
Conclusions
This retrospective study has shown that mechanical prostheses produce comparable 
mid-term results both in terms of survival and freedom recurrent infection. However, 
this is in combination with extensive excision of destructive tissue in a specifi c patient 
subset. Furthermore, allograft reoperation rates increase with time. The infl uence of 
the choice of a valve substitute on long-term results requires further study.
Key words: Aortic valve, replacement; Endocarditis; Heart valve, allograft; Heart 
valve, mechanical; Outcomes
Loes bw.indd   66 31-10-2007   14:40:42
Surgical Treatment Of Active Native Aortic Valve Endocarditis
67
Introduction
Active aortic valve endocarditis is a life threatening disease associated with 
considerable morbidity and mortality. Initial treatment of active endocarditis is 
antibiotic therapy. If medical treatment fails, in patients with signs of peripheral 
emboli or heart failure, in case of extensive endocarditis, or when a prosthetic valve is 
involved, surgery is indicated. Surgery remains challenging in this particular patient 
population that often presents with acute symptoms, deteriorating haemodynamics 
and destruction of the aortic or other adjacent structures.
According to the ACC/AHA guidelines for management of patients with heart valve 
disease, surgical treatment of active native aortic valve endocarditis(NVE) should 
preferably consist of valve repair because of the risk of infection of prosthetic 
materials.[1] Thus far, there are no fi rm specifi c recommendations for use of 
particular valve prosthesis for surgical treatment of active NVE besides the general 
criteria for aortic valve selection. Currently, two commonly used substitutes to 
replace the infected native aortic valve are allografts and mechanical prostheses.[2] 
In patients with active native aortic valve endocarditis allografts are a good option. 
Particularly when there is extensive destruction of the surrounding tissue, allografts 
can cover defects with preservation of the natural anatomy of the aortic valve and 
adjacent structures.[3] Furthermore, allograft patients do not require life-long 
anticoagulation and reinfection rate is low with a constant phase compared with 
mechanical prostheses and bioprostheses.[2] However, allografts have limited 
durability, which makes reoperation inevitable in the long-term, are not always 
readily available and implantation requires specifi c surgical training.
Mechanical prostheses, on the other hand, are designed to last a life time, are readily 
available and easier to implant. Furthermore, risk of endocarditis reinfection is 
reported to be very low.[4] On the downside, these valves are thrombogenic and 
require life-long anticoagulation with a high risk of bleeding and thrombo-embolic 
events.[5-7] 
It remains a matter of debate whether there is a preferred valve substitute for active 
native aortic valve endocarditis treatment. In this regard, outcome of patients who 
underwent aortic valve replacement in two centers with an allograft or a mechanical 
prosthesis for active native aortic valve endocarditis were analyzed.
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Material and methods
Patients
Between March 1980 and December 2002, 138 consecutive patients underwent aortic 
valve replacement for active NVE with allografts (n=106) or mechanical prostheses 
(n=32). Patients were operated by different surgeons at Erasmus University Medical 
Center Rotterdam, the Netherlands (n=86; 58 allografts, 28 mechanical prostheses) 
and by a single surgeon (MHY) at Harefi eld Hospital, United Kingdom (n=52; 48 
allografts, 4 mechanical prostheses).
For allograft patients who were operated in Rotterdam, information on patient 
characteristics, perioperative details and follow-up was obtained from the ongoing 
prospective cohort study.[8] For mechanical prosthesis patients, these data were 
collected retrospectively from hospital records, correspondence with treating 
physicians and through the civil registry. For all patients who were operated in 
Harefi eld, all patient data was collected retrospectively in a similar fashion.
Diagnosis of endocarditis was based on clinical criteria, including signs of fever, 
new or altering cardiac murmurs, positive blood cultures and echocardiographic 
fi ndings.[9] Endocarditis was considered active if patients underwent surgery before 
completing a 6 weeks course of antibiotic treatment.
Operative technique
All operations were performed on cardiopulmonary bypass with moderate 
hypothermia. In 2 Rotterdam patients circulatory arrest with deep hypothermia 
was needed because of ascending aorta and arch surgery.
Follow-up
Valve-related evens were defi ned according the guidelines for reporting morbidity 
and mortality after cardiac valvular operations.[10] The database was frozen on 
January 1st, 2006. Follow-up was 92.7% complete, ten patients had incomplete 
follow-up due to emigration.
Statistical analysis
For data analysis SPSS 12.0.1 for Windows (SPSS, Chicago, Illinois) was used. 
Continuous data are displayed as mean ± 1 SD and comparison between groups were 
made using the unpaired T-test or the Mann-Whitney U-test where appropriate. 
Discrete data are presented as proportions and compared using the Chi-Square Test 
or Fisher’s exact test. 
For each patient a propensity score for receiving either an allograft or a mechanical 
prosthesis was calculated. First, by means of univariate logistic regression variables 
were identifi ed that were potentially associated with valve substitute selection. 
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Variables with p<0.05 in the univariable analysis and variables that from a clinical 
point of view may be considered to affect prosthetic valve selection[1] were included 
in the multivariable model. 
Variables included in the model were: age at operation (continuous variable), women 
at childbearing age (defi ned as women aged <45 years at operation), surgical center, 
time period, left ventricular function (LVF, defi ned as good: ejection fraction >50%, 
impaired: ejection fraction 40-50% and moderate/bad: ejection fraction <40%), 
presence of abscesses, emergent surgery (<24hrs after diagnosis) and concomitant 
mitral valve replacement. The propensity score was used as a co-variable in logistic 
and Cox regression models that studied mortality after operation.
Univariable and multivariable logistic regression was used to determine factors 
associated with hospital mortality. The following factors were analyzed: age at 
operation, sex, women at childbearing age, New York Heart Association Class 
(defi ned as I, II, III IV, and cardiogenic shock NYHA V), preoperative creatinin level 
(micromoles/L), preoperative ventilation support, preoperative atrial fi brillation, LVF, 
emergent surgery, presence of abscesses, type of infection causing microorganism , 
concomitant procedures, valve substitute used, cardiopulmonary bypass time (CPB, 
in minutes) and propensity score. 
Cumulative survival, freedom from reoperation or reintervention or freedom from 
valve-related events, including reoperations, were analyzed using the Kaplan-Meier 
method. The Tarone-Ware test was used to compare Kaplan-Meier curves correcting 
for signifi cant difference in follow-up time between allograft and mechanical 
prosthesis patients. Age-matched survival in the general population was calculated 
using the Dutch population life tables. (http://statline.cbs.nl/).
We used the life tables-method to calculate the hazard rate of structural failure for 
allografts over time by subdividing the follow-up period after operation into fi ve 
year intervals.
The Cox proportional hazards model was used for univariable and multivariable 
(stepwise backward method) analysis of time-related events. The following factors 
were considered: age at operation, sex, women at childbearing age, surgical center, 
type of infection causing microorganism, presence of atrial fi brillation preoperatively, 
LVF, presence of abscesses, urgency of surgery, valve substitute used, concomitant 
procedures, CPB time and propensity score. A p-value ≤ 0.05 was considered 
statistically signifi cant. All testing was two-sided.
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Results
Preoperative patient characteristics by implanted valve substitute are shown in 
Table 1. 
Table 2 displays perioperative details. Details on the 106 implanted allografts are 
displayed in Table 3 and causative microorganisms are shown in Table 4.
Valve selection
After univariable analysis presence of root abscesses showed a trend towards allograft 
selection (OR 2.6, 95% CI 1.0-6.9; p=0.05) whilst surgical center Rotterdam 
(OR 5.8, 95% CI 1.9-17.7; p=0.002), concomitant mitral valve replacement (OR 
10.6, 95% CI 3.3-33.6; p<0.001) and operation performed before 1990 (HR 
8.7; 95% CI 3.6-21.1; p<0.001) were potential factors for selecting mechanical 
Table 1. Preoperative details
Allograft
(n=106)
Mechanical prosthesis 
(n=32)
Mean age (years (SD; range)) 47 (14-76) 46 (16-75)
Male gender 79% (n=84) 88% (n=28)
Women of childbearing age 8% (n=8) 3% (n=1)
Surgical centera
Erasmus MC Rotterdam
Harefi eld Hospital
55% (n=58)
45% (n=48)
88% (n=28)
12% (n=4)$
Systolic LVF (n=94)
Good
Impaired
Moderate/bad
72% (n=48)
22% (n=15)
6% (n=4)
 74% (n=20)
            19% (n=5)
 7% (n=2)
Preoperative rhythm (n=134)
Sinus rhythm
Atrial fi brillation
Other
84% (n=87)
6% (n=6)
 9% (n=10)
84% (n=26)
6% (n=2)
           10% (n=3)
Creatinin (μmol/L (range) 145 (49-900) 138 (63-364)
NYHA class (n=136)
I
II
III
IV/V
16% (n=17)
13% (n=14)
27% (n=28)
43% (n=45)
-
9% (n=3)
34% (n=11)
57% (n=18)
Ventilation support 8% (n=9) -
Antibiotic treatment 89% (n=94) 91% (n=29)
Type operation (n=135)
Emergent (< 24hrs)
Urgenta
Elective
39% (n=40)
60% (n=62)
1% (n=1)
22% (n=7)
78% (n=25)
-
ap<0.05 allograft versus mechanical prosthesis
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prostheses. After multivariable analysis surgical center (OR 6.1, 95% CI 1.8-20.4; 
p=0.03) and concomitant mitral valve replacement (OR 11.3, 95% CI 3.2-39.8; 
p<0.001) remained signifi cant factors for mechanical prosthesis selection.
Table 2. Perioperative data
Allograft
(n=106)
Mechanical prosthesis
(n=32)
Operative fi ndingsa
Abscesses/fi stulab
Destroyed cusps
Vegetations
38% (n=40)
34% (n=36)
74% (n=78)
          18%  (n=6)
 56% (n=18)
 78% (n=25)
CPB timec(min, (range)) 155 (58-483) 150 (60-375)
Cross clamp time (min, (range)) 117 (25-326) 114 (43-192)
Circulatory arrest (min) 14,16 (n=2) -
Concomitant procedures
CABG
Mitral valve surgery
     Mitral valve replacementb
     Mitral valve repair
Extended root
Otherd
3% (n=3)
17% (n=18)
 5% (n=5)
 12% (n=13)
2% (n=2)
8% (n=8)
-
  34% (n=11) 
  34% (n=11)
-
-
6% (n=2)
Complications
Rethoracotomy for bleeding
Pacemaker
6% (n=6)
5% (n=5)
13% (n=4)
6% (n=2)
Hospital death 9.4% (n=10) 3% (n=1)
aOverlapping categories
b<0.05 allograft versus mechanical prosthesis 
cCPB= cardiopulmonary bypass time 
dIncluding VSD closure, covering fi stula with pericardial patches
Table 3. Allograft properties
Rotterdam
(n=58)
Harefi eld
(n=48)
p-value
Type allograft 
Pulmonary
Aortic
2% (n=1)
98% (n=57)
15% (n=7)
85% (n=41)
0.01
Type donor 
Heart beatinga
Non heart beating
67% (n=39)
33% (n=19)
79% (n=38)
21% (n=10)
0.17
Preservation method
Cryopreserved
Antibiotic-sterilized 
Fresh
Antibiotic-sterilized 
98% (n=57)
84% (n=49)
2% (n=1)
-
21% (n=10)
100% (n=10)
79% (n=38)
47% (n=18)
<0.001
0.21
<0.001
0.35
aBrain death multi organ donors or heart transplant recipients
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Age at operation, sex, women in the childbearing age, NYHA class, stroke in history, 
preoperative renal failure, causing microorganism, preexisting atrial fi brillation, and 
urgency of surgery had no effect on valve selection.
Hospital mortality
Overall hospital mortality was 8% (n=11).Ten allograft patients (9%) and 1 
mechanical prosthesis patient died (3%) (p=0.25). Three allograft patients died in 
theatre; one died of persistent bleeding, and two died of heart failure. 
Three allograft patients died of intracranial haemorrhage 8, 9 and 10 days 
postoperative. One allograft patient died of a stroke 48 days postoperative and 3 
allograft patients died of multi organ failure on postoperative days 5, 8, and 11. The 
mechanical prosthesis patient died of heart failure 1 day postoperative.
Potential risk factors for hospital mortality were female gender (OR 4.2, 95% CI 
1.2-5.1; p=0.03), endocarditis caused by S. aureus (OR 5.6, 95% CI 1.2-25.2; 
p=0.03), preoperative increased creatinin (OR 1.01; 95% CI 1.01-1.02; p<0.001), 
NYHA class IV (OR 6.1, 95% CI 1.3-29.3; p=0.02), emergent surgery (OR 3.8, 
1.05-13.7; p=0.04) and longer perfusion time (OR 1.01 95% CI 1.01-1.02; p=0.002). 
After multivariable analysis preoperative increased creatinin (OR 1.01 95% CI 
1-003-1.02; p=0.006) and longer perfusion time (OR 1.01, 95% CI 1.003-1.02; 
p=0.01) were risk factors for hospital mortality. The propensity score had no effect 
on hospital mortality.
Follow-up and late mortality
Mean follow-up was 8.8±6.5 years, (max follow-up 25 years, 1223 patient years). 
Mean follow-up for allograft patients was 7.7±5.6 years (max follow-up 25 
Table 4. Causative microorganisms
Allograft
(n=106)
Mechanical prosthesis
(n=32)
Streptococcia
S.viridans
Pneumococcia
Enterococci
S. aureus
CNSb
HACEKc
Culture negative
Other
44% (n=47)
13% (n=14)
7% (n=7)
3% (n=3)
7% (n=7)
10% (n=9)
1% (n=1)
16% (n=17)
1% (n=1)
22% (n=7)
22% (n=7)
-
13% (n=4)
13% (n=4)
-
 6% (n=2)
19% (n=6)
 6% (n=2)
ap<0.05 allograft versus mechanical prosthesis
bCNS = Coagulase negative staphylococci,
cHACEK = Haemophilus species (H parainfl uenzae, H aphrophilus, and H paraphrophilus), Actinobacillus 
actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella species
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years, 820 patient years). For mechanical prosthesis patients mean follow-up was 
12.5±7.8 years (max follow-up 24 years, 403 patient years). Mean follow-up time 
was signifi cantly different between the 2 groups (p<0.001).
During follow-up 33 patients died (Linearized occurrence rate LOR 2.7%/patient 
year); 22 allograft patients (LOR 2.7%/patient year) and 11 mechanical prosthesis 
patients (LOR 2.7%/patient year).
Causes of death in allograft patients were recurrent endocarditis (n=3), intracranial 
haemorrhage (n=1) and sudden death (n=1), non valve-related death (n=17). Causes 
of death in mechanical prosthesis patients were sudden death (n=2) and non valve-
related death (n=9).
Figure 1 shows survival for the valve substitute groups compared with 47-year old 
males in the general Dutch population. Overall 1 year survival was 89.6%±3.0% 
and 15 years survival was 61.3%±5.2%. For allograft patients 1 year survival was 
89.6%±3.0% and 15 years survival was 58.7%±6.6%. For Rotterdam allograft 
patients 1 year survival was 91.4%±3.7% and for Harefi eld patients 87.3%±4.9% 
(p=0.43). Fifteen year survival for Rotterdam patients receiving an allograft was 
64.3%±8.2% and for Harefi eld patients 53.8%±10.0% (p=0.76).
For mechanical prosthesis patients 1 year survival was 93.8%±4.3% and 15 years 
survival was 65.6%±9%. For Rotterdam mechanical prosthesis patients 1 year 
survival was 92.9%±4.9% and for Harefi eld patients 75.0%±21.7% (p=0.55). 
Fifteen year survival for Rotterdam mechanical prosthesis patients was 64.2%±9.7% 
and for Harefi eld patients 75.0%±21.7% (p=0.74).
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Figure 1. Survival after active NVE per valve substitute  compared with the general age-matched 
Dutch population. ALLO=Allograft, MP=Mechanical prosthesis
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Preexisting atrial fi brillation (HR 4.0, 95% CI 1.4-11.4; p=0.01) and older patient 
age (HR 1.05, 95% CI 1.02-10.7; p<0.001) were potential risk factors for increased 
late mortality. No other factors associated with increased late mortality. 
After multivariable analysis preexisting atrial fi brillation (HR 4.2, 95% CI 
1.4-12.6; p=0.01) and older patient age (HR 1.04, 95% CI 1.02-1.07; p=0.001) 
were signifi cant risk factors for increased late mortality, even after including the 
propensity score in the model.
No survival differences were observed for allograft patients with root abscesses 
compared with patients in whom root abscesses were absent (p=0.34). Also, when 
comparing these patients between the two centers, no survival differences were 
observed (p=0.30).
Recurrent endocarditis 
Six allograft patients (LOR 0.73%/patient year) and one mechanical prosthesis 
patient (LOR 0.25%/patient year) had recurrent endocarditis, all late episodes 
(range 1.5-13.5 years postoperative). Of these patients, 4 allograft patients 
underwent reoperation and survived. Two allograft patients and one mechanical 
prosthesis patient received only antibiotic treatment and died before reoperation 
could be performed. 
One year freedom from recurrent endocarditis was 100% (Figure 2). Fifteen years 
freedom from recurrent endocarditis was 89.1%±4.3%. For allograft patients 15 
years freedom from recurrent endocarditis was 85.9%±6.5% and for mechanical 
prosthesis patients 94.7%±5.1% (p=0.29). No variables were identifi ed to be 
associated with recurrent endocarditis.
Reoperation 
Twelve allograft (LOR 1.5%/patient year) and 1 mechanical prosthesis patient 
required reoperation. Reoperative mortality was 9% for allograft patients (n=1) 
and 0% for mechanical prosthesis patients. Reoperation causes for allograft patients 
were structural failure (n=5, LOR 0.61%/patient year), non-structural failure (n=2, 
LOR 0.24%/patient year) and endocarditis (n=5, LOR 0.61%/patient year), of 
which one patient had a persistent endocarditis. The mechanical prosthesis patient 
required reoperation due to pannus overgrowth.
The hazard rate of structural failure for allografts increased with time since 
operation: from 0.23%/patient year in the fi rst 5 years after operation to 0.82%/
patient year in 5-10 years after operation and 1.0%/patient year in 10-15 years after 
operation to fi nally 6.7%/patient year at 15-20 years after operation.
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Overall 15-year freedom from reoperation was 81.4%±6.2% (Figure 3); for 
allograft patients 75.8%±9.0% and for mechanical prosthesis patients 92.9%±6.9% 
(p=0.02). The only potential risk factor for increased reoperation rate was allograft 
use (HR 10.7, 95% CI 1.3-87.3, p=0.03).
Other valve-related events
One allograft patient, on anticoagulation medication, had an intracranial 
haemorrhage during follow-up (LOR 0.12%/patient year). No valve thrombosis 
or thrombo-embolic complications were observed in both groups. Overall 15 years 
valve-related-event-free-follow-up was 72.4%±6.5%, for allografts 67.3%±8.8% 
and 84.3%±8.8% for mechanical prostheses (p=0.06, Figure 4).
Comments
This study of a large cohort of patients requiring operation for active NVE 
provides important insights into infl uence of valve substitute choice on mid term 
survival, infection recurrence and reoperation. Early and late survival and recurrent 
endocarditis rates after aortic valve replacement for active NVE are comparable 
for allografts and mechanical prostheses, while over time allograft reoperation risk 
increases.
Valve selection 
Selecting a valve substitute in active endocarditis seems in our study dependent 
on patient-related factors. A trend towards allograft selection as the preferable 
valve substitute in patients with root abscesses was observed. It is confi rmed by 
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Figure 2. Freedom from recurrent endocarditis. ALLO=Allograft, MP=Mechanical prosthesis
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others that extensive destruction of the left ventricular outfl ow tract and adjacent 
structures is one of the indications for allograft implanting in active NVE.[3,11] 
At Erasmus University Medical Center Rotterdam the decision for using allografts 
or mechanical prostheses in active endocarditis nowadays depends strongly on 
resulting anatomy after extensive debridement and excision of infected material 
or abscesses, fi stula or annulus involvement. In the 1990’s allografts were almost 
exclusively used in any endocarditis type, regardless of the lesion extent. This is 
0
0.2
0.4
0.6
0.8
1
0 2 4 6 8 10 12 14 16
Time(years)
%
 F
re
ed
o
m
Mechanical prosthesis
Allograft
Nr at risk:
ALLO      90              76               53               42               26               16              11              6
MP          29               27               23               22               19               15              14             11 
MP vs Hg
Tarone Ware-test 
p=0.02
Figure  3. Freedom from reoperation. ALLO=Allograft, MP=Mechanical prosthesis
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Figure 4. Freedom from valve-related events. ALLO=Allograft, MP=Mechanical prosthesis
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also refl ected by the co-variable time period in our valve selection propensity score 
analyses. Before 1990 hardly any allograft was inserted and mechanical prostheses 
were valve substitutes of choice, simply because of limited experience with allografts 
and their scarce availability. 
Furthermore, mechanical prostheses were more often used in our study patients, in 
whom active NVE destroyed the mitral valve, necessitating mitral valve replacement, 
thus warranting lifelong anticoagulation. Mechanical prostheses were implanted 
after extensive debridement and excision of infected material.
Although patient age is important for valve selection according the ACC/AHA 
guidelines[1], in our study patients it did not play a role. Moreover, our patients were 
relatively young patients with mean age of 47 years and according to the guidelines in 
these patients mechanical prostheses are the recommended valve substitute of choice, 
biological prostheses merely recommended in patients older than 65 years.[1] 
Early mortality 
Surgery for active NVE remains challenging with high operative mortality and 
the necessity of early surgery being reported.[2,12-16] Overall hospital mortality 
in this study was 8%. This is line with mortality rates described in the literature 
(9%-31%).[4,11,14,15] 
No signifi cant difference in early mortality between allograft patients and mechanical 
prosthesis patients was observed in the present report. Other factors determined in 
this study that potentially infl uenced early mortality were preoperative increased 
creatinin, NYHA class IV, emergent surgery, longer perfusion time and endocarditis 
caused by S. aureus. These variables were also reported by other authors to infl uence 
early mortality in active NVE.[2,4,13,15]
Late mortality 
Fifteen years survival was 58.7% for allograft patients and 65.6% for mechanical 
prosthesis patients, which is comparable to other reports.[14,17] Furthermore, only 
seven patients died of valve-related causes (5 allograft patients and 2 mechanical 
prosthesis patients). The majority of our study patients died of non-valve related 
causes and only three allograft patients died of recurrent endocarditis.
Atrial fi brillation and older patient age were associated with increased late mortality 
risk, refl ecting once again that suboptimal cardiac function and ageing play an 
important role in predicting late survival rates. Although there was a trend towards 
allograft selection in patients with root abscesses, and patients with abscesses may 
be more severely ill and could have adverse outcome, no differences in survival were 
observed between patients with presence of abscesses and without. Furthermore, no 
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differences in outcome were observed in these allograft patients between the two 
centers. Other underlying co-morbidities of patients may play a more profound role 
in outcome. 
Recurrent endocarditis
Freedom from recurrent endocarditis after active NVE was approximately 90% and 
was comparable for both valve substitutes and is comparable to other series.[15,18] 
When our linearized rate of recurrent endocarditis for mechanical prostheses and 
allografts are compared with other observational studies on these valve substitutes, 
our results are in range with these reports.[5,13] The recurrent infection rate was 
lower for mechanical prostheses than for allografts in our study, and although this 
difference was not signifi cant this is observed by other authors as well.[11,19] 
Furthermore, Haydock and colleagues found a constant phase of recurrent 
endocarditis for allografts in contrast to an early peaking phase for mechanical 
prostheses.[2] In contrast, in our study there was no early peaking phase of 
recurrent endocarditis in the fi rst year postoperative for the mechanical prosthesis 
(0%/patient year) and only one mechanical prosthesis patient had an episode of 
recurrent endocarditis. For allografts the hazard rate for recurrent endocarditis in 
the fi rst fi ve years after operation was 0.23%/patient year and increased over time 
to 6.7%/patient year. Although this seems to be signifi cant it may be biased due to 
the small number of events that are observed and may be due to chance. 
Reoperations 
Allograft reoperations are perceived to be complex procedures potentially carrying 
high mortality and morbidity risk. In this series low reoperative mortality for 
allografts was found, a good result compared with other reports.[20,21] Two main 
causes for reoperation in our study were recurrent endocarditis and structural 
failure. Reoperation rates for recurrent endocarditis were 0.61%/patient year for 
allografts and 0% for mechanical prostheses. McGriffi n and colleagues[22] studied 
that patients who had active NVE are more prone to have another episode of 
endocarditis. In the study of Tyers and colleagues, endocarditis was an important 
reoperation cause in mechanical prosthesis patients[23] and O’Brien and colleagues 
showed low reoperation rate for recurrent endocarditis after allograft implantation.
[24] Although these two studies describe an incidence of reoperation for recurrent 
endocarditis favoring the allograft, reoperation rates for any cause are much higher 
in allograft patients than in mechanical prosthesis patients.[13,20,24-27] The 
present study confi rms these results, by showing that reoperation risk for allografts 
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increases with time since operation, and is mainly determined by the increasing 
hazard of structural failure over time.
Yankah and colleagues describe also a high reoperation rate for structural failure 
in allograft patients, and especially in patients with undersized allografts.[3] In 
contradiction, in a recent report from our group a larger allograft diameter was an 
independent predictor for structural valve deterioration.[25] 
Younger patient age is another risk factor for reoperation mentioned in the 
literature[2,13], which was not a signifi cant factor in this report. This might be 
due to the small number of structural valve deterioration reoperations observed 
and limited mean follow-up duration of the study. Careful follow-up of allograft 
patients over time will prevent emergent reoperations in decompensated patients 
with degenerated allografts. Elective reoperations can be performed with good 
results and low mortality.[25] So, particular in active NVE patients with relatively 
long life expectancy reoperation is the most important limitation of allograft use, 
and should be considered when selecting a valve substitute.
Other valve-related complications 
Bleeding complications during follow-up were rare in our study; only one allograft 
patient on anticoagulation medication had an intracranial haemorrhage. No events 
of valve thrombosis or thrombo-embolism were observed in our mechanical and 
allograft recipients. The low occurrence rates of valve-related events is in agreement 
with other reports.[14,17] 
Limitations
The partially retrospective nature of study may have lead to underestimation of 
valve-related events during follow-up, in particular for mechanical prosthesis 
patients. Moreover, follow-up is slightly over 92% complete, leaving possible valve-
related events during follow-up of approximately 8% of patients unresolved, which 
might have infl uenced our results.
This study is a combined series involving two centers with different policies for 
allograft and mechanical prosthesis use, and may not apply to other centers.
Furthermore, question remains whether all patients were eligible for an allograft 
or a mechanical prosthesis and vice versa. Patient selection bias can occur due to 
different treatment policies and due to the fact that implanting allografts remains 
diffi cult and requires specifi c surgical skills.
On the other hand, not all allograft patients could have been treated with a 
mechanical prosthesis, especially those with extensive destruction of the aortic root. 
A case controlled study or a randomized trial could give a better insight in which 
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valve best to implant in active aortic valve endocarditis, although the last mentioned 
is hardly achievable. Finally, timing of surgery after antibiotic treatment was not 
profoundly analyzed in this study and this may have an infl uence on the outcomes 
we observed. 
Conclusions
Our study indicates that in this two center study both the allografts and mechanical 
prostheses provide a good solution in active native aortic valve endocarditis in 
terms of survival and recurrent endocarditis. However, when it comes to inserting a 
mechanical prosthesis in active endocarditis, this should be combined with extensive 
excision of infected tissue and done in patients without presence of aortic root 
abscesses. More reoperations for structural valve deterioration can be expected for 
the allograft in the second decade after operation given the increasing reoperation 
hazard with time. Whether the choice for a particular valve substitute in active aortic 
valve endocarditis has an infl uence on long-term results requires further study.
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REPLACEMENT IN YOUNG ADULT PATIENTS 
WITH CONGENITAL AORTIC VALVE DISEASE
Autograft or Allograft Aortic Valve Replacement in Young Adult Patients with 
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ABSTRACT
Aims
We analyzed outcome of young adults with congenital aortic valve disease who 
underwent allograft or autograft aortic valve or root replacement in our institution 
and evaluated whether there is a preference for either valve substitute.
Methods and results
Between 1987 and 2007, 169 consecutive patients with congenital aortic valve 
disease aged 16-55 years, participating in our ongoing prospective follow-up study, 
underwent 63 autograft and 106 allograft aortic valve replacements. Mean age 
was 35 years(SD 10.8), 71% were males. Etiology was 71% bicuspid valve(BV), 
14% other congenital, and 15% BV endocarditis. 22% underwent previous cardiac 
surgery; 11% had an ascending aorta aneurysm. Two patients died in hospital. 
During follow-up 6 more patients died and 45 patients required valve-related 
reoperations. Thirteen-year survival was 97% for autograft and 93% for allograft 
recipients; 13-year freedom from valve-related reoperation was 63% for autograft 
patients and 69% for allograft patients. 
Conclusions
In patients with congenital aortic valve disease autograft and allograft AVR show 
comparable satisfactory early and long-term results, with the increasing reoperation 
risk in the second decade after operation remaining a major concern.
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Introduction
Prosthetic valve selection for patients who require aortic valve replacement remains 
a delicate and complicated topic of discussion, as evidenced by the major criteria 
for aortic valve selection in ACC/AHA 2006 Guidelines for the management of 
patients with valvular heart disease.[1] For young adult patients with congenital 
aortic valve stenosis this is particularly true. The guidelines state that “although the 
Ross operation, homograft, heterograft, and valve repair each appear to offer an 
attractive alternative to a mechanical valve for those with a relative contraindication 
to warfarin for anticoagulation (e.g., athletes or women desiring pregnancy), in 
the absence of long-term results, it is not believed that the indications for surgery 
with the Ross operation, heterograft, or homograft differ from those for mechanical 
valve replacement at this time”.[1] 
In our own institution we started using autografts and allografts for aortic valve 
replacement in the late eighties, assuming that their durability would be better 
compared to bioprostheses, their haemodynamic profi le superior to mechanical 
prostheses and bioprostheses, and because they offer (in particular young adult) 
patients the option of an active life without the limitations of anticoagulation that 
would be required after implantation of a mechanical prosthesis. We systematically 
and carefully followed patients over time[2-4] and are now able to present reliable 
observations on valve performance and patient outcome well into the second decade 
after operation. 
The aim of this study is to analyze the clinical results of aortic valve and root 
replacement with autografts versus allografts in young adult patients with congenital 
aortic valve disease that are participating in our center’s prospective cohort study 
and assess whether there is a preference for one of these valve substitutes in this 
particular patient population.
Materials and Methods
Patients
Between April 1987 and January 2007, 499 consecutive patients underwent 
autograft or allograft aortic valve or root replacement at Erasmus University Medical 
Center Rotterdam. All patients who received an autograft or allograft in aortic 
position in our center are enrolled in our ongoing prospective follow-up study[2-4]. 
Institutional Review Board approval was obtained for this prospective follow-up 
study; the Institutional Review Board waived informed consent. 
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For the purpose of this study we selected out of the 499 patients those patients with 
congenital aortic valve disease, no previous aortic valve replacement, and an age 
at operation between 16 and 55 years. Congenital aortic valve disease was defi ned 
as: bicuspid aortic valve or discrete subaortic obstruction, resulting in subvalvular 
or valvular aortic stenosis, aortic regurgitation, or a prolapse of one of the aortic 
cusps into a ventricular septal defect causing aortic regurgitation.[1] The enrollment 
was based on the presence of congenital aortic valve disease, either determined on 
preoperative echocardiography or based on the abnormalities seen at operation.
A total of 330 patients were excluded. Of these patients 70 patients were younger 
than 16 years of age and 106 were older than 55 years. These patients were excluded 
Table 1. Preoperative patient characteristics
Autograft n=63 Allograft n=106 p-value
Mean age (years (SD; range)) 29 (9; 16-52) 38 (10; 16-55)  <0.001
Male/female ratio 35/28 85/21 0.001
Prior cardiac surgery*
Left ventricular outfl ow tract
Coarctectomy
27% (n=17)
22% (n=14)
5% (n=3)
20% (n=21)
7% (n=7)
9% (n=10)
0.28
0.003
0.27
Prior aortic valve balloon dilatation 8% (n=5) 3% (n=3) NS
Actual diagnosis
Aortic valve regurgitation (AR)
Aortic valve stenosis (AS)
AR + AS
AS + Subvalvular AS
22% (n=14)
38% (n=24)
35% (n=22)
5% (n=3)
39% (n=41)
29% (n=31)
31% (n=33)
1% (n=1)
0.03
0.24
0.61
0.11
Etiology
Bicuspid valve
Other congenital
Endocarditis on bicuspid valve
 Active endocarditis
78% (n=49)
19% (n=12)
3% (n=2)
-
67% (n=71)
11% (n=12)
22% (n=23)
11% 
0.14
0.16
0.005
0.006
Aneurysm ascending aorta 6% (n=4) 13% (n=14) 0.17
Sinus rhythm 100% (n=63) 97% (n=103) 0.18
Creatinin (μmol/L, (SD;range)) 72 (16; 38-121) 92 (36; 39-371) <0.001
Systolic LVF (1 missing)
Good
Impaired
91% (n=57)
9% (n=5)
78% (n=83)
22% (n=23)
0.04
0.02
NYHA class 
I/II
III/IV
80% (n=50)
20% (n=13)
70% (n=74)
30% (n=32)
0.18
0.18
Type operation
Emergency
Urgent
Elective
-
10% (n=6)
90% (n=57)
4% (n=4)
18% (n=19)
77% (n=83)
0.12
0.14
0.04
Ventilatory support - 2% (n=2) 0.27
LVF = left ventricular function measured by angiography or 2D-echocardiography, NYHA class = New York Heart 
Association classifi cation, * = overlapping categories
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because they did not fi t the age criteria. Furthermore, 154 patients were between 
16 and 55 years of age, but were excluded because these patients required surgery 
for another etiology than congenital aortic valve disease. Other etiologies were 
rheumatic disease (n=21), endocarditis (n=44), senile degeneration of a tricuspid 
valve (n=20), aneurysm (n=15), dissection (n=13) or reoperation (n=41). 
This selection resulted in 169 patients: 63 autograft patients and 106 allograft 
patients. Preoperative patient characteristics are displayed in Table 1. Overall mean 
patient age was 35.0 years (SD 10, range 16-55 years).
Operation
Root replacement was performed as a freestanding root with reimplantation of the 
coronary arteries in 61 autograft patients and 66 allograft patients. In 2 autograft 
patients an inclusion cylinder aortic root replacement was done [5] and 40 allograft 
patients underwent subcoronary allograft implantation.[6] The autograft or allograft 
root was placed in the left ventricular outfl ow tract and annulus with a short rim of 
right ventricular muscle, which was kept to a minimum and no measures were taken 
to reinforce the aortic root or sinotubular junction. Either continuous or interrupted 
sutures were used for the proximal anastomosis, depending on the surgeon’s 
preference. Initially in this series the autograft was placed on the annulus, in more 
recent years particular attention was paid to place the autograft inside the annulus. 
During the autograft procedure reconstruction of the right ventricular outfl ow tract 
Table 2a. Characteristics of allografts used in the RVOT at pulmonary autograft procedure
RVOT allograft
n=63
Type allograft 
Pulmonary
Aortic
100% (n=63)
-
Size allograft (mm)
Mean (SD; range)
≤ 24 mm
>24 mm
25 (2; 19-30)
63% (n=40)
37% (n=23)
Type donor (4 missing)
Heart beating
Non heart beating
Domino
44% (n=28)
54% (n=34)
2% (n=1)
Donor age
Mean (SD; range) 43 (11;10-59)
Donor sex (7 missing) 42 male/ 21 female
Preservation method
Cryopreserved
Fresh
100% (n=63)
-
Loes bw.indd   87 31-10-2007   14:40:47
Chapter 5
88
(RVOT) was done using an allograft. Details on these allografts are displayed in 
Table 2a and Table 2b. Surgical procedures were performed on cardiopulmonary 
bypass with moderate hypothermia. Crystalloid cardioplegia and topical cooling 
were used for myocardial protection.
Follow-up
All patients who received an autograft or allograft at Erasmus MC are followed 
prospectively by annual telephone interviews and through visits to their 
cardiologist. Echocardiographic follow-up is obtained at 6 months postoperative, 
1 year postoperative and thereafter biennially by means of serial standardized 
echocardiography.[2-4] Valve-related complications were defi ned according to 
the 1996 guidelines for reporting morbidity and mortality after cardiac valvular 
operations.[7] The mode of autograft and allograft failure was determined at time 
of reoperation or death. 
The study database was frozen for analysis on April 1st, 2007. Follow-up was 96.5% 
complete.[8] Overall median follow-up duration was 10.1 years (interquartile range 
6.9 years), with total follow-up of 1743 patient years, for autograft patient mean 
follow-up was 10.3 years (SD 3.8, range 0-18.4 years) with 650 patient years and 
for allograft patients mean follow-up was 10.3 years (SD 4.9, range 0.1-19.8 years) 
with 1093 patient years. 
Table 2b. Allograft characteristics
Allograft n=106
Type allograft 
Pulmonary
Aortic
2% (n=2)
98% (n=104)
Size allograft (mm)
Mean (SD; range)
≤ 24 mm
>24 mm
23 (2; 20-28)
80% (n=85)
20% (n=21)
Type donor (4 missing)
Heart beating
Non heart beating
Domino
51% (n=54)
31% (n=33)
14% (n=15)
Donor age
Mean (SD; range) 40 (12; 15-62)
Donor sex (7 missing) 65 male/ 34 female
Preservation method
Cryopreserved
Fresh
96% (n=102)
4% (n=4)
Loes bw.indd   88 31-10-2007   14:40:47
Autograft Or Allograft AVR in Congenital Aortic Valve Disease
89
Statistical methods
Continuous data are presented as mean ± 1 standard deviation, and compared with 
the unpaired T-test or the Mann-Whitney U-test. Categorical data are presented 
as proportions, and compared with the Fisher’s exact test or the Chi-Square test. 
To account for the infl ation of the experiment wise Type I error due to multiple 
testing we used the Bonferroni post-hoc test in case of comparison of more than 2 
categories.
Univariable logistic regression was used to determine factors associated with the 
different valve substitute groups. The following factors were analyzed: age at 
operation (continuous variable expressed in years), sex, previous surgery on the left 
ventricular outfl ow tract (LVOT), New York Heart Association Class (defi ned as I, 
II, III and IV), preoperative creatinin level (micromoles/L), preoperative ventilation 
support, abnormal cardiac rhythm preoperative (other preoperative rhythm than 
sinus rhythm), left ventricular function (defi ned qualitatively as good or impaired 
on either angiography or echocardiography), active endocarditis (operated on 
before completing a standard course of antibiotics) and preoperative haemodynamic 
diagnosis. 
Cumulative survival and freedom from reoperation or reintervention were analyzed 
using the Kaplan-Meier method. Survival curves were compared using the Log-
rank test. Univariable Cox regression was used for analysis of time-related events. 
The following factors were analyzed as potential risk factors for reoperation for 
structural failure:
Patient age, gender, previous cardiac surgery, endocarditis as the etiology for 
operation and allograft characteristics (as mentioned in Table 2).
Age-matched survival in the general population was calculated using the Dutch 
population life tables. (http://statline.cbs.nl/).A p-value of ≤ 0.05 was considered 
statistical signifi cant. All testing was performed 2-sided. 
For all analyses SPSS 12.0 for Windows statistical software (SPSS, Chicago, Ill) was 
used. 
Using Egret, the incidence of structural valve deterioration requiring reoperation 
was described by a Weibull curve, which is a generalization of the exponential 
distribution that accommodates a changing risk over time.[9,10] 
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Results
Valve selection
Patients who received an autograft were younger at the time of operation (OR 1.09, 
95% CI 1.06-1.14; p<0.001), were more often females (OR 3.2, 95% CI 1.6-6.5; 
p=0.001), had more previous surgery on the LVOT (OR 4.0, 95% CI 1.5-10.7; 
p=0.005), underwent more commonly elective surgery (OR 2.6, 95% CI 1.01-6.6; 
p=0.05) and had a good preoperative left ventricular function (OR 2.6, 95% CI 
1.01-6.9; p=0.05). On the other hand, endocarditis on a bicuspid valve (OR 8.5, 
95% CI 1.9-37.2; p=0.005), increased preoperative serum creatinin level (OR 1.05, 
1.03-1.08; p<0.001) and aortic regurgitation as the haemodynamic diagnosis (OR 
2.2., 95% CI 1.1-4.5; p=0.03) were more common in allograft recipients.
Two allograft patients received a pulmonary allograft in the aortic position (see 
Table 2b). One of the patients required a reoperation within 2 weeks after initial 
implantation of the pulmonary allograft and received a new aortic allograft. Six 
Table 3. Perioperative data
Autograft n=63 Allograft n=106 p-value
Concomitant procedures*
CABG (planned)
CABG (unplanned)
Replacement ascending aorta
LVOT enlargement
Mitral valve surgery
Tailoring ascending aorta
Closure VSD
-
3% (n=2)
1% (n=1)
1% (n=1)
1% (n=1)
1% (n=1)
-
8% (n=8)
3% (n=3)
11% (n=12)
3% (n=3)
6% (n=6)
2% (n=2)
1% (n=1)
0.04
0.90
0.02
0.61
0.20
0.90
0.44
Aortic cross clamp time (min (SD; range)) 145 (30; 90-225) 123 (29; 68-217) <0.001
CPB time (min (SD; range)) 206 (76; 114-685) 165 (42; 79-344) <0.001
Circulatory arrest 2% (n=1) 4% (n=4) 0.42
Bleeding requiring reoperation 18% (n=11) 7% (n=7) 0.02
Permanent pacemaker for AV block - 2% (n=2) 0.28
Reoperation paravalvular leak - 2% (n=2)
Stroke - 1% (n=1) 0.44
Perioperative myocardial infarction 2% (n=2) 2% (n=2) 0.59
Hospital death 3.2% (n=2) - 0.07
Postoperative hospital stay (days)
Mean (SD)
Median
Range
11 (4)
10
6-39
13 (10)
10
6-56
0.07
CABG= coronary artery bypass grafting, LVOT = left ventricular outfl ow tract, VSD = ventricular septal defect, 
CPB = cardiopulmonary bypass, SD = standard deviation, min = minutes, AV = atrioventricular, * = overlapping 
categories
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years after this allograft implantation this patient required another reoperation and 
received a mechanical prosthesis. This patient is alive today.
The other pulmonary allograft patients required a reoperation 6 years after allograft 
implantation. Unfortunately, this patient died 3 years after the reoperation due to 
an intracerebral bleeding.
Early morbidity and mortality
Perioperative details are displayed in Table 3. Two patients, both autograft recipients, 
died in hospital (3.2%). One patient died during a long and complicated autograft 
procedure due to low output failure (see details below). The other autograft patient 
died on the 13th postoperative day due to mediastinitis and sepsis. 
Five patients, two autograft patients and three allograft patients (all root 
replacements), required coronary artery bypass grafting due to procedural 
complications. Furthermore, 11 autograft patients required a rethoracotomy for 
persistent bleeding. Circulatory arrest was employed in 4 allograft root replacement 
patients because additional replacement of the ascending aorta with a vascular 
prosthesis was required, and in 1 autograft patient because the ascending aorta 
perforated during sternotomy.
Follow-up and survival
During follow-up 6 more patients died (3.6%), all allograft recipients (linearized 
occurrence rate (LOR) 0.55%/patient year). Causes of death were: Stroke (n=1), 
sudden unexplained death (n=5) and non-valve related death (n=1)
Overall cumulative survival was 94.6%±2.1 at 13 years, for autograft recipients 
96.8%±2.2% and 92.7%±3.3% for allograft recipients (p=0.45). Figure 1 shows 
overall survival for autograft and allograft recipients compared with 35-year old 
males in the general Dutch population. 
Reoperation
During follow-up 45 valve-related reoperation were required: 37 for structural 
valve deterioration, 7 for non-structural valve deterioration and 1 for recurrent 
endocarditis. 
Sixteen autograft recipients (LOR 2.5%/patient year) and 21allograft recipients 
(LOR 1.9%/patient year) required reoperation for structural valve deterioration. 
Structural valve deterioration in autografts was caused by progressive dilatation 
of the neo-aortic root and subsequent aortic regurgitation, while in allografts 
it was characterized by degeneration and calcifi cation. In 4 of the 10 autograft 
reoperations a degenerated pulmonary allograft was concomitantly replaced with 
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another cryopreserved pulmonary allograft. One autograft patient underwent an 
isolated pulmonary allograft replacement with a cryopreserved allograft. 
The 7 reoperations for non-structural valve deterioration or technical valve failure 
occurred all in allografts that were implanted using the subcoronary technique 
(LOR 0.64%/patient year). 
Table 4 . Details on reoperations
Autograft
 (n=16)
Allograft
 (n=29)
Total patient years 650 1093
Cause for aortic valve reoperation
Structural failure
Non-structural valve deterioration
Endocarditis
n=16
-
-
n=21
n=7
n=1
Valve substitute inserted at reoperation
Mechanical prosthesis
Bentall procedure
Autograft
Allograft
Stentless bioprosthesis
-
n=13
-
n=2
n=1
n=15
n=6
n=4
n=3*
n=1
Mean CPB time (minutes; range) 237 (129-389) 182 (79-321)
Mean clamp time (minutes; range) 151 (96-271) 120 (59-196) 
* subcoronary allografts 
0
0,2
0,4
0,6
0,8
1
0 2 4 6 8 10 12 14 16
Time(years)
S
u
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a
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%
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Autograft
Allograft
35-year old Dutch male
Log-rank test 
p=0.45
Figure 1 Survival after allograft or autograft operation compared with 35-year old males in  the 
general Dutch population. 
ALLO= allograft, AUTO= pulmonary autograft, 95% C.I.= 95% confi dence interval
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Finally, one patient with a subcoronary allograft required a reoperation for recurrent 
endocarditis (LOR 0.09%/patient year). See Table 4 for details on reoperations.
There was no reoperative mortality. One autograft patient who received a mechanical 
valve conduit had a major stroke in the immediate postoperative period.
Overall freedom from aortic valve reoperation was 94.5%±1.8% at 5 years 
and 61.4%±5.5% at 13 years. For autograft patients freedom from aortic valve 
reoperation was 100% at 5 years and 63.4%±9.6% at 13 years, for allograft patients 
91.2%±2.8% at 5 years 59.8%±6.8% at 13 years (p=0.48). See also Figure 2. 
Freedom from aortic valve reoperation for structural valve deterioration for all 
valves was 98.8%±0.9% at 5 years and 67.2%±5.2% at 13 years, for autograft 
patients 100% at 5 years and 63.4%±9.6% at 13 years and for allograft patients 
98.0%±1.4% at 5 years and 68.8%±6.3% at 13 years (p=0.44). No factors were 
found to be associated with an increased risk on reoperation for structural failure 
in both the allograft and autograft group. Figure 3 shows the observed freedom 
from reoperation from structural valve deterioration and the corresponding 
Weibull functions representing the increasing hazard with time of structural valve 
deterioration for both allografts and autografts. 
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Log-rank test 
p=0.48
Figure 2 Freedom from reoperation for any cause
ALLO= allograft, AUTO= pulmonary autograft, 95% C.I.= 95% confi dence interval
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Figure 3 Freedom from reoperation for structural failure
ALLO= allograft, AUTO= pulmonary autograft, 95% C.I.= 95% confi dence interval
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Figure 4 Freedom from any valve-related event
ALLO= allograft, AUTO= pulmonary autograft, 95% C.I.= 95% confi dence interval
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Other valve-related events
In the autograft patient group, one patient had a recurrent episode of endocarditis 
(0.15%/patient year), and one patient had a pulmonary embolism (0.15%/
patient year). In the allograft patients group, one patient had a recurrent episode 
of endocarditis (0.09%/patient year) and two allograft patients had a TIA (LOR 
0.18%/ patient year). Figure 4 shows the freedom from any valve-related event. 
Overall freedom from any valve-related event at 13 years was 59.1%±5.5%, for 
autograft patients 59.2%±9.5% and for allograft patients 59.0%±6.8% (p=0.62).
Functional and echocardiographic status at last follow-up.
Table 5 shows aortic regurgitation for both allograft and autograft patients, pulmonary 
regurgitation for autograft patients at echocardiography and NYHA class at last 
follow-up. Echocardiographic measurements of patients who underwent reoperation 
or died during follow-up were excluded. Autograft patients had a larger aortic annulus 
at last follow-up compared with allograft patients (p<0.001) and no differences were 
observed in functional exercise capacity. 
Discussion
Our study shows satisfactory results on early and long-term survival for both the 
autograft and the allograft in patients with congenital aortic valve disease. On the 
other hand, it also shows that durability of both procedures is limited and the majority 
of patients will require a reoperation later in life. 
Early morbidity and mortality
Aortic valve replacement with an autograft or allograft is a complex operation 
illustrated by the long cardiopulmonary bypass and cross-clamp times. Still, this can 
safely be performed evidenced by the low hospital mortality of 3% for autograft 
patients and no hospital mortality for allograft patients. 
Survival
No differences were observed in late survival between both valve substitutes and 
late survival was comparable to that of the general age-matched Dutch population. 
Allograft patients more often underwent aortic valve replacement for endocarditis 
on the aortic valve or valve prosthesis, a factor that may have affected long-term 
survival. However, only 1 of the 6 late deaths was in a patient with endocarditis 
etiology, and all other late deaths were in patients who did not have a previous AVR 
for endocarditis. On the other hand, a survival difference between the autograft 
and allograft in favour of the autograft is observed in a randomized controlled 
study of Aklog and colleagues, although survival differences between the two valve 
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substitutes were not signifi cant.[11] When comparing patient survival after aortic 
valve replacement with an autograft or allograft to the patient survival of other valve 
substitutes available in patients under 55 years of age, long-term survival rates for 
autograft and allograft patients are better than other valve substitutes in this patient 
population.[12-14] Whether this is due to patient selection or the haemodynamic 
superiority of human tissue valves is a question that requires further exploration.
Reoperation
Although freedom from reoperation for any cause was comparable for both the 
allograft and autograft, causes for reoperation differed considerable between the valve 
types. Indications for reoperation for allograft patients were endocarditis, perivalvular 
leakage and structural failure. Structural allograft failure was characterized by 
degeneration and calcifi cation, an observation that is confi rmed by several other 
institutions.[15-17] 
Indication for autograft patients to return for reoperation was solely structural failure. 
The autograft failed due to progressive dilatation of the neo-artic root with subsequent 
Table 5. Echocardiographic and functional outcome at last follow-up visit
Autograft Allograft p-value
AR n=42 n=72
Grade 0-0.5+ 21% (n=9) 28% (n=20) 0.44
Grade 1+  41% (n=17) 39% (n=28) 0.90
Grade 2+  26% (n=11) 29% (n=21) 0.71
Grade 3+ 10% (n=4) 4% (n=3) 0.26
Grade 4+ 2% (n=1) - 0.19
PR n=44 -
Grade 0-0.5+  86% (n=38) - -
Grade 1+ 12% (n=5) - -
Grade 2+ 2% (n=1) - -
Grade 3+ - - -
Grade 4+ - - -
Diameter aortic annulus (mm) 
< 30
30 -< 40
40 -< 50
> 50
n=38
 13% (n=5)
41% (n=16)
41% (n=16)
5% (n=2)
n=65
20% (n=13)
74% (n=48)
6% (n=4)
-
0.38
0.001
<0.001
0.19
Mean diameter aortic annulus (mm, 
(range))
37 (26-52) 33 (21-44) <0.01
NYHA class
I/II
III/V
n=45
98% (n=44)
2% (n=1)
n=73
92% (n=67)
8% (n=6)
0.18
AR = aortic regurgitation, PR = pulmonary regurgitation
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aortic regurgitation. No age-dependency was observed for autograft structural valve 
failure in this study. 
In the present study the autograft roots were placed in the left ventricular outfl ow 
tract and annulus with a short rim of right ventricular muscle, which was kept to 
a minimum and no measures were taken to reinforce the aortic root or sinotubular 
junction. Minimization of the length of the autograft root may result in less dilatation 
and may produce better durability. Furthermore, reinforcement of the aortic root or 
sinotubular junction may enhance durability as well. 
The majority of our study patients have a bicuspid valve, the most common congenital 
valvular abnormality, which comprises 1% of the general population. It remains 
debatable if presence of a bicuspid valve is a risk factor for reoperation after the 
pulmonary autograft procedure.[18-22] A bicuspid valve is reported to be associated 
with a high incidence of aortic root dilatation due to aortic wall abnormalities.[23] 
Moreover, Schoof and coworkers observed in a recent autograft explant study that 
there was no association between bicuspid valve disease and histological changes in 
explanted pulmonary autografts.[24] 
The necessity for reoperation will increase for both valves in the second decade after 
operation and this increase seems larger for autograft patients. This trend is already to 
some extent seen in Figure 3 and is also reported in other series.[5,25-27] Structural 
failure is the main disadvantage of allografts and autografts compared to mechanical 
prostheses, which have an unlimited durability.[14] Comparing allografts with stented 
biological prostheses a comparable age-dependent structural failure rate is observed in 
adult patients,[28] which is not observed in adult autograft patients.[29] This suggests 
an advantage of the autograft in younger patients and of a biological prosthesis or 
allograft in older patients. However, Svensson and colleagues provided an overview 
of different surgical strategies in young adult patients and compared the available 
valve substitutes. They concluded that the structural failure rate of biological valves 
is much higher and of mechanical prostheses much lower in young adults compared 
with the allograft or autograft and would therefore be not a good solution in young 
adults.[30] Yet, the main disadvantage of the mechanical prostheses remains the 
anticoagulation use and the related complications, such as bleeding events and higher 
thrombo-embolic event rates.[31] 
Furthermore, reoperation on a calcifi ed homograft takes a lot more effort than on a 
dilated pulmonary autograft. The dilated autograft root allows the surgeon a clear 
view of the insuffi cient autograft and its dilated annulus, on which an anastomosis is 
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easier to perform. The calcifi ed aortic allograft on the other hand is rigid causing a 
smaller operation fi eld.
Valve-related events
Occurrence rates of valve-related events other than reoperations are low in our study 
population. 
Concha and colleagues compared the pulmonary autograft to the mechanical 
prosthesis regarding early and long-term results and observed no other valve-related 
events than pulmonary stenosis in the pulmonary autograft group compared with 
major bleeding, thromboembolic complications related to coumarin, and prosthetic 
valve endocarditis in mechanical prosthesis group.[32] Other reports comparing 
the allograft to the mechanical prosthesis show similar results, suggesting that these 
human tissue valves provide a superior valve substitute in this regard compared with 
mechanical prostheses.[11,12,33] 
Conclusions
In young adult patients with congenital aortic valve disease, our study shows that both 
the allograft and autograft are valve substitutes with satisfactory results regarding 
early and long-term patient survival, with late survival even comparable with the 
general age-matched population. These patients comprise a young patient population 
with little co-morbidity, who have an active lifestyle with a long life-expectancy and in 
whom preferably anticoagulation treatment should be avoided. However, the major 
limitation of human tissue valves is the increasing high incidence of reoperations for 
structural valve deterioration in the second decade after operation.
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AORTIC VALVE REPLACEMENT WITH 
HUMAN TISSUE VALVES IN YOUNG WOMEN: 
OUTCOME AND EFFECTS OF PREGNANCY
Aortic Valve Replacement with Human Tissue Valves in Young Women: Outcome 
and Effects of Pregnancy. Klieverik LMA, Yap SC, Roos-Hesselink JW, Bogers AJJC, 
Takkenberg JJM. Submitted
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SHORT ABSTRACT
We studied outcome of 98 female patients younger than 45 years who underwent 
aortic valve replacement with either a pulmonary autograft or an allograft at our 
institution between 1987 and 2007 and were part of our ongoing prospective 
follow-up study. Furthermore, we evaluated whether there was an infl uence of 
pregnancy on the durability of these tissue valve substitutes. During follow-up 7 
patients died and 18 required a reoperation. Twenty-three patients contemplated 
37 pregnancies and pregnancy had no effect on valve durability. In young female 
patients contemplating pregnancy within the next decade, human tissue valves 
provide good valve substitutes.
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ABSTRACT
Objectives 
We studied outcome of aortic valve replacement in young female patients who 
received human tissue valves and the effect of pregnancy on the durability of these 
valve substitutes.
Background 
Young women with congenital heart valve disease remain a special group regarding 
valve selection due to their potential desire to have children.
Methods 
Between 1988 and 2007, 98 women younger than 45 years underwent aortic valve 
replacement with an autograft (n=50) or allograft (n=48) in our center. Patient 
characteristics, early and long term outcome of patients and characteristics of 
pregnancies were analyzed.
Results 
Mean age at operation was 25 years (0-44 years), haemodynamic diagnosis was 
aortic stenosis in 37%, aortic regurgitation in 37% and mixed lesions in 28%. 
Sixty-two percent had congenital etiology, including bicuspid valve. Hospital 
mortality was 5% (n=5).
During follow up (94% complete, mean 9.2, max 18 years) 7 patients died (2 
autografts, 5 allografts). Overall 15-year survival was 80.5%±6.7%, for autograft 
patients 89.8%±4.3% and 67.6%±13.8% for allograft patients (p=0.41). Twenty-
three patients completed 37 pregnancies. 
There were 18 valve-related reoperations for structural failure (LOR 2.0%/
patient year). Overall 15-years freedom from reoperation for structural failure was 
69.3%±9.9% for autograft patients and 61.3%±15.4% for allograft (p=0.91). 
Pregnancy had no effect on durability of the allograft or autograft (p=0.60).
Conclusions
 In young women who underwent aortic valve replacement with autografts or 
allografts, a considerable proportion had pregnancies without complications. 
Pregnancy had no infl uence on valve durability. Therefore, in young female patients 
contemplating pregnancy within the next decade, human tissue valves provide good 
valve substitutes. 
Key words: pregnancy, aortic valve replacement, allograft, autograft, outcome
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Introduction
The introduction of paediatric cardiothoracic surgery has resulted in a dramatic 
improvement of survival in children with congenital heart disease. However, at 
adolescent or adult age these patients may encounter particular problems related to 
their previous heart surgery. Especially, young girls and women of childbearing age 
who have undergone AVR are a patient population that requires special attention, 
due to their potential desire to have children. 
Aortic valve replacement is not without consequences, irrespective of the valve 
substitute used. The pulmonary autograft procedure is presumably the most 
suitable valve substitute in children and young adults, because of diameter increase 
along with somatic growth and the absence of anticoagulation treatment.(1,2) The 
pulmonary autograft is normally situated in the right ventricular outfl ow tract and 
is transplanted in the left ventricular outfl ow tract, a high pressure system. The 
exact mechanism of pulmonary autograft adaptation to the high pressure system 
of the LVOT is not well understood, but in recent years an increasing number of 
reoperations due to autograft root dilatation is observed.(3-5)
The allograft can also be applied in children with aortic valve disease. No 
anticoagulation treatment is required, and good haemodynamic performance is 
observed. On the down side, allografts do not grow or increase in diameter with 
the growing child, and valve degeneration rate is inversely correlated with patient 
age. For these reasons, in children allografts have become a less favourable option 
to replace the aortic valve or root.(6,7)
During pregnancy signifi cant haemodynamic changes occur with an important 
demand on cardiac function.(8,9) There is an increase in cardiac output, heart 
rate and blood volume and a decrease in systemic vascular resistance resulting in a 
lower blood pressure, despite the increase in cardiac output. These cardiac changes 
may have an infl uence on progressive deterioration of the pulmonary autograft and 
allograft.(8)
The aim of this study was to analyze outcome of young female patients who received 
a human tissue valve in aortic position and evaluate the infl uence of pregnancy on 
the durability of these tissue valve substitutes and patient outcome after pregnancy. 
To achieve this, we studied all young female patients who underwent aortic valve 
replacement with either an autograft or an allograft in our institution and were 
annually followed according to a prospective predefi ned protocol. 
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Methods
Patients
Between April 1987 and January 2007, 486 patients underwent 501 consecutive 
autograft or allograft aortic valve or root replacement in Erasmus University Medical 
Center. All patients who receive an autograft or allograft in aortic position in our 
center are enrolled in our ongoing prospective follow-up study.(10-12) Approval 
from the Institutional Review Board was obtained for this prospective follow-up 
study; the Institutional Review Board waived informed consent.
For the purpose of this study we selected out of the total of 501 procedures 
all operations in female patients who were less than 45 years of age at time of 
operation. 
Operation
Root replacement was performed as a freestanding root with reimplantation of the 
coronary arteries in 48 autograft patients and in 35 allograft patient. In 2 autograft 
patients an inclusion cylinder aortic root replacement was done(3) and 14 patients 
underwent a subcoronary allograft implantation.(13) Surgical procedures were 
performed on cardiopulmonary bypass with moderate hypothermia. Crystalloid 
cardioplegia and topical cooling were used for myocardial protection. Eight patient 
required circulatory arrest due to surgery on the ascending aorta or arch.
Follow-up
All patients were followed prospectively and annually contacted and interviewed by 
telephone. Echocardiographic follow-up at Erasmus MC is obtained at 6 months 
postoperative, 1 year postoperative and thereafter biennially by means of serial 
standardized echocardiography.(10-12)
In case of suspected complications the attending physician was contacted for 
verifi cation. Valve-related events were defi ned according to the guidelines for 
reporting morbidity and mortality after cardiac valvular operations.(14) Failure 
of the autograft or pulmonary allograft was determined at time of reoperation or 
death. Patient survival started at time of the Ross operation and ended at time of 
death or at last follow-up. Survival of the autograft or pulmonary allograft started 
at time of operation and ended when a reoperation or reintervention was done, 
when the patient died or at last follow-up. 
Pregnancy
To obtain information on pregnancy after operation, all patients were contacted 
by telephone after obtaining informed consent and subjected to a structured 
questionnaire. If a patient could not be reached by telephone, a questionnaire was sent 
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to the patient. The patient had to complete a questionnaire with detailed information 
on every completed pregnancy. Even when a patient had not been pregnant during 
follow-up, the questionnaire was completed with information on the reason why the 
patient remained childless after operation. The questionnaires consisted of questions 
regarding the occurrence of cardiac and obstetric complications during pregnancy. 
Part of the questionnaire was according to the ZAHARA protocol, with minor 
adjustments for the purpose of our study.(15) ZAHARA is a Dutch collaboration of 
cardiologists that analysed pregnancy and delivery in women with congenital heart 
disease (CHD) by reviewing cardiologic hospital records and interviewing all Dutch 
women with CHD aged 20-45 years that enrolled in the CONCOR database (= 
national registry of adult CHD patients, www.concor.net) 
Cardiac complications that were documented: clinically signifi cant symptomatic 
arrhythmia or symptomatic heart failure requiring treatment (according to attending 
cardiologist); NYHA class deterioration (as evaluated by their cardiologist during 
trimesters and comparison of pre-pregnancy and post-partum). 
Obstetric complications: pregnancy-induced hypertension (PIH, new onset 
hypertension after 20 weeks of gestation: blood pressure (140 mmHg systolic or 90 
mmHg diastolic without signifi cant proteinuria); pre-eclampsia (PIH criteria and 
.0.3 g of proteinuria/ 24 h); eclampsia (pre-eclampsia with grand mal seizures); 
haemolysis elevated liver enzymes low platelets (HELLP) syndrome; thrombo-
embolic complications; stroke; and gestational diabetes. Obstetric complications: 
assisted delivery (forceps/vacuum/caesarean); premature rupture of membranes 
(membrane rupture before the onset of uterine contractions); prolongation of 
second stage of delivery (according to the gynaecological guidelines); premature 
delivery (spontaneous onset of delivery < 37 weeks gestation).
Neonatal complications: premature birth (delivery < 37 weeks of gestation); small 
for gestational age birth weight (<10th percentile); recurrence of CHD; and neonatal 
death (within the fi rst year after birth).
Statistical methods 
For data analysis SPSS 12.0.1 for Windows (SPSS, Chicago, Illinois) was used. 
Continuous data are displayed as mean ± 1 standard deviation and compared 
using the unpaired T-test or the Mann-Whitney U-test. Discrete data are presented 
as proportions and compared using the Chi-square test or Fisher’s exact test. 
Cumulative survival and freedom from reoperation or reintervention were analysed 
using the Kaplan-Meier method. The log-rank test was used to compare Kaplan-
Meier curves. The Cox proportional hazards model was used for univariate and 
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multivariate analysis (stepwise backwards method) of time-related events. A p-value 
of ≤ 0.05 was considered statistical signifi cant. All testing was performed 2-sided. 
Results
A total of 96 female patients underwent 98 aortic valve replacements with a tissue 
valve and were young than 45 years of age at time of operation. Preoperative 
and operative details are displayed in Table 1. One subcoronary allograft patient 
underwent a reoperation due to structural failure 4.8 years after operation and 
received another subcoronary allograft and one autograft patient underwent a 
reoperation due to structural failure 7.0 years after the initial procedure and received 
an allograft root. Both patients were included twice in the study and did not become 
pregnant during follow-up. 
Early morbidity and mortality
Hospital mortality was 5.1% (n=5). Three autograft patients and 2 allograft patients 
died. 
Two autograft patients died during operation. One autograft patient had a lesion 
to the main stem of the left coronary artery and died in theatre due to low output 
failure despite revascularization. The other patient, a child, died in theatre due to 
heart failure. 
The third autograft patient died due to mediastinitis and sepsis on the 13th day 
postoperative.
Of the 2 allograft patients who died in hospital, one died due to a major intracerebral 
bleeding on the 9th day after operation. This patient was on anticoagulation treatment, 
required for a dialysis shunt. The other patient died of a stroke caused by septic emboli 
as a result of an acute persistent endocarditis on postoperative day 21.
Nine patients required rethoracotomy for persistent bleeding, six autograft patients 
and three allograft patients. Furthermore, two allograft patients had a non-lethal 
stroke postoperatively and one allograft patient had a non-lethal intracranial 
haemorrhage.
Follow-up
The database was frozen on May 1st, 2007. Mean follow-up duration was 9.2 years 
(range 0-18.6 years) with a total of 886 patient years and was 94.2% complete.
(16) Mean follow-up duration for autograft patients was 9.5 years (range 0.02-18.4 
years) with a total of 478 patient years. Mean follow-up duration for allograft 
patients was 8.8 years (range 0.02-18.6 years) with a total of 408 patient years.
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Table 1. Preoperative details
Autograft (n=50) Allograft (n=48)
Mean age (years, (range)) 22.5 (0.1-44.9) 28.6 (4.9-44.7)
Previous cardiac surgery
Valvulotomy
Aortic valve replacement
 20% (n=10)
6% (n=3)
6% (n=3)
8% (n=4)
Haemodynamic diagnosis
Aortic valve regurgitation (AR)
Aortic valve stenosis (AS)
AR + AS
None
26% (n=13)
46% (n=23)
28% (n=14)
 -
 52% (n=25)
 29% (n=14)
15% (n=7)
 4% (n=2)
Etiology
Rheumatic
Congenital (incl. bicuspid valve)
Endocarditis
 Active
Senile native valve degeneration
Aneurysm/Dissection
Other
4% (n=2)
82% (n=41)
6% (n=3)
-
2% (n=1)
6% (n=3)
-
15% (n=7)
 42% (n=20)
13% (n=6)
8% (n=4)
4% (n=2)
15% (n=7)
 10% (n=5)
NYHA class
I/II
III/IV
62% (n=31)
37% (n=19)
56% (n=26)
44% (n=21)
Left ventricular function (6 missing)
Good
Impaired
87% (n=41)
 13% (n=6)
 87% (n=39)
13% (n=6)
Sinus rhythm 100% (n=50) 92% (n=44)
Creatinin (μmol/L) 62 (28-121) 89 (22-634)
Type operation
Emergent
Urgent
Elective
-
20% (n=10)
80% (n=40)
10% (n=5)
15% (n=7)
 75% (n=36)
Concomitant procedures
CABG
Mitral valve surgery
Extended Ross 
Extended root
Other*
6% (n=3)
2% (n=1)
12% (n=6)
2% (n=1)
6% (n=3)
 4% (n=2)
15% (n=7)
-
13% (n=6)
 21% (n=10)
Mean CPB time (min) 225 (114-685) 181 (79-435)
Mean cross clamp time (min) 146 (90-240) 127 (68-247)
Circulatory arrest
(min, (range))
n=2 
(15,64)
n=6
70 (5-163)
Rethoracotomy for persistent blood loss 12% (n=6) 6% (n=3)
Hospital death 6% (n=3) 4.2% (n=2)
* Including surgery for discrete subaortic stenosis, closure patent ductus arteriosus, closure ventricular
 septal defects and tailoring ascending aorta
Loes bw.indd   110 31-10-2007   14:40:51
AVR With Human Tissue Valves In Young Women
111
Survival
During follow-up 7 patients died (0.79%/patient year), 2 autograft patients and 5 
allograft patients.
One 12 year old autograft patient had severe juvenile rheumatic disease causing 
severe aortic valve regurgitation and mitral valve incompetence resulting in 
progressive heart failure and death 6 months after operation. The other autograft 
patient, a 1.5 year old girl, died of a septic shock caused by Candida Albicans 51 
days after operation. Although we are aware that these two patients were too young 
to contemplate pregnancy at time of death, for completeness of the study they were 
described.
One allograft patient with an abnormal functioning allograft died a sudden 
unexplained death 9.5 years after operation just before reoperation and one allograft 
patient died of heart failure 14.3 years after operation with a normal functioning 
allograft. 
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Allograft
26-year old female Dutch population
Nr. at risk:
ALLO    40              38              32              24               19              16               8               3 
Auto     42               42              41              32              24               19              10              6
95% CI
ALLO [41%-94%]
Auto  [81%-98%]
Figure 1. Survival of female patients after operation with autograft or allograft 
95% CI= 95% confi dence interval, ALLO = allografts, Auto= autografts
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Finally, three allograft patients died of non-valve related causes 4.3, 8.3 and 8.7 
years after operation, respectively. For these patients who died during follow-up no 
pregnancies were reported in the annual follow-up records. 
Overall 15-year survival was 80.5%±6.7%, for autograft patients 89.8%±4.3% and 
for allograft patients 67.6%±13.8% (p=0.41). Figure 1 shows overall survival for 
autograft and allograft patients compared with 26-year old females in the general 
Dutch population.
Reoperations
During follow-up there were 18 valve-related reoperations, all for structural 
failure (LOR 2.0%/patient year). Ten autograft patients required reoperation 
due to dilatation of the neo aortic root and 8 allograft patients for a calcifi ed and 
degenerated allograft. Of these 18 patients, 7 patients had been pregnant during 
follow-up. Mean time after the fi rst pregnancy until reoperation was 5.9 years 
(range 0.4 – 11.5 years).
Ten autograft patients requiring reoperation (2.1%/patient year), of which 5 had 
been pregnant. Autografts were replaced by a mechanical valve conduit in 7 patients, 
a bioprosthesis in one patient and an allograft in one patient. In 3 autograft patients 
a degenerated pulmonary allograft was concomitantly replaced with another 
cryopreserved pulmonary allograft. One autograft patient underwent an isolated 
pulmonary allograft replacement with a cryopreserved allograft. 
One autograft patient underwent an aortic valve sparing reoperation before her 
pregnancy. 
Out of the 8 allograft patients requiring reoperation (1.96%/patient year), 2 had 
been pregnant. Allografts were replaced by mechanical valves in 6 patients, an 
aortic valve conduit in 1 patient and another allograft in one patient.
Figures 2 and Figure 3 display the freedom from reoperation for structural failure 
for the autograft and the allograft patients. Overall freedom from reoperation for 
structural failure at 15 years for autograft patients was 69.3%±9.9%. Freedom 
from reoperation for structural failure at 15 years for autograft patients who 
had been pregnant was 53.6%±18.9% and for non-pregnant autograft patients 
78.3%±10.5% (p=0.36). 
Overall freedom from reoperation for structural failure at 15 years for allograft 
patients was 61.3%±15.4%. Freedom from reoperation for structural failure at 15 
years for allograft patients who had been pregnant was 75.0%±21.7% and for non-
pregnant allograft patients 57.0%±18.1% (p=0.48).
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Nr. at risk:
Preg       11          11            11              11             8              6              3              3 
Npreg    30           30            29             20             13            9               6             3 
95% CI
Preg [17%-100%]
Npreg [58%-99%]
Figure 2. Freedom from reoperation for structural failure for autograft patients
95% CI= 95% confi dence interval, Preg = pregnant, Npreg = non-pregnant
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Nr. at risk: 
Preg      10              10              8                 5               5               3                2              1
Npreg   32              29             22               17             11             10               5              1
95% CI
Preg [33%-100%]
Npreg [22%-93%]
Figure 3. Freedom from reoperation for structural failure for allograft patients
95% CI= 95% confi dence interval, Preg = pregnant, Npreg = non-pregnant
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Valve related events
One autograft patient had a recurrent episode of endocarditis, 3 years postoperative, 
and was treated medically (LOR 0.21%/patient year). Another autograft patient 
had a recurrent episode of rheumatic disease 0.4 years after operation and died 
(LOR 0.21%/patient year, see details described above). Two autografts patients had 
supravalvular pulmonary stenosis; one underwent enlargement of the pulmonary 
outfl ow tract and the other underwent balloonvalvuloplasty of the pulmonary 
outfl ow tract (LOR 0.42%/patient year). One allograft patient had a stroke 2.5 years 
after operation (LOR 0.23%/patient year) and 3 patients a TIA, 0.3, 3.7 and 5.8 
years after operative, respectively (LOR 0.70%/patient year). No valve thrombosis 
or bleeding events were observed.
Pregnancies
Sixty-eight patients, of the 84 patients that were still alive, returned 84 completed 
questionnaires (81%). Reasons for not responding were: 3 patients did not want to 
participate, 3 patients were lost to follow up due to emigration and in 10 patients 
unknown.
Seventeen patients reported to have had children before the initial operation with no 
intent to become pregnant after operation. Twenty-seven patients reported to have 
remained childless after operation. Reasons were: too old age (n=1), too young age 
(n=15), Marfan’s disease (n=1), regurgitant aortic valve (allograft) (n=1), decision 
to have no children to avoid potential congenital heart disease in offspring (n=1), 
recent aortic valve surgery (n=1), previous hysterectomy (n=1), mentally retarded 
(n=1), systemic lupus erythematodes (n=1), social factors (n=4). 
Twenty-three patients completed 37 pregnancies. Three patients were still pregnant 
at time of the questionnaire. Two autograft patients had an elective abortion and 
one autograft patient had a spontaneous miscarriage. Twelve autograft patients 
completed 19 pregnancies and 11 allograft patients 18 pregnancies. Table 2 displays 
details of these pregnancies. 
Mean maternal age at fi rst delivery was 29.3 years (range 23-35 years). Mean time 
interval between operation and fi rst pregnancy was 5.0 years (range 0.1-16.3 years) 
and mean pregnancy duration was 37.9 weeks (range 27-42 weeks). 
Cardiac complications during pregnancy: 5 patients (14%) developed cardiac 
complications during pregnancy. Two patients reported episodes of arrhythmias; 
one patient had an episode of idiopathic tachycardia and one patient had episodes 
of atrioventricular reentry tachycardias. Two patients had an episode of chest pain; 
one patient was suspect for pulmonary embolism and one had angina pectoris. One 
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autograft patient developed heart failure after delivery, this was initially ascribed 
to the pregnancy, but turned out to be caused by severe pulmonary regurgitation, 
for which the patient underwent a pulmonary allograft reoperation 1.6 years after 
delivery.
Pregnancy complications Seven patients (19%; 2 with an autograft and 5 with 
an allograft) developed hypertension during pregnancy, in range from week 21 to 
week 40, which was treated medically and additionally 5 of these patients required 
hospital admission. In 3 of these 5 patients hypertension was a reason of induction 
of labor. 
Table 2 Maternal and perinatal outcome
Autograft Allograft
Number of pregnancies n=21 n=19
Number of completed pregnancies (n=37)
 1
 2
 3
n=19
 63% (n=12)
32% (n=6)
5% (n=1)
n=18
 61% (n=11)
28% (n=5)
11% (n=2)
Mean maternal age at the time of delivery (years, (range)) 30.7 (24.9-38.0) 29.7 (23.1-34.5)
Interval between operation - 1st pregnancy (years, (range)) 6.6 (1.4-16.3) 3.9 (0.2-8.9)
Mean duration pregnancy (weeks, (range)) 37 (29-42) 38 (27-41)
Cardiac complications during pregnancy
Arrhythmias
Angina pectoris
Heart failure
11% (n=2)
-
5% (n=1)*
-
6% (n=1)
-
Obstetric complications
Hypertension
Deep venous thrombosis
Pre-eclampsia
Premature rupture of membranes
Vaginal blood loss
Prolongation of second stage of delivery 
Bleeding in placenta
11% (n=2)
 5% (n=1)*
5% (n=1)
5% (n=1)#
5% (n=1)
21% (n=4)
5% (n=1)#
28% (n=5)
-
11% (n=2)
-
-
11% (n=2)
-
Delivery (1 missing)
 Vaginal
 Caesarean section
 79% (n=14)
21% (n=4)
 83% (n=15)
17% (n=3)
Premature delivery (< 37 wks) 26% (n=5) 6% (n=1)
Instrumental use at delivery based on maternal cardiac status
Epidural analgesia 
Artifi cial rupture of membranes
Vacuum extraction
11% (n=2)
-
5% (n=1)
11% (n=2)
17% (n=3)
-
Birth weight (gram, (range)) 2544 (700-3590) 2992 (580-4200)
Small for gestational age 21% (n=4) 22% (n=4)
Neonatal mortality 5% (n=1) -
*post partum, # same patient
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Two allograft (5%) and one autograft patient (3%) developed pre-eclampsia during 
pregnancy. In one allograft patient medication was started in week 37 and the 
patient delivered a healthy girl at 38 weeks. The other allograft patient developed 
pre-eclampsia at 21 week with haemolysis, elevated liver enzymes and low platelets 
(suspected for HELLP syndrome), for which medication was started. However, the 
patient required a caesarian section at 27 weeks, and gave birth to a girl weighting 
only 580 grams. The child was born with a patent arterial duct and bronchial 
pulmonary dysplasia but survived. 
One autograft patient required low-molecular heparin due to previous deep venous 
thrombosis after the fi rst pregnancy. During the 2nd pregnancy the patient had 
premature rupture of membranes in the 18th week of pregnancy. Due to premature 
rupture of membranes and emboli present in the placenta, insuffi cient oxygen 
supply and obstruction of the blood fl ow occurred, resulting in intrauterine growth 
retardation and premature delivery. At 30 weeks the patient gave birth to a girl 
weighting only 700 grams. Unfortunately, this child died 11 hours after delivery due 
to a pneumothorax and cardiac arrest. 
Another autograft patient was admitted at 26 weeks of pregnancy for vaginal blood 
loss suspected for a solutio placenta. At 29 weeks an emergency caesarian section 
was performed and a boy was delivered with a birth weight of 1380 grams.
Seven patients required a caesarian section, 4 autograft patients and 3 allograft 
patients. In 1 allograft and 3 autograft patients the indication for the caesarian 
section was maternal congenital heart disease. One of the 37 newborns was 
diagnosed to have congenital heart disease (see details above).
Discussion
This study shows that young female patients who underwent aortic valve 
replacement with an autograft or an allograft in our institution have a good 
prognosis, and considerable proportion of patients was able to start a family. 
However, these pregnancies were not without complications, and compared to the 
general population, pregnancy duration was shorter and birth weight was lower. 
Although the incidence rate of reoperations increases with time since operation, and 
more reoperations should be anticipated, there was no difference between autograft 
and allograft patients, and pregnancy was not a factor associated with increased 
reoperation rates.
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Survival
Hospital mortality was 5% in our study population, and this is high compared 
with other studies on aortic valve replacement at a young age. This can partly be 
explained by the fact that women have a higher risk on operative mortality.(17) 
Furthermore, these female patients were all young patients with congenital heart 
disease, and 3 of the patients who died had a previous operation. These patients 
had severe co-morbidities, such as renal failure, a factor that is also predictive of 
increased hospital mortality.(18,19) Also, during operations complications occurred 
during reimplantation of the coronary arteries, emphasizing the complexity of the 
operation.
Fifteen-year survival was 80% for the total study population and appears to be 
slightly better for the autograft patients compared with the allograft patients, 
although this difference was not signifi cant. Furthermore, the autograft patients 
had a late survival that was comparable to the general age-matched population, in 
contrast to patients that received an allograft. Patient-related factors, such as patient 
age or etiology may be associated difference in survival between the two groups. 
Reoperations
There was no difference in reoperation rate between autograft and allograft patients, 
neither was there any difference between female patients that had become pregnant 
and those who had not. Pregnancy theoretically may have an adverse effect on 
durability of the human tissue valves due to haemodynamic changes that occur 
during pregnancy and delivery, and this concern is also mentioned in the literature.
(20,21) However, our fi ndings support other reports that also describe that pregnancy 
has no effect on the durability of both the autograft and the allograft.(8,22) Of 
note, the sample size of our study is small and we only investigated reoperation 
for structural valve deterioration as an endpoint for durability. Larger clinical and 
echocardiographic outcome studies are necessary to investigate the potential effect 
of pregnancy on human tissue valve durability.
Valve-related events
Thrombo-embolic events during follow-up did not occur in autograft patients 
and only in a small number of allograft patients. However, the occurrence rate of 
thrombo-embolic events in allografts is still much lower when compared with the 
mechanical prostheses in young adult patients (23,24) and also in female patients 
who became pregnant.(22) 
Due to the absence of anticoagulation treatment, no bleeding events or valve 
thrombosis during follow-up were observed in our study. This is a major advantage 
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of the tissue valves, especially for these female patients who have a desire to have 
children, or those who want to become pregnant again. Pregnancy is a thrombogenic 
state and patients with a mechanical prosthesis are at high risk of developing 
complications. Anticoagulation treatment used in pregnancy will decrease this 
risk for the female patient, but may have adverse effects on the outcome of the 
foetus. Warfarin is known to be teratogenic in the fi rst trimester and associated 
with increased risk of foetal intracerebral haemorrhage. Heparin is much safer for 
the foetus, but has an increased risk of events for the mother due to the adequate 
adjustment of the INR levels.(8)
Pregnancies
Although the majority of patients that became pregnant delivered healthy children, 
these pregnancies were not all uneventful. In 5 of the 37 pregnancies cardiac 
complications occurred, necessitating reoperation on the pulmonary allograft 
1.6 years after delivery in one autograft patient. Due to intensifi ed cardiologist 
monitoring during pregnancy in female patients with a known (congenital) heart 
disease and the improved medical treatment, with less foetal side-effects, these 
complications can be reduced to a minimum. Pregnancy duration was observed 
to be shorter than average in our study patients compared with normal healthy 
pregnant women, which may be caused by placental insuffi ciency.(25) 
Furthermore, adverse foetal outcome was present in one newborn. This newborn 
was delivered prematurely but had fatal co-morbidity and died several hours after 
delivery
Also, eight newborns were too small for gestational age. This phenomenon is more 
often observed in women that underwent aortic valve replacement. (25-27) The 
incidence of adverse outcome is much higher in mechanical prosthesis and mainly 
related to the use of anticoagulation.(28-30)
Limitations
Unfortunately, not all patients returned a completed questionnaire, which may have 
infl uenced the results of the study. 
Conclusions
With the growing experience in our center with implantation of autografts and 
allografts it has become clear that although patient survival is good, the durability 
of both human tissue valves is limited. In this particular study in young females, the 
implantation of human tissue valves allowed a considerable proportion of patients 
to have pregnancies that were not complicated by anticoagulant use. Nevertheless, 
these pregnancies were not uneventful. Pregnancy did however not infl uence valve 
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durability. Therefore, in young female patients who have plans to start a family 
within the next decade, human tissue valves provide an adequate valve substitute at 
the cost of a reoperation later in life. 
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SHORT ABSTRACT
The Ross procedure remains controversial in adults. We studied 264 consecutive 
adult patients who underwent the Ross operation in 2 institutions and were followed 
for 1634 patient years. Etiology was mainly congenital and degenerative. Thirty-day 
mortality was 2.3%. Cumulative survival was 95.4% at 10 years, and comparable 
to the general population. Freedom from any reoperation was 89.7% at 10 years; 
for pulmonary homograft reoperation 94.9 and for autograft reoperation 92.9% 
respectively. The question whether the excellent survival rates are due to patient 
selection or to the potential advantages of the Ross procedure should be addressed 
in a randomized trial.
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ABSTRACT
Background and aim of the study 
Pulmonary autograft replacement of the aortic valve (the Ross operation) is the 
operation of choice in infants and children. Although this procedure can offer 
theoretical advantages at any age, its use in adults remains controversial. We studied 
264 consecutive patients above the age of 18 years (18-66, mean 35) who underwent 
the Ross operation in 2 institutions and were followed for 1634 patient years.
Methods 
There were 203 males and 61 females, mean age was 36.9 years (SD 12.4). The 
etiology was mainly congenital (52%), degenerative (22%), and rheumatic (8%). 
Twenty-one percent of patients underwent prior aortic valve replacement. 
Results 
Thirty-day mortality was 2.3% (N=6) and 4 more patients died during follow-up 
(mean follow-up 6.2 years, range 0-15.4). Cumulative survival at 5 years was 96.8% 
and at 10 years 95.4%. Eleven patients underwent re-operation on the aortic valve, 
due to progressive dilatation and aortic regurgitation in 10, and dissection of the 
arterial wall of the autograft in one. Overall freedom from pulmonary homograft 
reoperation was 94.9% at 10 years; for autograft reoperation 92.9%. Estimated 
freedom from autograft reoperation in Harefi eld was 98.6% at 5 and 10 years, in 
Rotterdam 96.0% at 5 years and 88.2% at 10 years (p=0.10, Tarone-Ware). No risk 
factors for early and late mortality and reoperation were detected.
Conclusions 
In this combined series the Ross operation in adult patients resulted in excellent 
survival and acceptable reoperation rates. A prospective randomized trial is proposed 
to study whether this observation truly refl ects the potential advantages of the Ross 
procedure or whether it is caused by patient selection.
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Introduction
Although aortic valve replacement has been shown to improve the course and 
prognosis of patients with severe aortic valve disease(1), the choice of a valve 
substitute may infl uence both the early and long term outcome after aortic valve 
replacement. Furthermore, the pattern of survival after aortic valve replacement 
appears to be inferior to age matched controls from the general population(2). This 
can be attributed at least in part to the valve substitute. There is increasing realization 
that the normal aortic valve performs many sophisticated functions which depend 
on the biological properties of its living components(3). The Ross operation is the 
only operation that provides, in the longer term, a living valve substitute capable of 
reproducing most or all the sophisticated function of the normal aortic valve(4,5). We 
theorize that this might have implications to survival and quality of life. There are, 
however, several legitimate concerns about the use of the Ross operation particularly 
in adults where there are many alternatives with a fairly long track record. These 
concerns include the perceived complexity of the operation that requires longer 
cardiopulmonary bypass and thus could increase the risks of the operation in the 
older patients. In addition, progressive dilatation of the neoaortic root resulting in 
valve malfunction requiring reoperations has been reported in adults(6-9). Other 
complications relate to the use of a pulmonary homograft in the right ventricular 
outfl ow tract(7,9,10). Furthermore, dissection of the autologous pulmonary valve 
necessitates dividing normal myocardial tissue in the right ventricular outfl ow tract 
and endangers the fi rst septal arteries which, at least in theory, could compromise 
right ventricular function and possibly predispose to ventricular arrhythmias and/
or sudden death. In an attempt to clarify some of these issues, we have reviewed 
our two center experience with 264 consecutive adult patients (over the age of 18 
years) who had their aortic valve replaced by a pulmonary autograft root (Ross) 
and followed up for up to 15 years (1634 patient years). In this study we analyzed 
the pattern of survival, the incidence and severity of early and late complications, 
particularly those related to aortic and/or pulmonary valve dysfunction and their 
possible determinants.
Material and methods
Patients 
Between November 1988 and May 2004 264 consecutive adult patients (aged 
18 years and older at the time of operation) underwent pulmonary autograft 
replacement of the aortic root in 2 institutions (in Harefi eld 178 patients, in 
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Rotterdam 86 patients). Indications for the Ross operation were similar in both 
centers: severe aortic valve or root disease in patients with an expected long life 
expectancy and a normal pulmonary valve. All patients were operated according 
to the recommendations for aortic valve replacement in the AHA/ACC Guidelines 
for the management of patients with valvular heart disease(11). Their pre-operative 
characteristics are displayed in Table 1.
Table 1. Patient characteristics at the time of autograft aortic root replacement
N=264
Mean age (years (SD; range)) 35 (11.5; 18-66)
Males (%) 76.9%
Previous cardiac surgery
Previous aortic valve surgery
Valve replacement
Valve repair or valvotomy
 39%
31%
21.5%
9.5%
Hemodynamic diagnosis
Aortic valve regurgitation (AR)
Aortic valve stenosis (AS)
AR+AS
unknown
44%
16%
36%
4%
Etiology (N=248)
Congenital 
Degenerative
Bacterial endocarditis 
Rheumatic
Other
Unknown
52%
22%
5%
8%
7%
6%
Valve requiring replacement
Native valve
Homograft
Mechanical valve
Bioprosthesis
Dura valve
81%
11%
4%
3%
<1%
Pre-operative NYHA-class (N=238)
I
II
III
IV
31%
45%
21%
3%
Urgency (N=252)
Elective
Urgent
Emergent
92%
5%
3%
Figure 1 displays the patient age distribution in the 2 centers. The Harefi eld patients 
were older compared to the Rotterdam patients (mean age 36.9 years (SD 12.4; 
median 35.0) versus 31.7 years (SD 8.5; median 29.9); p<0.001), and the proportion 
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of male patients was higher in Harefi eld compared to Rotterdam (84% versus 61%; 
p<0.001).
Operation
All surgical procedures were performed on cardiopulmonary bypass with moderate 
hypothermia. In Harefi eld either blood or crystalloid cardioplegia were used, while 
in Rotterdam crystalloid cardioplegia and topical cooling were used for myocardial 
protection. In Harefi eld one surgeon operated all patients, while; In Rotterdam 6 
different surgeons performed the procedure. In Harefi eld this resulted in a more 
consistent implantation technique. The autograft root was placed in the left 
ventricular outfl ow tract and annulus with a short rim of right ventricular muscle, 
which was kept to a minimum. No attempts were made to wrap the autograft or 
reinforce the base of the autograft.
In the Harefi eld series, the lower end of the autograft was scalloped to a level of 2 
mm below the attachment of the cusps. Then the autograft was inserted by a series 
of interrupted sutures placed outside the attachment of the autograft cusps and 
inside the aortic annulus of the patient thus providing support for the area of cusp 
attachment of the autograft and the lower part of the sinus of Valsalva that are lined 
by RV outfl ow muscle (Figure 2). 
In the Rotterdam series either a straight rim of muscle was left intact below the 
autograft valve or scalloping was performed to reduce the muscle rim to a minimum 
of approximately 3-4 mm. Then either continuous (N=65) or interrupted sutures 
(N=21) were used to insert the autograft in aortic position, depending on the 
Figure 1. Distribution of patient age at the time of the autograft procedure in the 2 centers.
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surgeon’s preference. In Rotterdam 6 autografts were implanted using the inclusion 
root cylinder technique, and in 2 patients the proximal suture line was supported by 
an autologous pericardial strip.
Table 2. Peri-operative details
N=264
Concomitant procedures (n=31)
CABG
Mitral valve repair
Aortic arch replacement
Other
2.7%
3.4%
1%
4.9%
Cross-clamp time (minutes (SD)) 125 (33)
Cardiopulmonary bypass time (minutes (SD)) 183 (65)
Hospital death 2.3% (n=6)
Complications
Bleeding/tamponade
Infection
Permanent pacemaker
CVA/TIA
Procedure-related CABG
Acute myocardial infarction
14%
4.2%
1.9%
1.5%
0.8%
0.4%
Figure 2. Microphotographs of a normal aortic and pulmonary valve illustrating the distinct 
differences in the mode of attachment of the valve leafl ets.
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The pulmonary root was replaced by a homograft in all patients. Thirty-seven (14%) 
patients required a resternotomy because of persistent bleeding or tamponade. Two 
patients (0.8%) required coronary artery bypass grafting due to impaired perfusion of 
a coronary artery after reinsertion. Table 2 displays peri-operative characteristics.
Follow-up
Patients who receive an autograft in Harefi eld Hospital are prospectively followed by 
visits to Harefi eld outpatients including yearly echocardiography. All patients who 
receive an autograft at ErasmusMC are followed prospectively by annual telephone 
interviews and through visits to their cardiologist. Echocardiographic follow-up 
at ErasmusMC is obtained at 6 months postoperative, 1 year postoperative and 
thereafter every other year by means of serial standardized echocardiography(12). 
Valve-related complications were defi ned according to the 1996 guidelines for 
reporting morbidity and mortality after cardiac valvular operations(13). Autograft 
and pulmonary homograft failure were determined at the time of reoperation or 
death. Indications for reoperation of the autograft due to structural failure were 
moderate to severe aortic regurgitation causing left ventricular dilatation and/or 
dilatation of the autograft root > 50 millimeters and/or symptoms. Indications for 
pulmonary homograft reoperation due to structural failure were allograft stenosis 
resulting in a right ventricular pressure >50% of systemic pressure and/or moderate 
to severe allograft regurgitation with gross right ventricular dilatation. The study 
database was frozen for analysis on October 1, 2004. Follow-up was 96.1% 
complete until at least 1 January 2004 (93.4% for Harefi eld, 100% for Rotterdam)
(14). The mean follow-up duration was 6.4 years (range 0-15.4 years, SD 3.1), 
with a total follow-up of 1634 patient years. Mean follow-up for Harefi eld was 5.6 
years, (range 0.02-11.0 years, SD 2.8) and total number of patient years of 951. For 
Rotterdam mean follow-up was 7.9 years (range 0.0-15.4 years, SD 3.3) and a total 
number of patient years of 683. 
Statistical methods 
Continuous data are presented as mean ± 1 standard deviation, and comparison 
was done using the unpaired T-test. Categorical data are presented as proportions, 
and comparison was done using the Fisher Exact test or the Chi-Square test. 
Cumulative survival and freedom from reoperation or re-intervention were 
analyzed using the Kaplan-Meier method. The Tarone-Ware test (correcting for the 
difference in follow-up duration between the 2 centers) was used to study possible 
differences in Kaplan-Meier survival estimates. Cox regression analysis was used to 
assess potential risk factors for reoperation over time. For all analyses mentioned 
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above SPSS 11.0 for Windows statistical software (SPSS, Chicago, Ill) was used. 
Using microsimulation(15) survival estimates were obtained for the age-matched 
general population in the United Kingdom, age-matched patients after aortic valve 
replacement with a SJM mechanical prosthesis(16) and age-matched patients after 
cryopreserved homograft aortic root replacement(17).
Results
Early and late survival
In total ten patients died. Six died in hospital (2.3% early mortality) and 4 more 
patients died during follow-up. Causes of death are described below by study center. 
Figure 2 shows that overall 10-year survival was 95.4% (S.E. 2.9%). No potential 
risk factors for death were detected. Microsimulation estimates of survival were 
98.4% at 10 year for age-matched individuals in the general population and after 
homograft and mechanical prosthesis implantation 84.8% and 84.4%, respectively 
(see Figure 3).
Harefi eld Three patients died in hospital. All died of multi-organ failure between 
the 6th and 16th day postoperative. Late death occurred in another 3 patients: two 
Figure 3. Cumulative survival after autograft aortic root replacement, survival of a 35-year-old male 
in the UK population, and microsimulation-based survival estimates of 35-year-old patient with a 
cryopreserved homograft or bileafl et mechanical prosthesis.
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patients died suddenly 0.5 and 6.6 years after operation. Another patient died of 
motor neuron disease 4.9 years after operation. 
Rotterdam Three patients died in hospital. Causes of death were low output failure 
in 2 patients (of which 1 myocardial infarction due to malperfusion of a reinserted 
right coronary artery; this patient died shortly after the operation). The third patient 
died due to pulmonary emboli in on the day of operation.
Late death occurred in 1 patient. This patient died of an acute myocardial infarction 
4.7 years after the initial Ross operation and 2.5 months after replacement of the 
autograft with a mechanical valve conduit for progressive neo-aortic root dilatation 
and aortic regurgitation.
Reoperation for autograft failure
The autograft required reoperation in 11 patients. Two were reoperated in Harefi eld 
and nine in Rotterdam. Progressive dilatation of the neo-aortic root and neo-aortic 
Table 3. Reoperations on the autograft 
Patient Sex
Age at 
Ross 
operation
Implantation 
technique
Years to 
Redo
Center
Replacement 
valve
Indication Result
1 M 53 Freestanding 
root
0,8 H Homograft RD, AR Alive
2 M 26 Freestanding 
root
3,2 H Homograft Dissection Died 3.4 years 
postop
3 F 26 Freestanding 
root
11,7 R Mechanical RD, AR Alive
4 M 28 Freestanding 
root
4,5 R Mechanical RD, AR Died 2.5 months 
postop
5 F 27 Freestanding 
root
6,7 R Mechanical RD, AR Alive
6 F 29 Freestanding 
root
8,3 R Mechanical RD, AR Alive
7 M 20 Freestanding 
root
5,7 R Mechanical RD, AR Alive
8 M 34 Freestanding 
root
7,3 R Mechanical RD, AR Alive
9 M 28 Freestanding 
root
6,7 R Homograft RD, AR Alive
10 M 26 Freestanding 
root
3,1 R Mechanical Reiter’s disease, 
RD, AR
Alive
11 F 21 Freestanding 
root
11,2 R Mechanical RD, AR Alive
M = male, F= female, H = Harefi eld, R = Rotterdam, RD = Root dilatation, AR= aortic regurgitation
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regurgitation was the main cause in ten patients. One patient in Harefi eld was 
reoperated for a dissection of arterial wall of the autograft. This dissection was 
located in the non-coronary sinus of the autograft and did not extend to any of the 
suture lines. One patient in Rotterdam who received a Ross operation for severe 
aortic regurgitation resulting from aortic valve damage caused by Reiter’s disease 
following a Shigella dysenteria, required autograft reoperation for regurgitation and 
dilatation of the autograft following a recurrent attack of Reiter’s disease. Details 
on the autograft reoperations are displayed in Table 3.
Reoperation for pulmonary homograft failure
The homograft failed in 9 patients. Six were operated in Harefi eld, three in Rotterdam. 
Main causes for homograft failure were pulmonary stenosis (7 patients), pulmonary 
insuffi ciency (1 patient) and bacterial endocarditis (1 patient). All failing pulmonary 
homografts were replaced by another pulmonary homograft. Two pulmonary 
homografts were replaced concomitantly with a failing autograft. 
Freedom from reoperation and possible determinants 
Overall freedom from any reoperation was 95.4% (S.E. 1.4%) at 5 years and 89.7% 
(S.E. 2.7%) at 10 years. For the Harefi eld cohort freedom from any reoperation 
was 95.1% (S.E. 1.8%) at 5 years and 94.0% (S.E. 2.1%) at 10 years. For the 
Rotterdam cohort the freedom from any reoperation was 96.1% (S.E. 2.2%) at 5 
years and 86.9% (S.E. 4.5%) at 10 years (p=0.85). 
Figure 4. Estimated freedom from reoperation comparing the Harefi eld and Rotterdam population.
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Overall estimated freedom from autograft reoperation was 98.1% (S.E. 1.0%) at 5 
years and 92.9% (S.E. 2.5%) at 10 years respectively. For Harefi eld the freedom from 
autograft reoperation was 98.6% (S.E. 1.0%) at 5 years and 10 years respectively. 
For Rotterdam the freedom from autograft reoperation was 96.0% (S.E. 2.3%) at 
5 years and 88.2% (S.E. 4.4%) at 10 years (Figure 4; p=0.10).
Univariate Cox regression analysis failed to identify any risk factors for autograft 
reoperation. In particular patient age (HR 0.96, 95% CI 0.90-1.03; p=0.26), 
hemodynamic diagnosis aortic regurgitation (HR 1.6, 95% CI 0.5-5.3; p=0.45), 
originally bicuspid valve disease (HR 0.4, 95% CI 0.1-1.4; p=0.15), prior aortic 
valve surgery (HR 0.44, 95% CI 0.1-2.0; p=0.28), rheumatic valve disease (HR 
0.05, 95% CI 0-20699; p=0.64), and Harefi eld center (HR 0.24, 95% CI 0.05-1.18; 
p=0.08) were not predictive of autograft reoperation.
The overall estimated freedom from pulmonary homograft reoperation was 96.4% 
(S.E. 1.3%) at 5 years and 94.9% (S.E. 1.9%) at 10 years. The freedom from 
pulmonary homograft reoperation was for Harefi eld 96.7% (S.E. 1.4%) at 5 years 
and at 95.7% (S.E. 1.8%) at 10 years. The freedom from pulmonary homograft 
reoperation was for Rotterdam 97.5% (S.E. 1.8%) at 5 years and 95.0% (S.E. 
3.0%) at 10 years (p=0.63). Univariate Cox regression analysis did not reveal any 
potential risk factors for pulmonary homograft reoperation. In particular patient 
age (HR 0.97, 95% CI 0.3-5.7; p=0.65), donor age (HR 0.98, 95% CI 0.93-1.04; 
p=0.47), and fresh versus cryopreserved homografts (HR 0.64, 95% CI 0.17-2.40; 
p=0.51) were not predictive of pulmonary homograft reoperation. 
Other valve-related events
One patient developed postoperative supravalvular pulmonary stenosis for which 
balloon dilatation was performed. Two years later this same patient underwent a 
reoperation to enlarge the pulmonary artery at the distal anastomosis of the pulmonary 
homograft. Two patients had a transient ischemic attack early postoperatively and 
two patients had cerebrovascular accidents, one shortly after operation and one 3.4 
years after operation (linearized occurrence rate 0.2%/patient year). No autograft 
endocarditis, valve thrombosis or non-structural valve deterioration was observed.
Functional and echocardiographic status at last follow-up
At last follow-up it was possible to determine functional status for 216 patients. Of 
these patients 89.3% (N=193) was in NYHA class I, 9.3% (N=20) was in NYHA 
class II, and 1.4% was in NYHA class III. For 190 patients aortic regurgitation 
was measured at last follow-up by means of 2D-echocardiography: 37% had no 
or trivial aortic regurgitation, 59% mild aortic regurgitation, 3% moderate aortic 
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regurgitation and 1% severe aortic regurgitation. Seven out of the 8 patients who had 
moderate to severe aortic regurgitation at last follow-up were from Rotterdam.
Comments
This study serves to defi ne further the mid term results of the Ross root replacement 
in adults with special emphasis on the pattern of survival, the function of the 
aortic and pulmonary roots and factors which could infl uence them. Although the 
autograft procedure is technically demanding, especially with regard to coronary 
translocation, the pulmonary autograft is currently the only valve substitute 
which continues to be living and therefore, arguably, can reproduce most or all 
the sophisticated functions of the normal aortic valve. These include capacity to 
change in shape and size during the cardiac cycle, growth and response to various 
hemodynamic and humoral stimuli as well as specifi c molecular cues(3). These 
unique features should translate into clinical benefi t, however, there are continuing 
concerns about the complexity of this technically demanding operation, regarding 
the capacity of the autograft to withstand the systemic pressure in adults, as well as 
the complications which may arise from removing the native pulmonary valve and 
inserting a foreign substitute.
Analysis of the pattern of survival in our combined series showed an actuarial survival 
of 95.4% (SE 2.9%) at 10 years, which is equivalent to age-matched controls from 
the normal population of the UK and superior to survival after other types of valve 
replacement(16,17). This is a remarkable observation since in particular young adult 
patients who undergo aortic valve replacement show a considerable excess mortality 
rate relative to the age-matched general population(2,15). Other investigators have 
reported excellent survival after the Ross operation in their selected series(7,9,18). 
The early mortality in our series was 2.3%, which is acceptable considering the 
inclusion of elderly patients with advanced disease and those requiring emergency 
operation in addition; approximately 21% of the patients had had previous valve 
replacement. Taken together, these data suggest that the Ross operation as described 
in this combined series may produce better survival compared to other types of 
valve. This fi nding needs to be validated.
The perceived complexity of the operation is due largely to lack of familiarity and 
can be circumvented by defi nable attention to detail, particularly with regard to the 
technique of explantation of the pulmonary valve, positioning of the autograft and 
avoiding tension, kinking or torsion of the relocated coronary arteries, which are all 
achievable. One of the most important concerns about the use of the Ross operation 
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as a root replacement is the occurrence of progressive aneurismal dilatation of the 
root resulting in severe aortic valve malfunction requiring reoperations(6,7,9). The 
incidence of this complication is different in different series. The increasing number 
of reoperations in Rotterdam for dilatation and regurgitation were an important 
reason for combining the Harefi eld and Rotterdam experience, and allowed for 
analysis of potential determinants of this complication. In the current study, the 
freedom from reoperations on the aortic root was 92.9% (SE 2.5%) at 10 years in 
the whole series (98.6% (SE 1.0%) in the Harefi eld series and 88.2% (SE 4.4%) 
in the Rotterdam series). In a recently reported series from Kouchoukos and co-
workers(7), the freedom from reoperations for this complication was 75% at 10 
years. The causes for these differences are not clear, however, several factors could be 
responsible. Although the aortic and pulmonary valves share many characteristics, 
there are several fundamental differences in the structure of the 2 valves due to 
both developmental and acquired factors (Figure 2). One of the most important 
differences that may be relevant to the Ross operation is the mode of attachment 
of the pulmonary valve leafl ets, which are fi xed to muscular tissue of the right 
ventricular outfl ow tract (19). The muscle extends along the proximal part of each 
cusp as well as outside the lowest parts of the sinuses of the pulmonary root. In 
contrast, the aortic leafl ets are attached to a well-defi ned crown shaped fi brous 
annulus (Figure 2). As the infundibular muscle attached to the pulmonary autograft 
is rendered acutely ischemic during mobilization of the valve, its support to the 
region of the attachment of the cusp and sinuses of Valsalva may be lost and could 
contribute at least in part, for the later dilatation of the root. We therefore believe 
that the technique of insertion of the autograft should take account of these points by 
scalloping the lower end of the autograft leaving minimal amount of muscular tissue 
and inserting this region inside the annulus of the aortic valve. Another potential 
factor relates to the structure of the pulmonary wall. Although at birth the media 
of the pulmonary arterial wall is identical in structure to that of the aortic wall, 
the elastic fi bers in the pulmonary arterial wall undergo progressive fragmentation 
during the fi rst 3-6 months of life (20). Furthermore, the media of the pulmonary 
wall is signifi cantly thinner than that of the aortic wall in both children and adults. 
These differences render the pulmonary arterial wall, less capable of withstanding 
excessive degrees of high distending pressures during the early post-operative period 
after Ross root replacement(5). However, as the pulmonary arterial wall is living 
and autologous, it is potentially capable of adapting to the increased pressure by 
progressive deposition of collagenous tissue in adventia (Figure 5), which renders 
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the vessel wall of adequate strength and prevents progressive dilatation. Changes in 
the stress-strain relationship of the pulmonary arterial wall after relocation in the 
aortic position have been documented after the Ross operation in humans(5). We 
believe, however, that this process of adaptation requires several weeks. For this 
reason in Harefi eld particular attention is paid not to subject the newly inserted 
pulmonary arterial wall to systolic arterial pressures higher than 110 mmHg during 
the fi rst three months. This did however thus far not result in a difference in the 
autograft reoperation rates between the two centers. Another undesirable effect of 
overstretching the pulmonary arterial wall before full adaptation is the possibility of 
producing an intimal or medial tear that can progress to acute or chronic dissection 
and predispose to massive dilation of the autograft root. This complication was 
encountered in one patient in Harefi eld. In the current series unlike reports from 
other institutions, age, sex, etiology of valve disease and presence of a bicuspid 
Figure 5. Photomicrographs of the sectors of normal human pulmonary arterial sinus with a thin 
almost areolar media (Fig.5A), the pulmonary autograft sinus wall (10 years after insertion; Fig. 5B) 
showing increased elastic content in the media and development of thick vascular neo-adventitia 
formed of mature fi brous tissue (see insert), and a normal aortic root showing a thick media with 
unfragmented elastic lamina (Fig 5C). All photomicrographs were stained with Elastic Van Giesson 
stain and are shown at the same magnifi cation.
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valve did not infl uence the incidence of progressive dilatation(6,8,21). It is hoped 
that the technical and management strategies suggested above, coupled with further 
understanding of the causes of this complication will reduce the incidence or prevent 
this complication.
The reoperation of a dilated autograft root (although thus far without reoperative 
mortality) is not just a reoperation. It is found to be a risk-carrying and demanding 
procedure where the aneurysmatic ascending aorta may be attached to the sternum, 
and the pulmonary homograft may be compressed by and attached to the dilated 
autograft root. Also, the coronary buttons may pose problems when they are 
removed from the autograft and reimplanted in a new root. The complexity of these 
reoperations should be taken into account when the original choice for an autograft 
is made, and every attempt at their prevention should be made as mentioned above. 
The other important late complication of the Ross operation is the development of 
malfunction of the valve conduit inserted in the right ventricular outfl ow tract usually 
a pulmonary homograft. In the current series, the freedom from reoperations from 
pulmonary dysfunction was 94.9% (SE 1.9%) at 10 years. This is comparable to 
previous reports(7,9,18,22). Multivariate analysis showed no association between 
several patient and graft related variables and the incidence of this complication. 
The exact cause of homograft stenosis is still unknown. Although an allogenic 
immune response has been suggested to be a contributing factor(23), a previous 
study failed to show correlation between the development of HLA antibodies and 
homograft stenosis(10). The use of decellularized homografts has been shown to 
reduce the frequency of postoperative anti-HLA antibodies(24). However, the effect 
of decellularization on homograft stenosis and/or calcifi cation still needs to be tested 
in a prospective randomized trial. An intriguing aspect of homograft stenosis is that it 
tends to develop during the fi rst 18 months after operation with marked reduction in 
the instantaneous hazard function of the developing the complication after that(10). 
A previous MRI study from Harefi eld showed compression of the homograft by 
mediastinal mass which proved to be dense fi brous tissue with chronic infl ammatory 
cells(10). In an attempt to reduce this complication, the Harefi eld center initiated 
a policy of using anti-infl ammatory drugs during the fi rst 6 months after operation 
and in addition recommended the use of the largest pulmonary homograft available 
with the use of interrupted sutures for the upper suture line of the homograft. This 
did however thus far not result in a difference in pulmonary homograft events 
between the two centers. Future development of a tissue engineered pulmonary 
valve may offer further steps towards a defi nite solution to this problem(1).
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In the current study, the incidence of other valve-related complications was very 
low. The extremely low occurrence rates of thrombo-embolic complications 
and pulmonary homograft endocarditis, the absence of any other valve-related 
complications and the fact that almost all patients live a life without physical 
impairment further illustrate the superiority of the autograft procedure.
In conclusion, this study strongly suggests that the Ross root replacement in adults 
may be associated with a decrease in excess mortality when compared to other 
valve substitutes. This however, needs to be confi rmed in larger series followed up 
for longer periods and, importantly, in prospective randomized trials. The optimal 
surgical technique should be meticulously applied and progressive dilatation in 
neo-aortic root warrants periodical close observation of all autograft patients. 
Homograft degeneration in the right ventricular outfl ow tract continues to be a 
problem but does not appear to undermine the overall value of the operation. 
Acknowledgements
We thank Marijke Rozema-Botermans for her excellent secretarial assistance in 
pursuing a complete follow-up of this patient cohort.
Loes bw.indd   139 31-10-2007   14:41:00
Chapter 7
140
References
1. Yacoub MH, Takkenberg JJM. Will heart valve tissue engineering change the world? Nature 
Cardiovasc Med 2005;2:60-61.
2. Kvidal P, Bergstrom R, Horte LG, Stahle E. Observed and relative survival after aortic valve 
replacement. J Am Coll Cardiol 2000;35:747-56.
3. Yacoub MH, Cohn LH. Novel approaches to cardiac valve repair: from structure to function: Part 
I. Circulation 2004;109:942-50.
4. Ross DN. Replacement of aortic and mitral valves with a pulmonary autograft. Lancet 
1967;2:956-8.
5. Carr-White GS, Afoke A, Birks EJ, et al. Aortic root characteristics of human pulmonary 
autografts. Circulation 2000;102:III15-21.
6. Luciani GB, Casali G, Favaro A, et al. Fate of the aortic root late after Ross operation. Circulation 
2003;108 Suppl 1:II61-7.
7. Kouchoukos NT, Masetti P, Nickerson NJ, Castner CF, Shannon WD, Davila-Roman VG. 
The Ross procedure: long-term clinical and echocardiographic follow-up. Ann Thorac Surg 
2004;78:773-81; discussion 773-81.
8. David TE, Omran A, Ivanov J, et al. Dilation of the pulmonary autograft after the Ross procedure. 
J Thorac Cardiovasc Surg 2000;119:210-20.
9. Takkenberg JJ, Dossche KM, Hazekamp MG, et al. Report of the Dutch experience with the Ross 
procedure in 343 patients. Eur J Cardiothorac Surg 2002;22:70-7.
10. Carr-White GS, Kilner PJ, Hon JK, et al. Incidence, location, pathology, and signifi cance of 
pulmonary homograft stenosis after the Ross operation. Circulation 2001;104:I16-20.
11. ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the 
American College of Cardiology/American Heart Association. Task Force on Practice Guidelines 
(Committee on Management of Patients with Valvular Heart Disease). J Am Coll Cardiol 
1998;32:1486-588.
12. Willems TP, Takkenberg JJM, Steyerberg EW, et al. Human tissue valves in aortic position : 
determinants of reoperation and valve regurgitation. Circulation 2001;103:1515-21.
13. Edmunds LH, Jr., Clark RE, Cohn LH, Grunkemeier GL, Miller DC, Weisel RD. Guidelines 
for reporting morbidity and mortality after cardiac valvular operations. Ad Hoc Liaison 
Committee for Standardizing Defi nitions of Prosthetic Heart Valve Morbidity of The American 
Association for Thoracic Surgery and The Society of Thoracic Surgeons. J Thorac Cardiovasc Surg 
1996;112:708-11.
14. Clark TG, Altman DG, De Stavola BL. Quantifi cation of the completeness of follow-up. Lancet 
2002;359:1309-10.
15. Takkenberg JJM, Puvimanasinghe JP, Grunkemeier GL. Simulation models to predict outcome 
after aortic valve replacement. Ann Thorac Surg 2003;75:1372-6.
16. Takkenberg JJM, Puvimanasinghe JPA, van Herwerden LA, et al. Prognosis after aortic valve 
replacement with SJM bileafl et prostheses: impact on outcome of varying thrombo-embolic 
hazard. Eur Heart J Supplements 2001;3 (Suppl. Q):Q27-32.
17. Takkenberg JJM, Eijkemans MJ, van Herwerden LA, et al. Prognosis after aortic root replacement 
with cryopreserved allografts in adults. Ann Thorac Surg 2003;75:1482-9.
18. Elkins RC. The Ross operation: a 12-year experience. Ann Thorac Surg 1999;68:S14-8.
Loes bw.indd   140 31-10-2007   14:41:00
An Evaluation Of The Ross Operation In Adults
141
19. Hokken RB, Bartelings MM, Bogers AJ, Gittenberger-de Groot AC. Morphology of the pulmonary 
and aortic roots with regard to the pulmonary autograft procedure. J Thorac Cardiovasc Surg 
1997;113:453-61.
20. Wagenvoort CA, Neufeld HN, Edwards JE. The structure of the pulmonary arterial tree in fetal 
and early postnatal life. Lab Invest 1961;10:751-62.
21. Bogers AJ, Kappetein AP, Roos-Hesselink JW, Takkenberg JJM. Is a bicuspid aortic valve a risk 
factor for adverse outcome after an autograft procedure? Ann Thorac Surg 2004;77:1998-2003.
22. Settepani F, Kaya A, Morshuis WJ, Schepens MA, Heijmen RH, Dossche KM. The Ross operation: 
an evaluation of a single institution’s experience. Ann Thorac Surg 2005;79:499-504.
23. Niwaya K, Knott-Craig CJ, Lane MM, Chandrasekaren K, Overholt ED, Elkins RC. Cryopreserved 
homograft valves in the pulmonary position: risk analysis for intermediate-term failure. J Thorac 
Cardiovasc Surg 1999;117:141-6; discussion 46-7.
24. Elkins RC, Dawson PE, Goldstein S, Walsh SP, Black KS. Decellularized human valve allografts. 
Ann Thorac Surg 2001;71:S428-32.
Loes bw.indd   141 31-10-2007   14:41:00
Loes bw.indd   142 31-10-2007   14:41:00
 CHAPTER 8 
THE ROSS PROCEDURE:
A SYSTEMATIC REVIEW
Discussion paper emerging from an expert meeting on the clinical, surgical/technical, 
and histological factors that may affect autograft durability, Rotterdam, the Netherlands, 
November 3, 2005.
The Ross Procedure: A systematic Review. Takkenberg JJM, Klieverik LMA, Schoof PH, 
van Suylen RJ, van Herwerden LA, Zondervan PE, Roos-Hesselink JW, Yacoub MH, 
Bogers AJJC. Submitted
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ABSTRACT
Background
To give a systematic review of outcome after the Ross procedure, and discuss the 
patient-related factors, surgical-technical considerations and histological aspects of 
the procedure to improve insight into potential determinants of success for this 
special operation.
Methods and results
A systematic review of reports published between 01/2000 and 08/2006 on outcome 
after the Ross procedure was done. Twenty-six papers met the inclusion criteria and 
were allocated to 3 partially overlapping categories of (1) consecutive series, (2) 
pediatric patient series and (3) adult patient series. Using straight pooling linearized 
occurrence rates of morbidity and mortality were obtained.
Pooled mortality rates were excellent (0.39, 0.44 and 0.45%/patient year for 
consecutive, pediatric and adult patients series respectively), and occurrence rate 
of most valve-related complications low. Reintervention rates for structural valve 
deterioration of the autograft were 1.1%, 1.2% and 0.6%/patient year respectively: 
and for pulmonary allograft 0.44%, 0.79%, and 0.41%/patient year respectively. 
Patient-related, surgical and histological factors were discussed in relation to the 
observed results of the systematic review.
Conclusions
The Ross procedure provides both children and young adults with satisfactory 
results, but has several limitations that become apparent by the end of the fi rst 
decade after operation. Whether these limitations may at least in part be addressed 
by the surgical details and postoperative measures discussed in this paper remains 
to be determined.
Keywords: epidemiology, prognosis, surgery, survival, valves 
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Introduction
The autograft or Ross procedure, developed in Norman Shumway’s research 
laboratory1 and was introduced in clinical practice by Donald Ross in 19672 . 
In this operation the pulmonary root is used to replace the diseased aortic valve 
or root, the pulmonary root being replaced with a substitute, often an allograft. 
Potential advantages are the use of the patient’s own living valve with favourable 
haemodynamic characteristics, low endocarditis risk, low thrombogenicity, 
avoidance of anticoagulant therapy, and autograft size increase in children. The 
autograft is the only valve substitute which guarantees long-term viability of most 
components of the valve. This could allow the valve to respond and/or adapt to 
environmental factors. However, the Ross procedure is a technically demanding 
operation and the autograft in aortic position and the valve substitute in the right 
ventricular outfl ow tract (RVOT) may develop structural failure over time. 
With the growing clinical experience with the Ross procedure in young adult patients, 
the notion arises that results with this procedure vary widely among implanting 
centers. Although survival of young adult patients after this procedure is almost 
uniformly excellent and comparable with the general population, durability of the 
autograft valve is in some centers clearly superior to other biological valve conduits 
while other centers report worrisome autograft reoperation rates comparable to 
other bioprostheses. It remains unclear why these individual results diverge so much 
and whether there are keys to success for a durable result.
Reviews are essential tools for health care workers and researchers to keep up 
with the accumulating evidence in their fi eld. They are also required to identify 
areas –such as outcome after the Ross procedure- where the available evidence is 
insuffi cient. Systematic reviews allow for a more objective appraisal of the evidence 
than traditional narrative reviews and may thus contribute to resolve uncertainty 
when original research, reviews and editorials disagree3. The goal of this discussion 
paper is to give a systematic review of reported outcome after the Ross procedure, 
and discuss patient-related factors, surgical-technical considerations and histological 
aspects of the Ross procedure in order to improve insight into potential determinants 
of success for this special operation.
Methods
Systematic review of reported outcome after the Ross procedure
On October 1, 2006 we performed a literature search of the MEDLINE database 
using the PubMed search engine for studies published between January 1, 2000 
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and July 31, 2006, to obtain the most recent reports with the longest follow-up. 
MeSH terms and text words used for the search were “autograft” and “aortic valve 
replacement”, limited to English publications. The search resulted in 120 publications. 
All titles and abstracts were screened for study design (reports of clinical experience 
with autograft aortic valve or root replacement), and completeness of follow-up 
(>90%), study size (N>39, refl ecting the center’s experience). References of selected 
papers were crosschecked for other potentially relevant studies. In case of multiple 
publications on the same patient population, the most recent report was selected. 
Ninety-four papers were excluded from the review for the following reasons: case 
report, review or comment (N=33), echocardiographic, MRI or other imaging 
studies (N=16), different subject (N=14), overlap with other publications (N=14), 
study size too small (N=13), <90% completeness of follow-up (N=3), unable to 
retrieve publication (N=1). The remaining 26 papers were reviewed and patient 
characteristics and results of each study were tabulated in a spreadsheet. 
After review, we allocated the papers to 3 partially overlapping categories: (1) 
consecutive series without selection criteria (N=15);4-18 (2) series reporting on 
outcome after the Ross procedure mostly in children (including children < 1 year at 
the time of the procedure) (N=6);9, 19-23 and (3) series reporting on outcome after the 
Ross procedure mainly in adults and/or children ages 10 and older at the time of the 
procedure (N=10).6, 12, 15, 17, 24-29 Events and outcomes in all studies were registered 
according to the guidelines for reporting morbidity and mortality after cardiac 
valvular operations.30 Structural and non-structural valve deterioration were defi ned 
as diagnosed either at reoperation or autopsy. In case the total number of patient 
years was not provided in the selected papers, we calculated it by multiplying the 
number of patients in the study with the mean follow-up duration of that study. 
Estimates of survival, freedom from autograft reintervention and freedom from 
RVOT reintervention were extracted from the selected papers. If these estimates 
were not provided (for survival in 1 paper, for freedom from autograft and/or RVOT 
reintervention in 9 papers), we either extracted them from the survival fi gures in 
that paper or calculated an estimate using the following formula: Freedom from 
event at x years = 1-((number of events/ the number of accumulated patient years) 
x follow-up years with more than 10% of the original population still at risk). 
Linearized occurrence rates of valve-related complications were calculated using 
straight pooling (pooled number of events/pooled number of patient years). When 
a particular valve-related event was not specifi ed in the methods section and/or 
its occurrence was not mentioned in the results section of a study, then this study 
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Table 1. Overview of selected cohort studies in the systematic review
First author Year of 
publication
Operative 
period
Number of 
patients
Surgical 
technique
Study type Mean 
follow-up 
(years)
Mean age 
(yrs; range)
Consecutive series of pediatric and/or adult patients
Moidl11 2000 1991-….. 109 root/sc prospective 2.8 32 (6-59)
Sharoni16 2000 1996-1999 40 root retrospective 1.0 ? (0-41)
Laudito9 2001 1993-2000 72 root/RK retrospective …… 9 (0-40)
Paparella12 2001 1990-1999 155 root/ic/sc retrospective 3.8 35 (17-57)
Pessotto13 2001 1992-1999 111 root/sc retrospective median 3.6 16 (0-67)
Takkenberg18 2002 1988-2000 343 root/ic/sc retrospective 4.0 26 (0-58)
Concha5 2003 1991-2002 169 root prospective# 3.0 30 (0-54)
Fullerton6 2003 1997-2002 44 root retrospective 3.2 49 (19-71)
Sakaguchi14 2003 1986-2000 399 root/ic/sc retrospective 4.5 ? (0-59)
Kouchoukos7 2004 1989-2002 119 root retrospective ….. 31 (5-56)
Kumar8 2005 1993-2003 153 root retrospective 6.4 28 (0-65)
Luciani10 2005 1994-2004 112 root/ic/sc retrospective 5.1 29 (6-49)
Settepani15 2005 1991-2003 103 root retrospective 6.0 35 (17-65)
Brown4 2006 1994-2002 167 root/RK retrospective 5.1 25 (0-61)
Sievers17 2006 1994-2005 347 sc prospective 3.8 44 (14-71)
Pediatric patient series
Elkins20 2001 1986-2001 178 root/ic retrospective 5.5 10 (0-18)
Laudito9 2001 1993-2000 72 root/RK retrospective …… 9 (0-40)
Al-Halees19 2002 1990-2000 53 root retrospective 4.0 8 (0-18)
Hazekamp21 2005 1994-2003 53 root retrospective 5.5 9 (0-18)
Takkenberg23 2005 1988-2003 47 root prospective 6.1 8 (0-15)
Ruzmetov22 2006 1993-…… 81 root/ic retrospective 6.8 ?
Adult patient series
Knott-Craig27 2000 1986-1999 154 root retrospective 3.0 36 (16-62)
Paparella12 2001 1990-1999 155 root/ic/sc retrospective 3.8 35 (17-57)
Fullerton6 2003 1997-2002 44 root retrospective 3.2 49 (19-71)
Concha24 2005 1997-2003 63 root prospective 2.5 35 (20-50)
Khwaja26 2005 1992-…… 53 root? retrospective 5.8 14 (10-21)
Duebener25* 2005 1990-2004 351 root prospective 3.9 43 (16-67)
Settepani15 2005 1991-2003 103 root retrospective 6.0 35 (17-65)
Kumar28 2006 1993-2003 81 root retrospective 7.7 30 (11-56)
Sievers17 2006 1994-2005 347 sc prospective 3.8 44 (14-71)
Yacoub27 2006 1988-2004 264 root/ic prospective 6.4 35 (18-66)
* Only information on the root replacement patients was included, since there was a more recent publication17 on 
the subcoronary patients); # prospective since 1998; Surgical technique: root=freestanding root replacement, sc= 
subcoronary, ic=inclusion cylinder, RK=Ross-Konno procedure
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was excluded from analysis of the pooled occurrence rate of that particular valve-
related event. This applied to the following valve-related events: thrombo-embolism 
(10 studies excluded), bleeding (15 studies excluded), valve thrombosis (15 studies 
excluded), endocarditis autograft (8 studies excluded), endocarditis RVOT (9 studies 
excluded).
Table 1 provides an overview of the publications obtained by the systematic review. 
Table 2 displays observed morbidity and mortality after the Ross procedure by 
category. 
Figure 1A shows observed survival, Figure 1B displays freedom from autograft 
reoperation, Figure 1C freedom from RVOT reintervention, and Figure 1D freedom 
from autograft and/or RVOT reintervention.
Discussion
This systematic review shows that a considerable experience with the Ross procedure 
has accumulated worldwide. Unfortunately, follow-up duration is still too limited 
to make projections of prognosis beyond the fi rst decade after operation. It also 
illustrates that the Ross operation is almost exclusively employed in children and 
young adults, in an age range where its advantages of avoidance of anticoagulant 
therapy, superior haemodynamics and size increase are very important.
Early mortality risk is acceptable, considering that the Ross procedure is a double 
valve procedure. In children early mortality is slightly higher compared to adults. 
This is mainly caused by increased mortality risk in infants with complex congenital 
lesions requiring a Ross-Konno procedure. Late survival is excellent (Figure 1A) and 
resembles in most series survival observed in the age-matched general population.
The occurrence of thrombo-embolic complications, bleeding, non-structural valve 
failure and endocarditis is low compared to other aortic valve substitutes.31-33 One 
randomized trial that compares outcome after allograft versus autograft aortic valve 
replacement shows no difference in freedom from valve-related complications.34 An 
update of this trial (Circulation 110 (17): 672-672 3117 Suppl. S, 2004) shows 
that autograft durability is superior to the allograft, freedom from reintervention is 
comparable and that overall survival of autograft patients is signifi cantly better. With 
time both the autograft and the valve substitute in the RVOT (usually an allograft) 
show limited durability, and autograft reoperation and RVOT reintervention for 
structural valve deterioration are the most common valve-related complications both 
for adult and pediatric patients. Noteworthy in this review is the large variation in 
freedom from autograft reoperation between the different reports. 
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Patient factors
Patient age, etiology of valve disease, and preoperative aortic regurgitation 
and dilatation are the most commonly reported patient-related determinants of 
durability of the autograft valve. Most studies are unable to determine any risk 
Table 2. Pooled mortality and morbidity after the Ross procedure
Consecutive series 
(adult and/or pediatric)
Pediatric patient series Adult patient series
Patients (N) 2,443 484 1,615
Patient years (N) 10,025 2,528 7,160
Pooled mean follow-up 4.1 yrs (median 4.0) 5.2 yrs (median 5.5) 4.4 yrs (median 3.9)
N % or LOR 
(range)
N % or LOR 
(range)
N % or LOR 
(range)
Early mortality 54 2.2% (0-6.8%) 15 3.1% (0-5.6%) 28 1.7% (0-6.8%)
Late mortality 39 0.39 (0-0.9) 11 0.44 (0-1.1) 32 0.45 (0-1.3)
SUUD 7 0.07 (0-0.5) 2 0.08 0-0.3) 7 0.10 (0-0.4)
Thrombo-embolism
(Patient years)
12
(6,663)
0.18 (0-0.5) -
(1,257)
- 20
(6,711)
0.30 (0-0.5)
Bleeding
(Patient years)
3
(4,920)
0.06 (0-0.1) -
(284)
- 1
(4,136)
0.02 (0-0.1)
Valve thrombosis
(Patient years)
-
(4,920)
- -
(284)
- -
(4,136)
-
SVD autograft
Reoperation
Death
108
3
1.1 (0-3.2)
0.03 (0-0.2)
31
-
1.2 (0-3.2)
-
41
2
0.6 (0-1.3)
0.03 (0-0.4)
SVD RVOT
Reintervention
Death
44
-
0.44 (0-0.9)
-
20
1
0.79 (0-1.1)
0.04 (0-0.3)
29
-
0.41 (0-1.1)
-
NSVD autograft
Reoperation
Death
4
1
0.04 (0-0.3)
0.01 (0-0.2)
-
-
-
-
3
-
0.04 (0-0.3)
-
NSVD RVOT
Reintervention
Death
-
-
-
-
-
-
-
-
-
-
-
-
Endocarditis autograft
Reoperation
Death
(Patient years)
13
6
5
(6,804)
0.19 (0-0.7)
0.09 (0-0.7)
0.07 (0-0.4)
2
1
-
(1,469)
0.14 (0-0.5)
0.07 (0-0.5)
11
6
1
(6,853)
0.16 (0-0.7)
0.09 (0-0.7)
0.01 (0-0.2)
Endocarditis RVOT
Reoperation
Death
(Patient years)
10
6
1
(6,804)
0.15 (0-0.7)
0.09 (0-0.3)
0.02 (0-0.2)
2
-
-
(1,257)
0.16 (0-0.4)
-
-
7
5
2
(6,853)
0.10 (0-0.3)
0.07 (0-0.3)
0.03 (0-0.2)
* LOR = Linearized occurrence rate (%/patient year); SUUD = sudden unexpected unexplained death, RVOT= right 
ventricular outfl ow tract, SVD = structural valvular deterioration, NSVD = non-structural valvular deterioration. For 
those events that were not reported in all studies, the patient years are displayed in parentheses). 
Loes bw.indd   149 31-10-2007   14:41:01
Chapter 8
150
factors, hampered by limited numbers of patients, follow-up duration and number 
of autograft failures. From the 26 reports in this systematic review, only a few could 
determine (potential) patient-related determinants of autograft durability.
Younger patient age was previously implicated to be associated with increased 
autograft dilatation, but not with late autograft dysfunction.10 In contrast, in 
another recent report freedom from reoperation for autograft valve failure is better 
in pediatric patients versus adults (92% versus 57% at 13 years postoperative; 
p=0.02).35 From Table 2 it appears that the reoperation rate for autograft structural 
failure is higher in children compared to adults (1.2 versus 0.6%/patient year). 
The pediatric reports in this systematic review have a considerably longer follow-
up duration compared to the adult patient series. Since the hazard of autograft 
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Figure 1A. Overview of reported survival in the consecutive series (), pediatric patient series (Δ), 
and adult patient series (ж)
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Figure 1B. Reported freedom from autograft reoperation in the consecutive series (), pediatric 
patient series (Δ), and adult patient series (ж)
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failure increases with time since operation it therefore appears from Table 2 that 
children are at higher risk of autograft failure. However, Figure 1B shows that at 
10 years postoperative freedom from autograft reoperation does not differ between 
children and adults. The next few years will reveal whether patient age is indeed a 
determinant of autograft durability and whether the observed increased autograft 
dilatation in children will translate to increased autograft failure.
Congenital aortic valve disease (predominantly bicuspid valve disease) was previously 
suggested to be associated with increased risk of dilatation of the autograft root over 
time.36 Although in our systematic review several reports studied the association 
between bicuspid valve disease and autograft durability, only one study found a 
possible association between bicuspid aortic valve and an increased occurrence 
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Figure 1C. Reported freedom from RVOT reintervention in the consecutive series (), pediatric 
patient series (Δ), and adult patient series (ж)
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Figure 1D. Reported freedom from autograft and/or RVOT reintervention in the consecutive series 
(), pediatric patient series (Δ), and adult patient series (ж)
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of aortic regurgitation during follow-up.15 In addition, a recent prospective serial 
echocardiography study failed to fi nd an association between bicuspid valve 
disease and (increase in) aortic regurgitation and neo-aortic dimensions over time.37 
Therefore, the infl uence of bicuspid valve disease on autograft durability remains 
highly debatable.38
Rheumatic valve disease is another etiology reported to be associated with impaired 
autograft survival. Two overlapping reports in the systematic review showed 
an association between rheumatic valve disease in young patients and increased 
autograft dysfunction.8, 28 With increasing patient age recurrence of rheumatic fever 
(and risk of subsequent involvement of the autograft valve) becomes infrequent; this 
explains why in particular young rheumatics are at risk for autograft dysfunction.
Two pediatric studies in the systematic review report an association between 
preoperative aortic regurgitation and autograft failure.9, 20 Both studies hypothesize 
that annular dilatation associated with aortic regurgitation may be a factor, and 
one of the studies suggests a role for altered geometry and tissue characteristics of 
the subvalvular left ventricular outfl ow tract (LVOT) resulting from chronic aortic 
regurgitation. In another study from the systematic review in 90 patients aged 6-49 
years, preoperative aortic root dilatation was predictive of autograft dilatation.10 
The latter paper therefore recommends resection of the dilated aorta rather than 
tailoring the ascending aorta, to prevent dilatation.
Surgical-technical considerations
The variability in durability results of the autograft procedure may also partly be 
explained by the surgical technique and by individual variation of the application of 
the root replacement technique.
The subcoronary implantation technique, as originally employed by Ross, was 
abandoned by most centers for multiple reasons including its technical complexity 
and the attractive option of the root replacement technique that preserves the 
geometry of the autograft valve apparatus. In the systematic review there is only one 
series that reports solely on results with the subcoronary implantation technique. 
Thus far these results are excellent and offer hope for true believers of the Ross 
procedure who are currently discouraged by the disappointing root replacement 
durability results.
Most patients in the systematic review received an autograft using the freestanding 
root replacement technique with reimplantation of the coronary arteries. This 
surgical technique can be applied in a variety of ways. The autograft can be inserted 
on the annulus or below the annulus and scalloping of the muscle rim can be done 
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to a minimum below the valve cusps. Also, either continuous or interrupted sutures 
can be used for the proximal suture line. Another option is to employ support 
to the proximal suture line using for example a strip of pericardium. Finally, the 
autograft root length can be varied. Some surgeons keep the neo-aortic root as 
short as possible above the sinotubular junction while others preserve its complete 
length distally. The variability in autograft durability results (Figure 1B) could be 
explained by the non-uniform application of the root replacement technique. In 
theory, supra-annular placement of the proximal suture line may predispose to 
dilatation and regurgitation. However, supra-annular positioning is not associated 
with dysfunction or poor autograft durability in children. Also, echocardiographic 
follow-up studies show that dilatation is most pronounced at the sinus and sino-
tubular junction level, and to a lesser extent at the level of the annulus.7, 36 These 
observations imply that minimization of the autograft root length may result in less 
dilatation and may produce better durability.
Probably the ascending aorta diameter should not exceed the autograft diameter at 
the outfl ow anastomosis. Most surgeons will match the size of the aortic annulus 
and receiving aorta to the dimensions of the pulmonary autograft when indicated. 
In patients with ascending aorta aneurysm the replacing Dacron graft may have a 
stabilizing effect on the aorta-pulmonary junction. In addition, the convexity of the 
autograft (anterior pulmonary root) should preferably come on the right side in 
aortic position (former ascending aortic convexity). The unsupported facing sinus 
of the pulmonary valve should be placed in the left coronary position where it 
derives support from surrounding tissues.
The third surgical technique used to insert the autograft is the inclusion cylinder 
technique. It is infrequently used: in 7.7% in the consecutive series, 7.9% in the 
pediatric patient series and 5.2% in the adult patient series in this review. The 
inclusion cylinder technique prevents dilatation of the neo-aortic root,12, 36 but its 
application requires an intact anatomy of the ascending aorta and aortic root and 
is limited by several technical challenges, including distortion of the reinserted 
coronary arteries.39
Another measure that may potentially increase autograft root durability is 
postoperative antihypertensive treatment. It was reported that the physical properties 
of the pulmonary root change after being in the aortic position for a short time.40 
Since the autograft will be subject to signifi cantly increased mechanical stress, blood 
pressure control may result in improved valve longevity. Whether this treatment is 
effective and whether it should be restricted to the early postoperative period29 or 
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for a prolonged period of time, has not yet been studied systematically. One can 
argue that prolonged use of beta blockers or other antihypertensive drugs defeats 
the purpose of the Ross operation, and may seriously impair quality of life in this 
young patient population.
The allograft is the valve substitute used to reconstruct the RVOT is in most patients 
in this review. A small proportion of patients received a bioprosthesis, mostly a 
bovine jugular vein conduit. The durability of the valve substitute in the RVOT is 
thus far quite good. From Table 2 it appears that structural valve deterioration of the 
valve substitute in the RVOT is more common in children compared to adults (0.79 
versus 0.41 %/patient year), but there is no apparent difference between the pediatric 
and adult patient reports from Figure 1C. However, 2 of the larger studies did fi nd an 
association between younger patient age and increased occurrence of structural failure 
of allografts implanted in the RVOT,17, 18 suggesting that patient age affects allograft 
durability. Measures to improve durability of the allograft in the RVOT are the use of 
pulmonary allografts41 and prescription of anti-infl ammatory drugs to suppress the 
specifi c immune response of the recipient to the allograft.42 Reintervention for allograft 
stenosis usually is a minor, elective procedure, associated with very little mortality, as 
shown in Table 2. Hopefully, with further development of tissue engineered valved 
conduits a more durable solution will be found for RVOT reconstruction.43 Also, 
the emergence of percutaneous pulmonary valve re-replacement, offers patients with 
degenerated RVOT allografts a less invasive reintervention.44
Histological aspects
Rabkin-Aikawa et al. reported that explanted autografts are viable and have a near-
normal trilaminar cuspal structure and collagen architecture, but autograft walls 
are damaged, with focal loss of normal smooth muscle cells, elastin, and collagen.45 
More recently, the centers participating in the Dutch Ross registry18, reported 
their histological fi ndings in 30 explanted autografts.46 This report illustrated 
that compared to normal pulmonary and aortic valves, explanted autograft 
valves also have an intact laminar architecture and cellularity, but apposition of 
fi brous tissue on the ventricular surface increases overall valve thickness, as can 
be seen in longstanding valvular insuffi ciency. The autograft wall typically shows 
severe aneurysm formation with intimal hyperplasia, and medial degeneration 
characterized by elastin loss and fragmentation, hypertrophy of smooth muscle cells 
and adventitial fi brosis containing functional vasa vasorum.
An important question arising from the observed histological features of autograft 
valves and walls is: do they represent appropriate repair with the adapted neo-aorta 
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as a functional and stable end product? The majority of explants was removed for 
clinical failure and thus proved unstable. Therefore one can argue that the observed 
changes, the result of adaptive remodelling, are pathologic and should be classifi ed 
as degenerative. The mode of adaptation conceivably differs between normal 
aorta and pulmonary root which each having their own typical functional design. 
Consequently, the pulmonary root has a different stress-strain curve than the aortic 
root with a greater extensibility at lower strain levels. One can therefore expect 
the neo-aortic root to stretch beyond its normal transitional point of high to low 
extensibility. This is supported by in vitro analysis of pulmonary root dynamics.47 
The theoretical consequence of this stretch is compliance loss and root stiffening, 
a mechanism supported by clinical MRI study, confi rming distensibility loss of the 
pulmonary autograft in adult patients.48 Adding to this the thin walled and dilated 
neo-aortic root, it is plausible that the autograft is subject to signifi cantly elevated 
stresses, and that observed histological changes of elastin loss (distensibility) and 
collagen increase (integrity) are conceivable modes of adaptation where functional 
priority is shifted to integrity maintenance. Despite this adaptation, as in any 
aneurysm, excess wall stress may induce intimal tearing causing a localized chronic 
dissection, which was indeed observed in two of our explants.
Obviously, changes in root geometry and dynamics infl uence valve function and 
durability. The failure of adaptation may be seated in the inability of the anatomic 
pulmonary root to adequately adapt to systemic pressures which are way off the 
limits of normal physiology. Remodelling without establishing a new steady state 
may become sustained activity that may eventually exhaust wall structure, clinically 
translating into autograft failure.
To further elucidate the mechanisms of autograft remodelling, more experimental 
studies are necessary, including immunohistochemical, biochemical, and molecular 
studies, uniform quantifi cation of observed histological changes, including 
proliferation, apoptosis and senescence of the autograft, and testing of mechanical 
properties
Limitations
Selection bias is likely in this systematic review of published cohort studies, due to the 
selection criteria employed and since unpublished data, abstracts and presentations 
were not included. Moreover, the occurrence of valve-related complications is 
probably underestimated since most of the studies had a retrospective design. 
Also, valve degeneration requiring reintervention is described in this paper using 
linearized occurrence rates. Valve degeneration has an increasing hazard with time 
Loes bw.indd   155 31-10-2007   14:41:03
Chapter 8
156
since implantation and may better be described using a Weibull distribution, which 
accommodates a changing hazard over time.49 However, since follow-up duration 
of most studies is limited to the fi rst postoperative decade, and no increasing hazard 
was yet observed, we chose to depict only linearized rates. In our own experience 
progressive aortic regurgitation and dilatation after autograft aortic root replacement 
shows a linear pattern over time37, but in the second decade there appears to be 
a worrisome increasing hazard with time for autograft valve reoperation due to 
progressive dilatation and aortic regurgitation.35 
We did not study echocardiographical valve performance in this review. It is extremely 
diffi cult to obtain this type of information since it is infrequently, incompletely and 
inconsistently reported in most included studies. Another factor complicating the 
assessment of the degree of aortic regurgitation and aortic dilatation is the fact that 
these are not hard endpoints but longitudinal outcomes, “snapshots” of autograft 
function, which may be taken repeatedly at prospectively specifi ed follow-up 
intervals, cross-sectionally, or opportunistically. These snapshots are subject to 
many biases, and precision of the measurements is very important and dependent 
on multiple factors, related to the haemodynamic status of the patient, and technical 
factors. In our opinion, the correct way to measure this type of longitudinal 
outcome, is to estimate the average outcome pattern over time and its variability 
in the patient group, and requires multiple serial echocardiographic measurements, 
that are analyzed using hierarchical models37.
Conclusions
From the considerable experience with the Ross procedure that has accumulated 
worldwide we can conclude that it provides both children and young adults an 
adequate biological solution in the fi rst decade after the operation. On the downside, 
it is a double valve procedure with several limitations that become apparent by the 
end of the fi rst decade after the procedure, as evidenced by Figure 1D. Whether these 
limitations may at least in part be addressed by surgical details and postoperative 
measures discussed in this paper remains to be determined.
The pulmonary autograft is a valve designed for a low pressure environment. Its 
durability in aortic position depends on the appropriate surgical technique applied 
in a systematic fashion and tailored to the individual patient. Only in this setting 
the ingenious concept developed by Donald Ross 40 years ago, will continue to 
provide young patients with aortic valve disease a solution that meets their needs 
and standards of living.
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ABSTRACT 
Aims 
The Ross operation is the operation of choice for children who require aortic valve 
replacement (AVR) and may also provide a good option in selected adult patients. 
Although the autograft does not require anticoagulation and has a superior 
haemodynamic profi le, concern regarding autograft and allograft longevity has 
risen. In this light, we report the 13-year results of our prospective autograft cohort 
study.
Methods and Results
Between 1988 and 2005 146 consecutive patients underwent AVR with a pulmonary 
autograft at Erasmus Medical Center Rotterdam. Mean age was 22 years (SD 13; 
range 4 months – 52 years), 66% were male. Hospital mortality was 2.7% (N=4), 
during follow-up 4 more patients died. 13-year survival was 94%±2%. Over time, 
22 patients required autograft reoperation for progressive neo-aortic root dilatation. 
Additionally, 8 patients required allograft reoperation. Freedom from autograft 
reoperation at 13 years was 69%±7%. Freedom from allograft reoperation for 
structural failure at 13 years was 87%±6%. Risk factors for autograft reoperation 
were previous AVR and adult patient age.
Conclusions
Although survival of the Rotterdam autograft cohort is excellent, over time a 
worrisome increase in reoperation rate is observed. Given the progressive autograft 
dilatation careful follow-up of these patients is warranted in the second decade after 
operation.
Key words: Ross operation, prospective study, survival, autograft dilatation, 
reoperation
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Introduction
The autograft procedure was introduced by Donald Ross in 1967.[1] Ross initially 
used the scalloped subcoronary implantation technique to insert the pulmonary 
valve into the left ventricular outfl ow tract with encouraging results.[2] It became 
a worldwide-accepted procedure for aortic valve replacement despite the need for 
specifi c surgical expertise to perform this complicated operation on both the aortic 
and pulmonary valve. 
Initially, the Ross operation was employed using the subcoronary implantation 
technique but over the years most centers shifted towards the root replacement 
technique, nowadays the most commonly used implantation technique. Conservation 
of the autograft root appeared to be more versatile and associated with a decreased 
incidence of early and late failure compared to the other techniques.[3,4] 
Several studies reported satisfactory midterm and long-term results of the Ross 
operation.[5-8] 
The pulmonary autograft has excellent haemodynamic adaptation, there is no need 
for anticoagulation, patients can live an active lifestyle and patient survival seems to 
be superior compared with survival of patients with other valve substitutes.[2,5,9] 
However, in recent years the number of reports on the reoperation rate after the Ross 
operation using root replacement is becoming more and more extensive[8,10-12] 
thus questioning the durability of the autograft.
The Ross operation has previously been claimed to be the next best thing to nature, 
but at present serious drawbacks are shown, raising the question whether or not 
this operation may turn out to be a Trojan Horse. In this regard we evaluated our 
prospective cohort study of the Ross operation with emphasis on patient survival, 
durability of the autograft and pulmonary allograft and the incidence of and potential 
risk factors for reoperation after the Ross operation in children and adult patients.
Methods 
Patients 
From 1988 until 2005 146 consecutive patients underwent the Ross operation at 
our institution. Preoperative patient characteristics are shown in Table 1. Twelve 
patients underwent previous aortic valve replacement: 6 subcoronary homografts, 
3 biological prostheses and 3 mechanical prostheses were used. Approval from the 
Institutional Review Board was obtained for this prospective follow-up study; the 
Institutional Review Board waived informed consent.
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Table 1. Preoperative patient characteristics
All patients
N=146
Patients <16 yrs
N=52
Patients ≥ 16 yrs
N=94
Mean age (years (SD; range)) 22.4 (13.4; 0.3-52) 8.0 (5.4; 0.3-15) 30.4 (9.1; 16-52)
Male gender 66% (n=96) 67% (n=35) 65% (n=61)
Prior cardiac surgery*
Prior aortic valve replacement
Prior valvulotomy
33% (n=48)
8% (n=12)
18% (n=26)
44% (n=23)
-
31% (n=16)
27% (n=25)
13% (n=12)
11% (n=10)
Prior balloon dilatation 20% (n=29) 46% (n=24) 5% (n=5)
Aetiology
Endocarditis 
Congenital (incl. bicuspid)
Other (mainly prosthetic valve)
Degenerative/Rheumatic
Aneurysm/Dissection
5% (n=8)
74% (n=108)
13% (n=18)
8% (n=11)
1% (n=1)
6% (n=3)
90% (n=47)
2% (n=1)
2% (n=1)
-
5% (n=5)
65% (n=61)
19% (n=17)
11% (n=10)
1% (n=1)
Diagnosis 
Aortic valve regurgitation (AR)
Aortic valve stenosis (AS)
AR+AS
30% (n=44)
32% (n=47)
38% (n=55)
17% (n=9)
33% (n=17)
50% (n=26)
37% (n=35)
32% (n=30)
31% (n=29)
Systolic LVF§ (n=140)
Good (EF >50%)
Impaired (EF 40-50%)
Moderate/bad (EF <40%)
83% (n=116)
11% (n=16)
6% (n=8)
83% (n=39)
17% (n=8)
-
82% (n=77)
9% (n=8)
9% (n=8)
Sinus rhythm 100% 100% 100%
Creatinin (μmol/L (SD; range), n=145) 63 (24; 12-157) 40 (13; 12-71) 75 (18; 38-157)
NYHA class (n=143)
I
II
III
IV/V
42% (n=61)
36% (n=53)
15% (n=22)
5% (n=7)
56% (n=29)
21% (n=11)
8% (n=4)
11% (n=5)
34% (n=32)
45% (n=42)
19% (n=18)
2% (n=2)
Ventilation support 2% (n=3) 4% (n=2) 1% (n=1)
Type operation 
Emergency (<24 hrs)
Urgent
Elective
1% (n=1)
13% (n=20)
86% (n=125)
-
23% (n=12)
77% (n=40)
1% (n=1)
9% (n=8)
90% (n=85)
*Some patients had other prior cardiac surgery, i.e. VSD closure, subvalvular membrane resection 
§ Systolic left ventricular function based on echocardiographic estimations, EF = ejection fraction.
Operation
Perioperative data are shown in Table 2. All surgical procedures were performed on 
cardiopulmonary bypass with moderate hypothermia, in 3 patients additional deep 
hypothermia with total circulatory arrest was needed for surgery on the aortic arch. 
Crystalloid cardioplegia and topical cooling were used for myocardial protection.
In most patients the root replacement technique was employed, and the pulmonary 
autograft was inserted at the level of the annulus while care was taken to reduce 
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the subannular muscular rim of the autograft to 3-4 mm. The proximal suture line 
of the autograft was constructed with interrupted sutures in 21% (n=30) of the 
procedures, with running sutures in the remainder. In 2 patients an autologous 
pericardial strip supported the proximal suture line. 
In all patients the right ventricular outfl ow tract (RVOT) was reconstructed using 
an allograft, in 98% a pulmonary allograft was used and 99% of the allografts used 
were cryopreserved. Three patients required concomitant coronary artery bypass 
grafting (CABG) due to a procedural complication.
Table 2. Perioperative details
All patients
n=146
Patients <16 yrs
n=52
Patients ≥ 16 yrs
n=94
Aortic valve
Bicuspid
Tricuspid
Prosthesis
61% (n=89)
32% (n=46)
7% (n=11)
69% (n=36)
31% (n=16)
-
56% (n=53)
32% (n=30)
12% (n=11)
Surgical technique
Autograft root replacement
Inlay autograft
96% (n=140)
4% (n=6)
100%
-
94% (n=88)
6% (n=6)
Concomitant procedures
CABG
LVOT enlargement
Mitral valve surgery
Other*
2% (n=3)
10% (n=14)
1% (n=1)
11% (n=17)
-
21% (n=11)
-
14% (n=8)
3% (n=3)
3% (n=3)
2% (n=1)
10% (n=9)
CPB time (min) 202 (114-685) 179 (118-465) 215 (114-685)
Cross-clamp time (min) 141 (90-240) 125 (90-240) 150 (90-238)
Circulatory arrest (N=3, min) 30 (11-64) 15 (n=1) 37 (11-64, n=2))
Complications
Bleeding/Tamponade
Pacemaker
Perioperative MI
13% (n=19)
1% (n=1)
1% (n=1)
2% (n=1)
2% (n=1)
-
19% (n=18)
-
1% (n=1)
Early mortality 2.7% (n=4) 2% (n=1) 3% (n=3)
*Includes patients requiring tailoring of the ascending aorta or subvalvular membrane resection
Follow-up 
All patients were followed prospectively and annually contacted and interviewed 
by telephone. Patients over 16 years underwent standardized echocardiography 
biannually.[13] 
In case of suspected complications the attending physician was contacted for 
verifi cation. Valve-related events were defi ned according the guidelines for reporting 
morbidity and mortality after cardiac valvular operations.[14] Hospital mortality 
and morbidity were registered and the causes of death were documented. Hospital 
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mortality was defi ned as death of the patient within any time interval of operation 
if the patient was not discharged from the hospital. Failure of the autograft or 
pulmonary allograft was determined at time of reoperation or death. Patient survival 
started at time of the Ross operation and ended at time of death or at last follow-
up. Survival of the autograft or pulmonary allograft started at time of operation 
and ended when a reoperation or reintervention was done, when the patient died 
or at last follow-up. Two patients moved abroad and were lost to follow-up. 
Echocardiographic measurements were obtained for patients who did not die or did 
not require reoperation related to the Ross operation during follow-up.
The database was frozen on October 1st, 2005. Total follow-up was 1269 patient 
years and was 99.3% complete.[15] Mean follow-up duration was 8.7 years (range 
0-17.1 years). 
Statistical methods 
Descriptive statistical analysis of perioperative data was done. Continuous data are 
displayed as mean ± 1 standard deviation and were compared using the unpaired 
T-test. Discrete data are presented as proportions and were compared using the Chi-
square Test or Fisher exact Test. Cumulative survival and freedom from reoperation 
or reintervention were analysed using the Kaplan-Meier method. Survival is 
displayed as a proportion ± standard error. Age-matched survival in the general 
population was calculated using the Dutch population life tables (http://statline.cbs.
nl/). The log-rank test was used to compare Kaplan-Meier curves. 
The Cox proportional hazards regression analysis was used to evaluate the following 
variables as predictors for autograft reoperation over time: previous aortic valve 
replacement, patient age, bicuspid valve disease, the surgical technique used (root 
replacement versus inclusion cylinder technique) and haemodynamic diagnosis 
(regurgitation versus stenosis versus combined regurgitation and stenosis). First, 
all variables were entered into a univariable analysis. Next, all variables that were 
signifi cant in the univariable analysis or showed a tendency towards signifi cance 
(P≤0.20) were forced into the multivariable Cox regression analysis (enter method); 
The proportional hazards assumption was assessed for each variable through 
graphical inspection of the log minus log survival and the linearity assumption 
for continuous variables though the partial residuals. There was no indication 
of violation of the assumptions. A p-value of ≤ 0.05 was considered statistical 
signifi cant. All testing was performed 2-sided. For all data analysis SPSS 12.0.1 for 
Windows (SPSS, Chicago, Illinois) was used. 
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Results
Hospital mortality and late survival
Hospital mortality was 2.7% (4 patients). Two patients, both female, died 
perioperatively. One 40-year-old patient died due to low output failure and the 
other patient, 4 months old, died of heart failure and severe arrhythmias. 
One 26-year-old male patient died due to massive pulmonary emboli shortly after the 
operation Finally, one 24-year-old female patient with Turner syndrome and extreme 
left ventricular hypertrophy died due to mediastinitis and sepsis 13 days after surgery. 
During follow-up 4 more patients died. There were 1 valve-related and 3 non-valve 
related deaths. The valve-related death was a 12-year-old girl with severe juvenile 
rheumatic disease and severe aortic valve regurgitation and mitral valve incompetence 
resulting in progressive heart failure. She died 6 months after operation.[16]
Causes of the non-valve related deaths included septic shock (Candida Albicans) in 
one infant 51 days after autograft operation, heart failure resulting in cardiogenic 
shock in another infant 1.7 years after autograft operation and an acute myocardial 
infarction in an adult patient 4.7 years after autograft operation. The latter patient 
died 2 months after autograft reoperation for structural valve deterioration with 
implantation of a mechanical prosthesis.
Overall 13-year survival was 94.4%±1.9% (Figure 1). For patients younger than 
16 years the 13-year survival was 92.0%±3.8%; for patients older than 16 years 
95.7%±2.1% (Log-rank test p=0.35).
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Figure 1. Observed cumulative survival after the Ross operation and survival of the age- and gender-
matched general Dutch population
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Reoperation
Twenty-four patients underwent a reoperation related to the Ross operation. Of 
these 24 patients, 16 patients required isolated pulmonary autograft replacement, 
6 patients required simultaneous replacement of both the pulmonary autograft and 
allograft and 2 patients required isolated pulmonary allograft replacement.
Table 3 Details on Ross operation-related reoperations
Patient Sex
Age at
Ross
Operation
Years
to
reop
 Indication Prosthesis
implanted Result
 Isolated pulmonary autograft reoperation
 1
 2
 3
 4
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
M
M
M
F
M
F
M
M
M
M
M
M
F
F
F
M
16
28
20
27
28
 8
34
16
33
39
25
26
21
26
22
22
 1.8
 4.5
 5.7
 6.7
 6.7
 7.0
 7.3
 7.6
 7.6
 8.6
 9.1
10.1
11.2
11.7
11.9
12.9
 RF, AR
 RD, AR
 RD, AR
 RD, AR
 RD, AR
 RD, AR
 RD, AR
 RD, AR
 RD, AR
 RD, AR
 RD, AR
 RD, AR
 RD, AR
 RD, AR
 RD, AR
 RD, AR
 MP
 MP
 MP
 MP
 ALL
 ALL
 MP
 MP
 MP
 MP
 MP
 MP
 MP
 MP
 MP
 MP
Alive
Died*
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
 Pulmonary autograft + pulmonary allograft reoperation
17
18
19
20
21
22
M
M
F
F
M
M
26
15
29
41
16
18
 3.1
 7.7
 8.3
 9.3
 9.5
13.1
 Reiter, RD, AR
 RD, AR, PR, PS
 RD, AR, PR
 RD, AR, PR
 RD, AR, PS
 RD, AR, PR
MP, pALL
 ALL, pALL
MP, pALL
MP, pALL
MP, pALL
 ALL, pALL
Alive
Alive
Alive
Alive
Alive
Alive
 Isolated pulmonary allograft reoperation
 1
 2
M
M
12
 4
 9.4
12.8
 PS, endocarditis
 PS, PR
 pALL
 pALL
Alive
Alive
 M = male, F= female, RF= Rheumatic fever, AR=aortic regurgitation, RD= root dilatation,
 Reiter= Reiter’s disease, PR= pulmonary regurgitation, PS=pulmonary stenosis, 
 MP= mechanical prosthesis implanted as a conduit, ALL =allograft, pALL= pulmonary allograft
 *This patient died 2.5 months after the reoperation
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Progressive dilatation of the neo-aortic root was the main cause for autograft 
reoperation. Table 3 shows details of each operation. 
Causes for allograft replacement were mainly structural failure, calcifi cation or 
senile degeneration of the valve. One patient had a recurrent episode of rheumatic 
fever involving the autograft, thus requiring a reoperation. Two patients underwent 
a reoperation without valve replacement. One patient underwent enlargement of 
the pulmonary outfl ow tract due to supravalvular pulmonary stenosis and the other 
patient required reoperation for constrictive pericarditis. One patient underwent 
balloonvalvuloplasty of the RVOT to relieve supravalvular pulmonary stenosis. 
Freedom from reoperation for autograft failure at 5 years was 97.7%±1.3% and 
at 13 years 69.2%±6.6% (Figure 2). Freedom from autograft reoperation was 
signifi cantly better for patients younger than 16 years compared to patients aged 
16 years and older at the time of operation (at 13 years 92.1%±5.4% versus 
56.7%±9.6% (Log-rank test p=0.02)). 
Freedom from allograft reoperation for structural failure at 5 years was 99.2%±0.8% 
and at 13 years 87.1%±5.5% (Figure 3). Freedom from allograft reoperation for 
structural failure did not differ for patients younger than 16 years compared to 
patients aged 16 years and older at the time of operation (80.0%±1.1% versus 
92.5%±3.8% at 13 years (Log-rank test p=0.73)). 
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Figure 2. Overall freedom from autograft reoperation and freedom from autograft reoperation for 
adult patients (16 years and older) versus children
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Univariable predictors of autograft reoperation were previous aortic valve 
replacement (HR 2.8; 1.1-7.1 p=0.03) and adult patient age (HR 5.0; 1.2-21.1 
p=0.03). After multivariable analysis adult patient age remained the only signifi cant 
predictor of autograft reoperation (HR 4.6; 1.01-21.1 p=0.05) (Table 4).
Other valve-related events
During follow-up two patients developed endocarditis (0.16%/patient year), 
complicated by a stroke in one patient. In one patient allograft endocarditis occurred 
and was treated with antibiotics. One patient developed pulmonary emboli (0.08%/
patient year). Bleeding events, valve thrombosis or non-structural failure were not 
observed.
Functional status at follow up
At last follow up, 95% of the patients were in New York Heart Association 
(NYHA) class I or II. Eleven percent of the patients had moderate to severe aortic 
regurgitation, 3% moderate to severe pulmonary regurgitation and 8% of the 
patients had moderate to severe pulmonary stenosis.
Discussion 
Our study shows that the autograft procedure initially fulfi ls the prospect with regard 
to excellent long term survival and avoidance of anticoagulation therapy. Especially 
children, patients who want to live an active lifestyle and women who want to 
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Figure 3. Freedom from pulmonary allograft reoperation for all 146 patients
The dotted lines indicates upper limit and the lower limit of the 95% confi dence interval
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become pregnant benefi t the most from this operation. However, with time we also 
observed an increase in reoperations related to the Ross operation, confi rming the 
scepticism about the superior durability of this procedure. 
In our prospective cohort study the survival of patients who undergo a Ross operation 
is excellent compared with survival of patients receiving other valve substitutes, 
and is even comparable with the general age-and gender-matched population. The 
question remains if this can be ascribed solely to the autograft procedure. Patient 
selection bias is not unlikely since our Ross patients are mainly patients who undergo 
elective surgery, present with no or mild symptoms of dyspnoea, usually have isolated 
aortic valve disease and a normal preoperative cardiac rhythm.[17] However, in the 
prospective randomised trial by Yacoub and colleagues, the pulmonary autograft 
was compared with the allograft, and a survival advantage on the long-term was 
observed in favour of the pulmonary autograft.[18] 
Nevertheless, we observed a worrisome increase in autograft reoperations in the 
second decade after the Ross operation. The main cause for reoperation after the 
Ross operation is dilatation of the neo-aortic root. Due to this dilatation coaptation 
of the cusps is lost and aortic regurgitation occurs. Reporting a small but persistent 
increase in root dimensions and neo-aortic root regurgitation over time, a previous 
study by our institution anticipated that more reoperations would be necessary in 
upcoming years.[19] These fi ndings are also confi rmed by other studies.[8,10] 
Table 4. Risk factors for autograft reoperation
Risk factors
Univariable 
analysis
 HR 95% C.I. P-value 
Multivariable
analysis
HR 95% C.I. P-value
Previous AVR
Adult patient age
Bicuspid valve
Sex
Surgical technique
Haemodynamic diagnosis
 AS
 AR 
 AR+AS
 2.8 (1.1-7.1) p=0.03
 
 5.0 (1.2-21.1) p=0.03
0.52 (0.23-1.2) p=0.13
0.80 (0.32-1.96) p=0.62
0.20 (0.0-24.8) p=0.53
1.0
1.5 (0.5-4.2) p=0.5
0.9 (0.3-2.7) p=0.9
1.2 (0.4-4.2) p=0.74
4.6 (1.01-21.1) p=0.05
0.6 (0.2-1.7) p=0.36
 
0.7 (0.3-1.8) p=0.45
0.0 (0.0-0.0) p=0.98
-
1.03 (0.3-3.2) p=0.96
0.7 (0.2-2.4) p=0.56
 HR = hazard ratio, with 95% confi dence intervals (C.I.)
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Although the exact causes of autograft root dilatation still have to be determined, 
several factors may play a role. One of those factors is the root replacement 
technique. 
Performing the autograft root replacement technique requires surgical expertise 
and among surgeons application of this technique varies.[9] The autograft can be 
inserted at annular or subannular level and with or without scalloping the muscle 
rim to a minimum below the valve cusps. Also, continuous or interrupted sutures 
can be used for the proximal suture line. Finally, the length of the autograft root 
can vary. Some surgeons keep it as short as possible while others leave the complete 
length of the pulmonary artery distal to the sino-tubular junction of the pulmonary 
artery. (http://www.ctsnet.org/doc/2380)
In our institution, all reoperations were in patients who underwent the root 
replacement technique. 
When the autograft is inserted as an inclusion cylinder, the native aorta is supporting 
the pulmonary autograft and may thus prevent it from dilatation. However, the 
number of autografts implanted as an inclusion cylinder in our institution is small 
and follow-up duration limited so any speculations should be interpreted with 
caution.
Sievers and colleagues[20] report the results of a single center, single surgeon’s 
experience with another implantation technique, the subcoronary implantation 
technique. They show good functional results with only 2.6% of the patients 
requiring a reoperation thus far. However, their follow-up period does not extend 
beyond 10 years, and longer-term follow-up may prove differently. Also the 
subcoronary implantation technique is technically much more challenging.
Interestingly, in the reports on the Ross operation that showed a high incidence 
of reoperation, more than one surgeon performed the initial operation.[8,10,12] 
In studies where only one surgeon performed the Ross operation, incidence of 
reoperation was lower.[9,20] This suggests that larger experience is correlated with 
improved durability. 
Another factor that is supposed to play a role in autograft dilatation is bicuspid 
valve disease.[21] It is known that a bicuspid aortic valve is associated with aortic 
wall abnormalities.[22] Since the pulmonary valve has the same embryonic origin as 
the aortic valve, these abnormalities could also be present in the pulmonary artery. 
Microscopic evaluation of pulmonary autografts reveals media abnormalities, 
intimal proliferation and adventitial fi brosis suggestive of chronic exposure to high 
pressure.[6,23,24] However, in a recent autograft explant study no association 
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was observed between bicuspid valve disease and histological changes in explanted 
pulmonary autografts.[25] 
In the present study adult patient age tended to be associated with higher autograft 
reoperation rates (8% at 13 years for patients under the age of 16 years compared to 
44% for adults). Other reports confi rm the observation that fewer reoperations are 
seen in children.[26-28] However, Luciani et al. found an opposite effect of patient 
age on autograft dilatation, but not on reoperation.[10] A possible explanation 
is that the pulmonary autograft has the capacity to increase in diameter in the 
paediatric patient.[27] Whether it grows or simply dilates in line with somatic 
growth, in children is still a matter of debate. 
Finally, patients who had previously undergone AVR (6 subcoronary homografts, 
3 biological prostheses, 3 mechanical prostheses) may also be at greater risk for 
pulmonary autograft reoperation in the future. In this regard, it might be relevant 
that after complete removal of the valve substitute, the remaining fi brotic annular 
area is removed in part as well, without leaving a fi xed plane for insertion of the 
pulmonary autograft. 
Despite the high autograft reoperation rate in our study population, the pulmonary 
allograft is well preserved; only 8 patients required reoperation, which is comparable 
to other studies.[5,8] The main reason for allograft reoperation in the present study 
was degeneration with calcifi cation of the allograft. Vogt et al.[28] determined in 
their study viability of cryopreserved allografts and found both total destruction of 
cellular elements in endothelial cells of allografts and immunological rejection in 
allografts used in the RVOT. Since the allograft is a non-viable valve substitute it is 
predisposed to calcify, and eventually at risk for reintervention and therefore affects 
the durability of the Ross operation on the longer term. Still, the ideal conduit 
for the RVOT in adults as well as in children has to be found. In the near future 
there might be an interesting role for tissue engineering for this valve substitute. 
Considering the limitations of the existing valve substitutes this new concept of 
creating a viable valve out of human cells shows encouraging results.[29] 
Another recent development, percutaneous valve implantation, may be applied 
to the degenerated pulmonary allograft. Since stenosis is the main indication for 
undergoing percutaneous valve replacement and since the homograft in the RVOT 
is subject tot calcifi cation, this could be an alternative to surgery.[30] 
During follow-up, endocarditis and thromboembolic complications were uncommon 
in our study patients; bleeding events and valve thrombosis did not occur. This 
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underlines that, in this regard, the Ross operation indeed allows patients to live their 
life to the fullest. 
Clinical implications
In our center the Ross operation is now an operation performed only in infants 
and children. In adults it has been abandoned because of the high reoperation rate 
and because of the great complexity and diffi culties that may be encountered at the 
eventual reoperation. 
Other alternatives for the Ross operation are the mechanical prosthesis, bioprosthesis 
and homograft with their advantages and disadvantages. Mechanical prostheses are 
designed to last a lifetime but require lifelong anticoagulation therapy due to their 
increased thrombogenicity. Even though anticoagulation therapy is relatively safe, 
it does increase the risk of bleeding complications. For smaller children no artifi cial 
valves of adequate size are available and the Ross operation remains the solution of 
choice. Furthermore, in children or patients who want to life an active lifestyle it is 
preferable to avoid the use of anticoagulation therapy. And also for women in child 
bearing age the mechanical prosthesis has several disadvantages, including not only 
a higher mortality risk during pregnancy mainly due to valve thrombosis, but also 
an higher risk of embryopathy with oral anticoagulants.[31]
After the Ross operation patients require no anticoagulation therapy, similar to 
the bioprosthesis and homograft. However, tissue valves have a limited durability 
and therefore the patient almost certain requires a reoperation later in life. Because 
of the large number of patients who return to center for reoperation in the second 
decade after the initial procedure, we need to ensure close follow-up of the patients 
and be prepared for more reoperations in the near future. 
Conclusions
While the Ross operation is associated with excellent patient survival in our 
institution, there is a considerable increase of autograft failure requiring reoperation. 
Careful follow-up is necessary in the second decade after the operation and greater 
insight into the mechanism of the pulmonary autograft dilatation is needed.
Finally, uniform well-defi ned and detailed technical guidelines for autograft root 
replacement need to be established if the Ross operation is to be maintained as a 
surgical option for aortic valve replacement with optimal benefi ts and enhanced 
durability for the patients. 
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Although the Ross procedure is still the favourable operation for aortic and root 
replacement in children and young adults, in recent years the number of reoperations 
for autograft root dilatation after the Ross procedure has increased. (1-4) 
In our ongoing prospective clinical and echocardiographic follow-up study of 
146 consecutive patients undergoing a Ross procedure with the root replacement 
technique since 1988, to date 29 patients have undergone pulmonary autograft 
reoperation. In most cases valve cusps are intact but due to progressive autograft 
root dilatation coaptation of the cusps is lost and aortic valve regurgitation occurs.
We report a patient who presented with severe aortic regurgitation due to asymmetrical 
autograft dilatation caused by a dissection in the non-coronary sinus of Valsalva.
Clinical summary
A 50-year-old female patient with a bicuspid native aortic valve, symptomatic moderate 
aortic regurgitation and dilated left ventricle with good systolic function, who had 
undergone a modifi ed Ross procedure using the root replacement technique, returned 
9 years after this procedure for reoperation. The patient had complaints of fatigue and 
dyspnoea on exertion. Echocardiographic examination 4 months prior to reoperation 
showed severe aortic and pulmonary regurgitation, a dilated left ventricle with end-
diastolic diameter of 62 mm and end-systolic diameter of 48 mm. Furthermore, the 
ascending neo-aorta was severely dilated with a diameter of 54 mm. 
At reoperation the neo-aortic root showed asymmetric dilatation with bulging of 
the non-coronary sinus of Valsalva. After opening the neo-aortic root, in the non-
coronary sinus of the autograft root a large transverse intimal tear that extended 
into the media was seen, causing the asymmetric dilatation (see Figure 1). This 
tear was limited to the autograft wall and had no connection with the distal suture 
line. The autograft valve leafl ets appeared normal. The pulmonary autograft was 
replaced with a mechanical valve conduit size 25 mm (St. Jude Medical Inc.) and the 
pulmonary allograft with a cryopreserved pulmonary allograft. The procedure and 
postoperative course were uneventful.
Microscopic examination revealed a viable pulmonary autograft valve and neo-
aortic wall. The valve leafl ets showed intimal hyperplasia on the ventricular side 
and intimal and adventitial fi brosis of the neo-aortic wall was present. In addition, 
throughout the media cystic medial necrosis with fragmentation, loss of elastic fi bres 
and deposition of mucopolysaccharides were found. The tear of the neo-aortic wall 
extended beyond the intima into the media. The defect was already covered with 
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mucopolysaccharides, but without neo-endothelization suggesting that this tear was 
at least a few months old, but existed no longer than one year.
Discussion
In most of the 29 reoperative autograft cases in our institution progressive dilatation 
of the neo-aortic root resulting in aortic regurgitation necessitated reoperation. 
Histological fi ndings in the explanted autografts comprised cystic medial necrosis 
with fragmentation, loss of elastic fi bres and deposition of mucopolysaccharides. 
(1) The current case is different from the other reoperative autograft cases in our 
experience and raises concern for the following reasons. 
The asymmetrical root dilatation was a result of an intimal tear of the non-coronary 
sinus extended into the media causing a limited dissection that potentially could 
lead to a free wall rupture. The autograft dissection presented 9 years after the 
initial Ross procedure. Luciani and colleagues previously reported an autograft 
dissection 8.5 years after the initial Ross procedure.(5) This dissection also occurred 
in the non-coronary sinus suggesting possible vulnerability of this specifi c location 
to rupture. Their intima rupture was in longitudinal direction and did not interfere 
with any of the suture lines (personal communication). Aortic dissection is usually 
characterized by longitudinal cleavage of the aortic media by a dissecting column of 
Figure 1. Explanted autograft root with a transverse dissection of the non-coronary sinus.
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blood, which was neither present in Dr Luciani’s nor our own explanted autograft 
root. 
A new observation emerging from our report is that apparently with progressive 
dilatation of the neo-aortic wall it becomes increasingly weak and may be prone to 
rupture late after the initial Ross procedure. 
Furthermore, the dissection in the neo-aortic wall existed for months without any 
clinical signs. Due to the limited size of the intimal tear and denervation of the 
neo-aortic root, the patient does not complain of pain and this potentially lethal 
complication is hard to recognize without careful echocardiographic monitoring. 
In conclusion, this report illustrates that the pulmonary autograft not only can show 
dissection but may also rupture causing a potentially life threatening complication. 
High awareness of potential neo-aortic root dissection is required in all autograft 
root patients and particularly those patients whose autograft root gradually dilates 
over the years. 
Therefore, continuing and frequent systematic echocardiographic surveillance 
of this patient group is highly recommended also in the second decade after the 
operation.
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ABSTRACT
Background
Reoperative aortic root replacement(RARR) is complex and a high risk operation. 
We studied outcome of patients who underwent RARR after previous surgery on 
aortic valve, aortic root or ascending aorta.
Methods
Between 1981 and 2006, 141 consecutive patients underwent 156 RARRs at our 
institution. Patient and peri-operative characteristics, short and long-term outcome 
were analyzed.
Results
Mean age was 37 years(0.3-76 years). RARR was performed on 56 prosthetic 
valves(PV), 23 allografts(ALLO), 28 pulmonary autografts(AUTO) and 49 native 
valves(NV).
RARR indications were: structural failure 46%(n=72), neo-aortic root dilatation 
18%(n=28), aneurysm/dissection 13%(n=21), endocarditis 15%(n=24), non-
structural failure 6%(n=10) and valve thrombosis 1%(n=1). Thirty-six percent(n=56) 
received an allograft, 34%(n=54) an aortic valve conduit(Bentall) and 30%(n=46) 
a pulmonary autograft. 
Hospital mortality was 9%(n=14): 14%(n=8) PV patients, 13%(n=3) ALLO 
patients, 6%(n=3) NV patients, and 0% AUTO patients died. Potential hospital 
mortality predictors were longer perfusion and cross clamp time, older patient 
age, female gender, unplanned CABG, concomitant mitral valve replacement and 
emergency surgery. 
During follow-up(mean 6.5years, range 0-18years) 13 patients died(LOR 1.3%/
patient year); 8 PV patients, 1 ALLO patient, 3 NV patients and 1 AUTO patient.
Overall 10-year survival was 78%±4%; for PV patients 65%±8%, for ALLO 
patients 82%±8%, for NV patients 87%±5% and for AUTO patients 96%±4%.
Conclusions
RARR can be safely performed. Especially, pulmonary autograft reoperation has 
low hospital mortality and morbidity rates with excellent survival. In this respect, 
these results may contribute to decision making in valve substitute selection in 
primary aortic valve replacement, especially in adolescents and young adults.
Keywords: reoperation, aortic root, heart valve (allograft), heart valve (autograft), 
statistics, survival analysis
Loes bw.indd   184 31-10-2007   14:41:07
Characteristics And Outcome Of Reoperative Aortic Root Replacement
185
Introduction
Primary aortic root replacement (ARR) is a reliable and relatively safe operation with 
a low mortality rate, especially in the elective setting and regardless of the composite 
graft used.[1-3] Recent developments in aortic valve and root surgery, including 
valve sparing procedures on the aortic root, pulmonary autograft implantation, 
aortic allograft implantation and aortic valve preservation in acute aortic dissection, 
will lead to an increasing incidence of secondary ARR after these procedures. 
Reoperative ARR is a complex and high risk operation. In particular reopening 
of the chest with possible adherence of the aorta to the sternum and the need for 
mobilization and reimplantation of the coronary arteries may contribute to the high 
risk character of the operation and therefore to a higher expected mortality risk in 
these patients.[4-6] In our centre we have performed a high volume of pulmonary 
autograft procedures and aortic allograft implantations over the past 2 decades. 
The use of these valve types has been questioned and recent reports have shown an 
increasing incidence of reoperations when using allograft and pulmonary autograft 
as valve substitutes in aortic valve or root replacement.[7-11] Furthermore, these 
reoperations are complex due to extensive calcifi cation of the allograft wall and at 
annular level and due to dilatation of the autograft, which might negatively infl uence 
reoperative and long-term outcome.[12-14]
In this perspective we analyzed our experience in reoperative aortic root replacement 
after surgery on the aortic valve, the ascending aorta or both.
Patients and Methods
Patients
Between 1981 and 2006 141 patients underwent 156 aortic root replacements as 
a reoperation. All patients underwent RARR after aortic valvulotomy, aortic valve 
replacement, aortic root replacement or surgery on the ascending aorta. All patients 
who receive an autograft or allograft in aortic position in our center are enrolled in 
our ongoing prospective follow-up study.[14-17] Approval from the Institutional 
Review Board was obtained for this prospective follow-up study; the Institutional 
Review Board waived informed consent. Patients who underwent previous isolated 
coronary artery bypass grafting or other cardiac procedures that were not aortic 
valve-related were not included. In fi fty-six patients a prosthetic valve (PV) was 
replaced (36 mechanical prostheses and 20 bioprostheses), in 23 patients an allograft 
(ALLO), in 28 patients a pulmonary autograft (AUTO) and in 49 patients the native 
valve (NV). In the latter group 36 patients had previously undergone aortic valve 
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Table 1. Patient characteristics per valve substitute in situ before RARR
All valves 
(n=156)
Prosthetic
 valve
(n=56)
Native valve
(n=49)
Allograft
(n=23)
Autograft
(n=28)
Mean age 
(yrs, (range))a 
37 (0.3-76) 51 (7-76) 22 (0.3-61) 38(16-65) 34 (15-50)
Male gendera 69% (n=107) 73% (n=41) 53% (n=26) 87% (n=20) 71% (n=20)
Systolic LVF
Gooda 
Impaired
Moderate/bad
80% (n=125)
14% (n=22)
6% (n=9)
71% (n=40)
18% (n=10)
11% (n=6)
90% (n=44)
10% (n=5)
-
78% (n=19)
9% (n=2)
13% (n=3)
82% (n=23)
18% (n=5)
-
Cardiac rhythm
Sinus rhythm
Atrial fi brillation
Other
90% (n=141)
4% (n=6)
6% (n=9)
86% (n=48)
5% (n=3)
9% (n=5)
96% (n=47)
-
4% (n=2)
82% (n=19)
9% (n=2)
9% (n=2)
96% (n=27)
4% (n=1)
-
Creatinin
(μmol/L)
79 (22-305) 95 (32-305) 61 (22-142) 79 (58-125) 79 (61-110)
NYHA
I
II/III
IV/Va 
37% (n=57)
31% (n=49)
32% (n=19)
32% (n=18)
43% (n=24)
25% (n=14)
41% (n=20)
53% (n=26)
6% (n=3)
26% (n=6)
65% (n=14)
9% (n=2)
46% (n=13)
54% (n=15)
-
Hemodynamic 
diagnosis
ARa 
ASa 
AR+AS
Nonea 
53% (n=83)
20% (n=31)
18% (n=28)
10% (n=15)
53% (n=30)
13% (n=7)
13% (n=7)
21% (n=12)
20% (n=10)
47% (n=23)
31% (n=15)
2% (n=1)
61% (n=14)
4% (n=1)
26% (n=6)
9% (n=2)
100% (n=28)
-
--
Time interval
(years,(range))
8 (0-33) 6 (0-20) 9 (0-33) 7 (0-14) 10 (4-16)
Indication RARRa 
SVD
NSVD
Endocarditis
 Active
Aneurysm/dissection
RD and/or AR
Valve thrombosis
47% (n=72)
6% (n=10)
15% (n=24)
12% (n=18)
13% (n=21)
18% (n=28)
1% (n=1)
18% (n=10)
16% (n=9)
41% (n=23)
n=18
23% (n=13)
-
2% (n=1)
84% (n=41)
-
2% (n=1)
-
14% (n=7)
-
-
92% (n=21)
4% (n=1)
-
-
4% (n=1)
-
-
-
-
-
-
100% (n=28)
-
Preop ventilation 
support 5% (n=8) 5% (n=3) 8% (n=4) 4% (n=1)
-
Type surgerya 
Emergent
Urgent
Elective
5% (n=7)
30% (n=47)
65% (n=102)
9% (n=5)
57% (n=32)
34% (n=19)
2% (n=1)
10% (n=5)
88% (n=43)
4% (n=1)
26% (n=6)
70% (n=16)
-
14% (n=4)
86% (n=24)
a Signifi cant differences between the groups with p<0.05
AR= aortic regurgitation, AS= aortic stenosis, LVF = left ventricular function, NSVD= non-structural valve 
degeneration, NYHA = New York Heart Association, Other cardiac rhythm = pacemaker rhythm and heart block, 
RD = autograft root dilatation, SVD= structural valve degeneration, Time interval = mean time interval between last 
aortic valve-related or ascending aorta-related operation and root re-replacement
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repair or a valvulotomy, 7 patients had had surgery of the ascending aorta for acute 
aortic dissection and 6 patients had had surgery of a discrete subaortic stenosis. 
Preoperative patient characteristics are displayed in Table 1. For patients who had 
an allograft or pulmonary autograft inserted at primary operation or reoperation, 
information was collected from the ongoing prospective cohort study.[15] For all 
other patients, information on patient characteristics, perioperative details and 
follow-up was collected retrospectively from hospital records, correspondence with 
the treating physicians and through the civil registry.
Surgical procedures
All operations were performed through a median sternotomy and on cardiopulmonary 
bypass with moderate hypothermia. We used central canulation in the ascending 
aorta and right atrium or caval veins. To anticipate on possible perforation of the 
heart or aorta when reopening the chest, we instituted cardiopulmonary bypass 
with canulation of the femoral vessels and deep cooling of 9 patients before 
performing the sternotomy. Crystalloid cardioplegia and topical cooling were used 
for myocardial protection. Total circulatory arrest with deep hypothermia was 
needed in 30 patients with ascending aorta or arch pathology.
In patients with a native aortic valve or valve prosthesis in situ, root replacement 
followed the removal of the valve or the prosthesis. In patients with an allograft 
in situ it was necessary to remove all calcifi ed allograft material before root 
replacement. The original coronary buttons were dissected from the allograft aortic 
wall. In patients with a pulmonary autograft in situ, the neo-aortic root was in 
most cases dilated without any signs of root or valve calcifi cation. After opening the 
autograft root, the autograft valve leafl ets were excised and the coronary buttons 
mobilized. Excess autograft wall tissue was removed, leaving parts of the autograft 
at annular level in situ. 
Mortality and Follow up
Mortality and other valve-related events were registered according to the guidelines 
for reporting morbidity and valve-related events.[18] The database was frozen on 
January 1st, 2007. Follow-up was 93.7% complete.[19] Three patients were lost to 
follow-up due to emigration.
Statistical analysis
For data analysis SPSS 12.0.1 for Windows was used (SPPS, Chicago, Illinois). 
Descriptive statistical analysis was done for preoperative and perioperative data. 
Continuous variables are displayed as mean ± 1 SD and compared using the unpaired 
T-test or Kruskal Wallis-test. Discrete variables are displayed as proportions and 
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compared using the Chi-square Test. Univariable logistic regression was used to 
determine factors of different valve substitute groups and to determine potential risk 
factors for hospital mortality. The following factors were analyzed: age at operation 
(continuous variable), sex, time period of operation (before and after 1998), New 
York Heart Association Class (defi ned as I, II, III IV, and cardiogenic shock as 
NYHA V), preoperative creatinin level (micromoles/L), preoperative ventilation 
support, abnormal cardiac rhythm preoperative (other rhythm preoperative than 
sinus rhythm), left ventricular function (defi ned as good when ejection fraction 
was >50%, impaired when ejection fraction was 40-50% and moderate/bad 
when ejection fraction was <40%), emergent surgery (<24hrs after diagnosis), 
concomitant procedures, indication for reoperation, active endocarditis (operated 
on before completing a standard course of antibiotics), cardiopulmonary bypass 
time (in minutes) and cross clamp time (in minutes). The variable valve prosthesis 
type used at reoperation was additionally analysed to determine its possible infl uence 
on hospital mortality.
Cumulative survival, freedom from reoperation and freedom from valve-related 
events were analyzed with the Kaplan Meier method. The Log-Rank test was used to 
compare the Kaplan-Meier curves and Tarone-Ware test was used where appropriate 
to correct for signifi cant differences in follow-up time between the different groups. 
The Cox regression proportional hazards model was used for univariable analysis 
for time-related events. The following factors were analyzed: age at operation, sex, 
time period of operation, NYHA class, preoperative creatinin level, preoperative 
ventilation support, abnormal cardiac rhythm, preoperative left ventricular function, 
active endocarditis, emergent surgery, concomitant procedures, valve prosthesis type 
used at reoperation, cardiopulmonary bypass time and cross clamp time. A p-value 
≤ 0.05 was considered statistically signifi cant. All testing was two-sided.
Results
Perioperative details are displayed in Table 2. In 46 patients a pulmonary autograft 
was inserted, in 56 patients an allograft root replacement, and in 54 patients an 
aortic valved conduit (Bentall procedure). 
Determinants of different valve substitute groups
Patients who received an allograft were more likely to be older (OR 1.04, 95% 
CI 1.02-1.06; p<0.001), had a prosthetic valve in situ (OR 8.3, 95% CI 3.9-17.5; 
p<0.001), endocarditis as the indication for reoperation (OR 13.3, 95% CI 4.3-41.7; 
p<0.001), were in NYHA class IV or V (OR 6.3, 95% CI 2.1-18.7; p=0.001), had an 
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impaired left ventricular function (OR 3.8, 95% CI 1.5-9.8; p=0.005), underwent 
more urgent surgery (OR 3.3, 95% CI 1.6-6.6; p=0.001) and had an increased 
preoperative creatinin level (OR 1.02, 95% CI 1.01-1.03; p=0.008). 
Patients who received a Bentall procedure were also more likely to be older (OR 1.02, 
95% CI 1.003-1.04; p=0.02), had a previously inserted pulmonary autograft (OR 
28.4, 95% CI 8.0-101.0 p<0.001) and had an aortic aneurysm as the indication for 
reoperation (OR 5.6, 95% CI 2.0-15.6; p=0.001). Finally, patients who received a 
pulmonary autograft were more likely to be younger (OR 1.09, 95% CI 1.06-1.12; 
p<0.001), had a normal preoperative creatinin level (OR 1.04, 95% CI 1.02-1.06; 
p<0.001), a good left ventricular function (OR 3.4, 95% CI 1.1-10.4; p=0.03) and 
underwent more elective surgery (OR 4.1, 95% CI 1.7-10.1; p=0.002).
Table 2. Perioperative data per valve substitute in situ before RARR
All valves 
(n=156)
Prosthetic valve
(n=56)
Native valve
(n=49)
Allograft
(n=23)
Autograft
(n=28)
CPB timea 
(min, (range))
236 (79-685) 246 (79-660) 217 (116-685) 278 (118-542) 214 (115-389)
Cross clampa 
(min, range))
151 (61-331) 158 (61-302) 139 (70-240) 175 (79-331) 137 (85-271)
Circulatory arresta
(min,((range))
n=30
27 (2-99)
n=9
20 (10-34)
n=5
55 (16-99)
n=7
22 (7-48)
n=9
22 (2-59)
Valve type inserteda
Aortic valved conduit 
(Bentall)
Allograft root
Pulmonary autograft
35% (n=54)
35% (n=56)
30% (n=46)
20% (n=11)
67% (n=38)
13% (n=7)
12% (n=6)
22% (n=11)
66% (n=32)
52% (n=12)
22% (n=5)
26% (n=6)
89% (n=25)
11% (n=3)
-
Concomitant 
procedures
Planned CABG
Unplanned CABG
MVR
MVP
PVRa
Extended root
Other
3% (n=4)
2% (n=3)
3% (n=4)
4% (n=6)
3% (n=5)
26% (n=17)
14% (n=22)
4% (n=2)
2% (n=1)
7% (n=4)
4% (n=2)
2% (n=1)b
16% (n=9)
7% (n=4)
-
3% (n=2)
-
-
-
12% (n=6)
20% (n=10)
9% (n=2)
-
-
9% (n=2)
-
17% (n=4)
4% (n=1)
-
-
-
7% (n=2)
14% (n=4)
25% (n=7)
25% (n=7)
Complications
Rethoracotomy
Stroke
Myocardial infarction
Permanent pacemaker
17% (n=26)
2% (n=3)
1% (n=1)
1% (n=2)
23% (n=13)
4% (n=2)
-
2% (n=1)
10% (n=5)
-
2% (n=1)
2% (n=1)
26% (n=6)
-
-
-
7% (n=2)
3% (n=1)
-
-
Hospital death 9.0% (n=14) 14% (n=8) 6% (n=3) 13% (n=3) 0%
a Signifi cant differences between the groups with p<0.05, b Other than the autograft procedure
CABG = coronary artery bypass grafting, MVP= mitral valve repair, MVR= Mitral valve replacement, Other= 
including surgery for discrete subaortic stenosis, closure patent ductus arteriosus and tailoring ascending aorta
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Early morbidity and mortality
A total of 14 patients died in hospital (9.0%). Details on hospital deaths are shown 
in Table 3. 
Patient 3 died on the fi rst day after RARR due to a perioperative myocardial 
infarction caused by a kink in the reimplanted right coronary artery. 
Patient 5 died on the 5th day after RARR due to multi organ failure. One day 
previously to RARR the patient received a biological prosthesis. The patient required 
reoperation for bleeding and a perioperative complication necessitated RARR. 
Patient 8 died on the 22nd day after RARR. Indication for RARR was an aortic 
dissection 60 days after aortic valve replacement with a bioprosthesis. 
Patient 10 died on the 5th day after RARR. On the same day as the RARR a subcoronary 
allograft was implanted but required replacement due to technical failure. 
Patient 12 was a 6 month old child with congenital mitral valve and aortic valve 
abnormalities, underwent previously aortic and mitral valve repair and surgery of a 
discrete subaortic stenosis, and died during RARR of heart failure. 
Patient 13 died during RARR of heart failure after CABG as a procedural 
complication.
Potential predictors of hospital mortality were longer perfusion time (OR 1.01, 
95% CI 1.01-1.02; p<0.001), longer cross clamp time (OR 1.02, 95% CI 1.01-1.04; 
p<0.001), older patient age (OR 1.07, 95% CI 1.03-1.10; p=0.001), female gender 
(OR 3.3, 95% CI 1.1-10.1; p=0.04), abnormal cardiac rhythm preoperative (OR 
7.3, 95% CI 2.1-26.1; p=0.02), NYHA class IV or V (OR 10.8, 95% CI 3.3-36.1; 
p<0.001), concomitant mitral valve replacement (OR 11.7, 95% CI 1.5-90.3; 
p=0.02), preoperative ventilation support (OR 14.7, 95% CI 3.1-68.5; p=0.006), 
emergency surgery (OR 18.5, 95% CI 3.6-94.5; p<0.001) and unplanned CABG (OR 
23.3, 95% CI 1.9-278.3; p=0.01). A good left ventricular function was associated 
with a lower hospital mortality (OR 0.2, 95% CI 0-07-0.63; p=0.006). The type of 
valve prosthesis type used at RARR had no effect on hospital mortality.
Follow-up and survival
Mean follow-up was 6.2 years, range 0-18.3 years with total follow-up of 973 
patient years.
For PV patients mean follow-up was 6.2 years, range 0-16.3 years with total follow-
up of 347 patient years. For NV patients mean follow-up was 9.3 years, range 
0-18.3 years with total follow-up of 455 patient years. For ALLO patients mean 
follow-up was 4.8 years, range 0-14.4 years with total follow-up of 110 patient 
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years. For AUTO patients mean follow-up was 2.1 years, range 0.1-8.8 years with 
total follow-up of 58 patient years. 
During follow-up 13 patients (LOR 1.3%/patient year) died; 8 PV patients, 3 NV 
patients, one ALLO patient and one AUTO patient died. Table 4 shows details on 
late deaths.
Overall 10-year survival after RARR was 78.3%±4.0%. For PV patients 10-year 
survival was 65.4%±7.6%, for NV patients 86.6%±5.2%, for ALLO patients 
82.4%±8.0% and for AUTO patients 10-year survival was 96.4%±3.6% (p=0.06). 
See also Figure 1.
Potential predictors for late mortality were longer perfusion time (HR 1.01, 95% 
CI 1.003-1.01; p=0.001), older patient age (HR 1.04, 95% CI 1.004-1.07; p=0.03), 
preoperative increased creatinin level (HR 1.01, 95% CI 1.001-1.02; p=0.03), 
active endocarditis (HR 4.1, 95% CI 1.2-13.7; p=0.02), abnormal cardiac rhythm 
Table 3. Details on hospital deaths
Nr In situ 
valve
Age
RARR
Time since
previous 
operation
Indication RARR Implanted Cause of death Days postop
1 Prosthetic 65 0.9 years Endocarditis Allograft Heart failure Peroperative
2 Prosthetic 69 19.8 years Endocarditis Allograft Myocardial 
infarction
Peroperative
3 Prosthetic 74 17 days Endocarditis Allograft Myocardial 
infarction
1
4 Prosthetic 53 8.1 years NSVD Allograft Heart failure 4
5 Prosthetic 71 1 day NSVD Allograft Multi organ 
failure
5
6 Prosthetic 66 9.7 years NSVD Allograft Heart failure 23
7 Prosthetic 63 5.8 years Aneurysm 
ascending aorta
Allograft Heart failure 34
8 Prosthetic 61 60 days Dissection 
ascending aorta
Bentall Heart failure 22
9 Allograft 49 14.4 years SVD Bentall Heart failure Peroperative
10 Allograft 63 0 days SVD Allograft Heart failure 5
11 Allograft 65 14.0 years SVD Bentall Heart failure 16
12 Native 
valve
0.3 31 days SVD Pulmonary 
autograft
Heart failure Peroperative
13 Native 
valve
40 9.2 years SVD Pulmonary 
autograft
Heart failure Peroperative
14 Native 
valve
24 13.7 years SVD Pulmonary 
autograft
Mediastinitis + 
sepsis
13
NSVD= non structural failure, SVD= structural failure
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preoperative (HR 4.4, 95% CI 1.2-16.2; p=0.03), the use of an allograft root at 
RARR (HR 10.0, 95% CI 2.2-45.5; p=0.003) and concomitant mitral valve repair 
(HR 23.6, 95% CI 5.6-99.5; p<0.001). RARR on a prosthetic valve showed a trend 
to be a risk factor for late mortality (HR 2.8, 95% CI 0.9-8.6; p=0.07).
Valve-related events
One PV patient, who received an allograft root at RARR, underwent an aortic 
valve re-reoperation for structural failure. The allograft was replaced 9.7 years 
after RARR by a stentless bioprosthesis and the patient survived the procedure. 
One patient who received an allograft root at RARR had a non-fatal stroke after 
14.1 years. Four patients had a TIA during follow up; one patient who underwent 
a Bentall procedure at RARR had a TIA after 0.1 years and three patients who 
received an allograft at RARR had a TIA respectively after 0.3, 3.6, and 4.5 years, 
of which one patient had two TIAs in the fi rst year after RARR at 0.3 and 0.5 years, 
respectively. Linearized occurrence rates for thrombo-embolic complications were 
1.2%/patient year for RARR with an allograft and 0.65%/patient year for RARR 
with a Bentall procedure. One patient who received an autograft at RARR had a 
late episode of recurrent endocarditis after 8.8 years (LOR 0.20%/patient year) and 
Table 4. Details on late deaths
Nr In situ valve Indication RARR Implanted Cause of death Years postop
1 Prosthetic Endocarditis Allograft Endocarditis 1.5
2 Prosthetic SVD Allograft SUUD 2.3
3 Prosthetic NSVD Allograft Heart Failure 3.8
4 Prosthetic Endocarditis Allograft Cancer 3.8
5 Prosthetic Endocarditis Allograft Heart Failure 6.2
6 Prosthetic Endocarditis Allograft COPD 8.2
7 Prosthetic Aneurysm ascending 
aorta
Allograft Heart Failure 10.4
8 Prosthetic Aneurysm ascending 
aorta
Bentall Heart failure 0.2
9 Allograft SVD Allograft Heart Failure 0.3
10 Pulmonary autograft SVD Bentall Myocardial infarction 0.1
11 Native Aortic dissection Allograft Myocardial infarction 0.3
12 Native Aneurysm ascending 
aorta
Allograft Heart Failure 4.3
13 Native SVD Allograft Traumatic intracerebral 
bleeding
8.4
RARR= reoperative aortic root replacement, NSVD= non-structural valve degeneration, SUUD = sudden unexplained 
unexpected death, SVD= structural valve degeneration 
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one allograft recipient at RARR had an episode of recurrent endocarditis after 1.5 
years (LOR 0.30%/patient year). Both patients were treated medically and survived. 
No bleeding events, valve thrombosis, or non-structural failure were observed.
Comment
Reoperative aortic root replacement remains a high risk and demanding procedure, 
however, our study shows that it can be performed with satisfying results, regarding 
operative mortality and long term survival.
Hospital mortality
Overall hospital mortality after reoperative aortic root replacement is comparable 
to other series that report on hospital mortality after this type of surgery.[4,6,20] 
Hospital mortality for RARR after a previously inserted prosthetic valve was 14% in 
our study. Although this seems high compared with most of the other valve substitutes, 
in the majority of these patients endocarditis was the indication for reoperation. 
Most of these patients were severely symptomatic, had an impaired left ventricular 
function and often underwent emergent or urgent surgery, which were all potential 
predictors of hospital mortality. This is also described by David and colleagues.[20] 
Furthermore, surgery for prosthetic valve endocarditis is known to be associated 
with a higher urgency of surgery and a high hospital mortality rate,[21,22] which 
can explain the high hospital mortality risk in these patients in our study. 
Reoperative aortic root replacement after a previous allograft valve or root 
replacement in our study resulted in 13% hospital mortality. A possible explanation 
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Figure 1 Patient survival after reoperative aortic root replacement per valve substitute in situ
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for this might be that RARR after a previous allograft implantation is a technically 
diffi cult and demanding procedure. It is complicated to make a proper proximal 
anastomosis due to the fact that the allograft not only calcifi es in the part of the root 
but also at the annular level. Furthermore, the coronary buttons need to be dissected 
from the calcifi ed allograft making it diffi cult to maintain a large enough button that 
can be properly reinserted without distortion or kinking. In some patients unforeseen 
bypass grafting is necessary. These factors contribute in our study to a signifi cantly 
longer CPB time and aortic cross clamp time compared with the other groups, which 
are potentially associated with higher hospital mortality in our study. 
Patients who had their native valve in situ and required RARR had a hospital 
mortality rate of 6%. All patients that died underwent a pulmonary autograft 
procedure. A pulmonary autograft procedure carries more risk than a conventional 
root replacement, especially as a reoperation, but after successful operation survival 
of these patients is comparable to the age-matched general population.[11]Patients 
reoperated on their native valve are the youngest of all study groups with low 
co-morbidity and required in most cases an elective reoperation with almost no 
concomitant procedures. 
The pulmonary autograft procedure is the optimal solution in pediatric patients 
requiring aortic valve replacement.[23,24].Many studies favor the pulmonary 
autograft procedure also in young adult patients [14,25,26], but enthusiasm for 
this operation has been tempered in recent reports due to the high incidence of 
reoperations.[8,11,27]However, in this study reoperation after the pulmonary 
autograft procedure shows a much better outcome with 0% hospital mortality so 
far, suggesting that reoperation after this procedure can safely be performed. This 
is comparable to the fi ndings of Brown and colleagues.[28] Main indication for 
reoperation was an aneurismal dilatation of the aortic root causing aortic valve 
regurgitation. Although an aneurismal aortic root is still diffi cult to reoperate on, 
it takes lesser effort to explant a dilated autograft root than a calcifi ed allograft 
root. The dilated aortic root allows a clear view at the insuffi cient autograft and 
its dilated annulus, on which an anastomosis is easier to perform. Furthermore, the 
dilated pulmonary autograft wall shows no signs of calcifi cation.[12] Although a 
reoperation after the pulmonary autograft procedure also requires reinsertion of the 
coronary arteries, the coronary buttons can be maintained to a larger size in absence 
of calcifi cation which necessitates resizing. However, reinsertion of the coronaries 
after a pulmonary autograft is also not without the risk of kinking of the coronary 
arteries sometimes necessitating coronary bypass grafting. 
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Three patients required an unplanned CABG due to distortion of the coronaries as a 
procedural complication; two autograft patients and one allograft patient, of which 
one autograft patient and one allograft patient died. In our study the need for an 
unplanned CABG is potential associated with a higher hospital mortality, which is 
also reported in other series.[4]
Long-term survival
The overall 10-year survival in our study is 78% at 10 years and is satisfactory and 
even better compared with other reports.[4,6,20]Comparing the four study groups, 
it shows that reoperation with a pulmonary autograft has the best long-term survival. 
Reoperation with an allograft root after previous surgery on the aortic valve or 
ascending aorta was one of the potential predictors of late mortality in our study 
and is also shown in Figure 2. Most of the allograft recipients were older patients 
with prosthetic valve endocarditis, which implies that not the inserted allograft 
but mostly patient and operative characteristics contributed to the increased late 
mortality we observed in allograft recipients. 
Limitations
The partially retrospective nature of study may have lead to an underestimation of 
the valve-related events during follow-up which might have infl uenced our results. 
Furthermore, the four study groups differ in baseline characteristics which make 
comparisons between the groups diffi cult.
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Conclusions
Our study indicates that reoperation after previous surgery on the aortic valve, 
ascending aorta or both, can be safely performed. Although several patient factors 
play role, reoperation after a pulmonary autograft procedure has low hospital 
mortality and morbidity rates with long-term survival that is better compared with 
patients in which a reoperation is necessary after native valve repair or valvulotomy, 
a previous inserted allograft or prosthetic valve. In this respect, these results may 
contribute in the decision making in selecting the proper valve substitute in primary 
aortic valve replacement, especially in adolescents and young adults.
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The aim of this thesis was to gain insight into the determinants of prognosis 
after aortic valve replacement in young adult patients with the different available 
valve substitutes and to study whether there is a preferred valve substitute for 
this particular age group. From the studies in this thesis it has become clear that 
prognosis of young adults who require aortic valve replacement is determined by 
multiple interrelated factors that are at least in part also affecting prosthetic valve 
selection. These observations will be discussed below by:
Providing an overview of valve substitute-related factors that infl uence prognosis 1. 
and discuss the magnitude of their impact on patient prognosis found in the 
studies in this thesis
Evaluating patient-related factors associated with prognosis and prosthetic 2. 
valve selection that were found in the studies in this thesis
Commenting on other factors that may be important for prosthetic valve 3. 
selection 
Furthermore, it will be discussed how these new insights obtained in the studies 
in this thesis may help clinicians to optimize prosthetic valve selection in young 
adult patients. Finally, recommendations with regard to future research will be 
presented.
VALVE SUBSTITUTE-RELATED FACTORS
When selecting a prosthetic aortic valve type for young adult patients who have 
a relatively long life expectancy, the increased hazard of thrombo-embolism and 
bleeding associated with the use of mechanical prostheses is weighed against the 
increased hazard of structural failure when using tissue valves.
Mechanical prostheses, durable and easy to implant
Mechanical prostheses are designed to last a life time, and the risk of a reoperation, 
although not absent, is very low. 
A major disadvantage of these valve substitutes is the required anticoagulation 
treatment with a high risk of thrombo-embolic complications and bleeding events.1 
Especially in younger patients, who lead an active lifestyle or young females who may 
want to become pregnant later in life, these valve substitutes may not always be the 
valve of choice, due to their increased thrombogenicity, increased bleeding hazard and 
maternal and fetal morbidity and mortality associated with anticoagulant use. 2, 3 
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In Chapters 2, 4 and 11 mechanical prostheses were studied. In Chapter 2 it was 
shown that patients who receive a mechanical prosthesis have an impaired survival 
compared with allograft and autograft recipients. However, the characteristics of 
patients who receive mechanical prostheses differ from patients who undergo aortic 
valve replacement with an allograft or an autograft, and may explain at least in 
part this observed difference in survival (see also section on patient related factors 
below). Bleeding and thrombo-embolic events proved to be quite common in 
mechanical prosthesis patients, one of the key issues when it comes to selecting the 
proper valve substitute. Ruel and colleagues studied the quality of life after aortic 
valve replacement with mechanical prostheses and biological prostheses.4 Aortic 
biological prostheses appear to be associated with better physical capacity, social 
functioning, and prosthesis satisfaction.4 Although long-term anticoagulation can 
cause some degree of discomfort from blood tests and may disrupt daily life, it 
does not have an important effect on quality of life.4, 5 Another characteristic of the 
mechanical prosthesis, the sound of valve leafl et closure, may infl uence the quality of 
life of patients. The majority of mechanical prosthesis patients have no complaints 
of valve noise and may adapt to the valve sounds over the years.6 However, being 
a female patient and younger patient age were signifi cant risk factors for greater 
disturbance by valve noise.6 
Recurrence of endocarditis, early and late mortality after aortic valve replacement 
for active native endocarditis is comparable between allografts and mechanical 
prostheses as shown in Chapter 4. Furthermore reoperation rates in mechanical 
prosthesis patients are considerably lower compared to allograft patients who 
underwent aortic valve replacement for active native endocarditis. Although 
reoperations are less frequent in patients that receive a mechanical prosthesis, 10 
years survival after reoperation is signifi cantly worse compared with the autograft 
or the allograft. This was described in Chapter 11.
Despite main advantage, the life-long durability of the mechanical prosthesis with 
a low reoperation rate, the use of anticoagulation, valve sound and worse outcome 
after reoperation compared with other valve substitutes, may have a greater impact 
on outcome after valve replacement with these valve substitutes and moreover on 
the quality of life in young adult patients.
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Human tissue valves and their characteristics
Allografts 
Allografts and autografts do not require anticoagulation, an important advantage 
for young and active adult patients. 
However, allografts valves have the major disadvantage that because of the non-
viable nature these valve substitutes are subject to calcifi cation resulting in a limited 
durability.7 Allografts induce an immunologic response by activating T-cells.8 This 
activation leads to chronic rejection and infl ammation, which results in the destruction 
of tissue. The calcifi cation process begins at the free walls of the allograft, where 
immunologic cells have the best access by ingrowing vessels from the surrounding 
scar tissue. Eventually, the calcifi cation process extents to the cusps.7
This almost inevitably will result in a reoperation later during life, in particular in 
young patients with a relatively long life expectancy. Other disadvantages include 
limited availability of allografts and the specifi c surgical expertise that is required 
to implant human tissue valves, especially when the subcoronary implantation 
technique is employed.
Chapter 3 showed that the limited durability of the allografts is inversely related to 
patient age. Younger patient age is associated with increased reoperation rates for 
structural valve deterioration, an observation confi rmed by several other reports9-11 
Furthermore, the effect of patient age on valve durability proved to be comparable 
to pericardial and stented biological prostheses, suggesting a common pathway of 
degeneration.11 
Comparing allograft implantation techniques it showed that freedom from any 
valve-related reoperation was better using the root replacement technique than the 
subcoronary implantation technique. This is in accordance with the observations 
in a recent systematic review of the effect of allograft implantation technique on 
reoperation rate.12 However, when only reoperation for degenerative structural 
valve deterioration is studied, reoperation rates are comparable for the allograft 
root replacement technique and the subcoronary implantation technique. Yet, the 
complexity of the reoperation between both implantation techniques differs.
Chapter 11 points out the complexity of reoperation after a previous allograft 
implantation. It is technically demanding to make a proper proximal anastomosis after 
previous allograft implantation due to the fact that the allograft not only calcifi es in 
the part of the root but also at the annular level. Furthermore, the coronary buttons 
need to be dissected from the calcifi ed allograft posing a challenge to maintain a large 
enough button that can be properly reinserted without distortion or kinking. 
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Reoperation after insertion of an allograft with the subcoronary implantation 
technique the coronary still remains complex, but technically less demanding, since 
the coronary arteries are not mobilized during initial implantation and therefore do 
not require remobilization and reinsertion at reoperation. Possible complications 
associated with this reinsertion of the coronary arteries are avoided and because the 
aortic root is untouched, only a mechanical prosthesis has to be reimplanted.
In endocarditis, the allograft is the preferred valve substitute of choice, due to the 
assumption of its excellent resistance to infection, the natural biocompatibility to 
absorb antibiotics and preservation of the natural anatomy of the aortic valve and 
the adjacent structures with excision of all infected tissue.13 Chapter 4 questions 
this indication and demonstrates that radical excision of infection tissue combined 
with implantation of a mechanical prosthesis is also a suitable option. The use of 
allografts may be refi ned to only those patients with active endocarditis with root 
abscesses, where it can be used to reconstruct the distorted anatomy. 
Insertion of an allograft at reoperation was a signifi cant predictor of late mortality. 
Although this might be related to the allograft, it is more obvious this is due to 
the patient characteristics of the allograft recipients, such as older patient age, 
endocarditis as cause for reoperation and worse preoperative condition. On the other 
hand, Yacoub and colleagues observed the opposite. Survival after a reoperation 
after a previous allograft with a new allograft is comparable to the fi rst operation 
and the mode of failure is not accelerated. 14
It is obvious, that the enthusiasm in the early 1990s selecting the allograft for a 
wide range of indications has been tempered, and narrowed down to patients with 
active endocarditis, in particular with extensive destruction of cardiac tissue. The 
attention has shifted to other valve alternatives of the allografts in more recent 
years. Stentless aortic biological prostheses provide a good alternative for the 
allograft regarding survival and other valve-related events, and in endocarditis these 
valve substitutes provide comparable results. Furthermore, these valve substitutes 
have the advantages to have an unlimited availability. 15, 16 Moreover, recently it 
was shown that stentless aortic biological prostheses show a trend towards lower 
calcifi cation rates compared with allografts. 17
Autografts
The autograft procedure is the only operation that provides, in the longer term, 
a living valve substitute capable of reproducing the function of the normal aortic 
valve.18, 19 The pulmonary autograft diameter increases parallel to somatic growth 
in children.20 However, a worrisome increase in autograft reoperations is observed 
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in the second decade after the Ross operation.21-24 The main cause for reoperation 
after the Ross operation is dilatation of the neo-aortic root. Due to this dilatation 
coaptation of the cusps is lost and aortic regurgitation occurs. A recent report on 
explanted autografts showed that compared to normal pulmonary and aortic valves, 
the explanted autograft valve also has an intact laminar architecture and cellularity, 
but apposition of fi brous tissue on the ventricular surface have let to an increase 
in overall valve thickness, as observed in long existing valvular insuffi ciency. The 
autograft wall typically shows severe aneurysm formation with intimal hyperplasia, 
and medial degeneration characterized by elastin loss and fragmentation, 
hypertrophy of smooth muscle cells and adventitial fi brosis containing functional 
vasa vasorum.25
Given the increasing autograft failure rates in the second decade after the procedure 
careful follow-up of autograft patients is required. Although the frequency of 
follow-up has to be further determined, an annual visit to the cardiologist with a 
structural echocardiography is highly recommended, since the failure rate of the 
autograft is observed to be accelerating in the second decade of operation and there 
is a potential chance of dissection of the autograft, as described in Chapter 10.
Reoperations for a failing autograft have a high risk and demanding character due 
to the possible attachment of the aneurysmatic ascending aorta to the sternum, 
and the fact that the pulmonary allograft may be compressed by and attached to 
the dilated autograft root. Also, the coronary buttons may pose problems when 
they are dissected from the autograft and reimplanted in a new root. Despite the 
complexity of these reoperations, satisfactory results are achieved, and these results 
are even better when compared to other valve substitutes. The outcome after 
reoperation on the pulmonary autograft can contribute to the debate of selecting 
the optimal valve substitute in young adults. In Chapter 11 it was described that 
none of these reoperative patients have died yet, an observation in concordance 
with other reports.22, 26 One can argue if this is an advantage or a disadvantage to 
the contribution of the debate, since the experience with reoperations on autografts 
is still very limited. The fact that yet no reoperative mortality for these patients 
was observed despite the complexity of the operation suggests that this reoperation 
can safely be performed, but is no guarantee for future patients returning for a 
reoperation after the pulmonary autograft procedure.
The variability in the durability results of the autograft procedure may also in part 
be explained by the surgical technique employed, and by individual variation of 
the application of the root replacement technique. The subcoronary implantation 
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technique, as originally employed by Donald Ross18 was abandoned by most centers 
for multiple reasons including its technical complexity and the attractive option of 
the root replacement technique that preserves the autograft valve geometry. 
Most patients nowadays receive an autograft using the freestanding root replacement 
technique with reimplantation of the coronary arteries. This surgical technique can 
be applied in a variety of ways. The autograft can be inserted on the annulus or 
below the annulus and scalloping of the muscle rim can be done to a minimum 
below the valve cusps. Also, either continuous or interrupted sutures can be used for 
the proximal suture line. It is also possible to use a strip of pericardium to support 
the proximal suture line. Finally, the length of the autograft root can be varied. 
Some surgeons keep the neoaortic root as short as possible above the sinotubular 
junction while others preserve its complete length distally.
In a number of centers where the pulmonary autograft procedure is still performed, 
results are adequate and the procedure is performed by only one surgeon.27, 28 Surgical 
expertise thus seems an important success factor. Although there seems to be a 
learning curve in the beginning of employment of this operation, a larger experience 
seems to enhance durability. Systematic application of the root replacement technique 
into the fi ne details may also represent an important determinant of durability. 
It may therefore be advisable for this operation to be concentrated in a restricted 
number of centers in which large experience can be obtained thus improving the 
results maintaining this particular operation with benefi ts for particular selected 
patient populations.
In Chapter 9 it described that durability of the autograft procedure not only 
depends on the pulmonary autograft but also on the valve substitute in the right 
ventricular outfl ow tract (usually an allograft). With time, both the autograft and 
the valve substitute in the right ventricular outfl ow tract show a limited durability 
and reoperation of the autograft and reintervention of the right ventricular 
outfl ow tract for structural valve deterioration are the most common valve-related 
complications both for adults and paediatric patients. Still, the ideal conduit for 
the right ventricular outfl ow tract in adults as well as in children has to be found 
and there might be an interesting role for tissue engineering for this valve substitute 
in the near future. Considering the limitations of the existing valve substitutes this 
new concept of creating a viable valve out of human cells shows encouraging results 
in the experimental setting.29 Another recent development, percutaneous valve 
implantation, may be applied to the degenerated pulmonary allograft. Since stenosis 
is the main indication for undergoing percutaneous valve replacement and since the 
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allograft in the right ventricular outfl ow tract is subject tot calcifi cation, this could 
be an alternative to surgery.30 
Magnitude of impact on patient prognosis of mechanical prostheses and 
human tissue valves
The different valve substitutes have their own characteristics and the magnitude of 
impact on patient prognosis varies per valve substitute. 
Aortic valve replacement can be done safely with a mechanical prosthesis and in 
selected cases of aortic valve endocarditis this valve substitute is also a good option. 
The prognosis after aortic valve replacement is mainly determined by the occurrence 
rate of the complications that are associated with anticoagulation use. Furthermore, 
the use of anticoagulation brings an extra burden of monitoring INR levels, affecting 
day to day activities of patients. Bleeding events, increased thrombogenicity and the 
increased risk of maternal and foetal adverse outcome in pregnancy, are reasons for 
using other alternative valve substitutes in these particular patients populations, 
thus improving patient prognosis and outcome.
Yet, the mechanical prostheses are still frequently used, suggesting that the durability 
of the valve outweighs the occurrence of side-effects of anticoagulation use, thus 
having a limited effect on patient prognosis. 
Human tissue valves do not require anticoagulation, an important advantage for 
young adult patients with an active lifestyle, and have low valve-related event rates. 
However, these valves have a limited durability, which has an important effect of 
prognosis. The complexity of the operation and the requirement of specifi c surgical 
expertise infl uence this durability. Furthermore, surgical variation in application 
of implantation techniques also has an infl uence on durability. For the autograft, 
durability depends not only on the pulmonary autograft but also on the valve 
substitute implanted in the right ventricular outfl ow tract. 
Due to the limited durability, a reoperation is inevitable later in life. These 
reoperations are not without risks and young adult patients who received a human 
tissue valve, face these risks a second time, thus infl uencing patient prognosis. 
Despite that characteristics of the valve substitutes have an impact on patient 
prognosis; other factors also infl uence prognosis after aortic valve replacement. 
These factors are patient-related factors.
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PATIENT-RELATED FACTORS
In the studies in this thesis, the characteristics of patients who received a mechanical 
prosthesis, an allograft or an autograft were clearly different. It can be concluded 
from Chapter 2 that patient factors play an important role in the type of valve 
substitute in that is implanted young adult patients. In this chapter various 
preoperative patient-related factors were analyzed and determined if these factors 
were associated with implantation of a particular valve substitute. It appeared that 
patients who received a mechanical aortic valve prosthesis were older, had more 
often an impaired left ventricular function and needed more often concomitant 
mitral valve surgery. Patients who received an allograft at operation, presented 
more often with acute symptoms, were in higher preoperative NYHA classes, had 
more often aortic root pathology, active endocarditis or Marfan’s disease. Finally, 
patients that received a pulmonary autograft, were the youngest of the three valve 
substitute groups, had mainly isolated aortic valve disease, and had more often 
a balloonvalvulotomy in preoperative history, indicating congenital heart disease. 
Apparently, there is refi ned strategy in valve substitute selection for young adult 
patients beyond the general guidelines. 31, 32 Over the years valve substitute selection 
according the guidelines available and also determined by experience and preference 
of the clinic the patient is referred to. 
Mechanical valves are in general implanted in patients younger than 65 years, with 
a long life ahead and no contraindications for anticoagulation treatment. 
The allograft was expected to be the valve substitute of choice in young adult 
patients, but due to disappointing results and the limited durability many centers 
have stopped using this valve substitute for aortic valve replacement or are only 
using it for specifi c indications. Nowadays the major indication for implanting an 
allograft is aortic valve endocarditis with complex aortic root pathology, although 
there are centers that believe in the function and capability of this valve and its 
major advantage of avoidance of anticoagulation treatment.
The pulmonary autograft procedure is the only operation in which the patient’s own 
living valve substitute is used and was widely applied due to the encouraging results 
on patient survival and few valve-related events reported. Pulmonary autograft 
recipients were mainly young adult patients, with isolated aortic valve disease and 
little co-morbidity. However, in recent years, most centers abandoned the use of 
the pulmonary autograft procedure in (young) adults due to its complexity and the 
high frequency of reoperation rates that have become apparent, with the potential 
accompanying operative mortality and morbidity risks. The operation still remains 
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a good treatment option in children with congenital aortic valve disease, in whom 
balloonvalvulotomy and aortic valve repair are not suffi cient enough to maintain a 
(near) normal life.
In the sections below, patient outcome after aortic valve replacement for different 
specifi c patient groups is discussed.
Endocarditis
According to the ACC/AHA guidelines for management of patients with heart 
valve disease, surgical treatment of active native aortic valve endocarditis should 
preferably consist of valve repair because of the risk of infection of prosthetic 
materials.31 When repair is not an option, valve replacement is necessary. Thus far, 
there are no specifi c recommendations for the use of a particular valve prosthesis for 
the surgical treatment of active native aortic valve endocarditis besides the general 
criteria for aortic valve selection. 
In patients with active aortic valve endocarditis the allograft is an adequate option. 
Particularly when there is extensive destruction of the surrounding tissue, the 
allograft can be modelled in such a way that defects are covered and natural anatomy 
of the heart is preserved.13, 33 The mechanical prosthesis is, however, also frequently 
used and the risk of reinfection being reported to be very low.34 Not surprisingly, in 
one of the studies in this thesis a trend was observed towards allograft implantation 
in patients with active native endocarditis with root abscesses. On the other hand 
a mechanical prosthesis was more often used in those patients, in whom the active 
endocarditis was not only limited to the aortic valve leafl ets but also affected the 
mitral valve, necessitating implantation of a mitral valve prosthesis and warranting 
lifelong anticoagulation medication for that reason. 
Although patient age is an important factor for valve selection according the ACC/
AHA guidelines31, it did not play a role for patients with active native aortic valve 
endocarditis as is described in Chapter 4. Underlying co-morbidities related to the 
severity of the infection, such as renal failure, may therefore play an important role 
and these should be taken into consideration when selecting a valve substitute.
Factors studied that were potentially associated with early mortality were 
preoperative increased creatinin, NYHA class IV, emergent surgery, longer perfusion 
time and endocarditis caused by S. aureus. These variables were also reported by 
other authors to infl uence early mortality in active native valve endocarditis.34-37 
Early mortality was comparable between the allograft and mechanical prosthesis. 
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Still, early mortality remains high, and indicates that in this serious condition early 
surgery is necessary.
In active native valve endocarditis, allografts did not met the expectations regarding 
improved early and long-term outcome and the resistance to recurrent endocarditis. 
Besides, durability was found to be limited. The mechanical prosthesis showed 
comparable results regarding survival, recurrence of endocarditis was lower, 
although not signifi cant and reoperation rate was lower. Other valve-related events 
such as bleeding or thrombo-embolic events were rare. One would expect higher 
rates of bleeding for mechanical prosthesis that are associated with the required 
anticoagulation treatment.
In conclusion, in active native aortic valve endocarditis no specifi c recommendations 
for valve substitute selection can be made. The general recommendation for use of 
an allograft in endocarditis may be refi ned to restricting the use an allograft to 
those patients in whom the endocarditis causes extensive tissue destruction and 
implantation of a mechanical prosthesis is not suffi cient enough to reconstruct all 
infected tissue. 
Congenital aortic valve disease
Prosthetic valve selection for young adult patients with a congenital aortic valve 
stenosis who require aortic valve replacement remains a delicate and complicated 
topic of discussion. The guidelines state that “although the Ross operation, allograft, 
heterograft, and valve repair each appear to offer patients with congenital aortic 
valve disease an attractive alternative to a mechanical valve for those with a relative 
contraindication to warfarin for anticoagulation (e.g., athletes or women desiring 
pregnancy), in the absence of long-term results, it is not believed that the indications 
for surgery with the Ross operation, heterograft, or allograft differ from those for 
mechanical valve replacement at this time”.31 
It was analyzed in Chapter 5 that late survival for patients with an autograft is 
comparable to that of the general age-matched Dutch population and for allograft 
patients slightly worse. This can partly explained by the fact that autograft patients 
are signifi cantly younger and in better preoperative condition than the allograft 
patients. Besides, allograft patients more often underwent aortic valve replacement 
for endocarditis on the aortic valve or valve prosthesis, another factor that may 
have an effect on long-term prognosis since active aortic valve endocarditis is a life 
threatening disease associated with considerable morbidity and mortality. 
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Although the survival seems slightly better with the autograft compared to the 
allograft, this is not signifi cant. However, it is still better when compared to survival 
of other young adult congenital patients with other valve substitutes.1 
No conclusive recommendation can be given regarding valve selection in this 
particular patient population. In this population with few co-morbidities and a 
relatively long life-expectancy both valve substitutes are an adequate treatment 
option. However, reoperations for structural failure remain of major concern. In 
this thesis an age-dependency of allograft durability was observed; younger patients 
with an allograft had an increased structural failure rate. Since most of the patients 
with congenital aortic valve disease present in childhood or at a young adult age, in 
this particular subset the autograft may be preferable. 
Pregnancy 
Young girls and women of childbearing age who have undergone AVR with an 
allograft or an autograft are a patient population that requires special attention, 
due to their potential desire to have children. During pregnancy signifi cant 
haemodynamic changes occur with an important demand on cardiac function with 
an increase in cardiac output, heart rate and blood volume. Furthermore, systemic 
vascular resistance decreases, resulting in a lower blood pressure, despite the increase 
in cardiac output. These cardiac changes may have an infl uence on progression of 
deterioration of the pulmonary autograft and allograft although hormonal changes 
may also play a role. 
Women with mechanical prostheses are at increased risk of developing thrombo-
embolic events during pregnancy, regardless of the type of anticoagulation used. 
During pregnancy, these patients also have a higher risk on foetal morbidity and 
mortality. The implantation of human tissue valves allows a considerable proportion 
of young female patients who contemplate pregnancy to have children without the 
risks associated with anticoagulant use. Pregnancy was not a factor associated 
with increased reoperation rates for valve failure, but given the small sample size 
and the fact that only clinical outcome was reported, further echocardiographic 
longitudinal studies may provide more insights into the potential effect of pregnancy 
on valve durability. Both the allograft and autograft both provide an adequate valve 
substitute at the cost of a reoperation later in life in young female patients who 
want to become pregnant within the next decade. The allograft and autograft are 
therefore preferred above mechanical prostheses.
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Reoperative patients
Recent developments in aortic valve and root surgery have established the aortic 
root replacement as a safe and commonly performed procedure. However, due 
to this increase, the limited durability of tissue valves and the relatively long life 
expectancy of young adult patients, more reoperations can be expected in the future. 
Reoperation after aortic valve or aortic root replacement is an operation with an 
increased risk, and high mortality and morbidity rates are expected. 38, 39 However, 
we observed that it can be performed with satisfying early and long-term results and 
patient related-factors played an important role. Although hospital mortality for 
reoperative aortic root replacement after a previously inserted mechanical prosthesis 
seemed high compared with most of the other valve substitutes, most of these 
patients were severely symptomatic, had an impaired left ventricular function and 
often underwent emergent or urgent surgery. Furthermore, in the majority of these 
patients endocarditis was the indication for reoperation and surgery for prosthetic 
valve endocarditis is known to be associated with a higher urgency of surgery and a 
high hospital mortality rate.40, 41
It appeared that the use of an allograft at reoperation is associated with worse long-
term outcome, but most of the allografts implanted were in patients with a mechanical 
prosthesis in situ. These allograft recipients were older patients, had prosthetic valve 
endocarditis, and were in worse preoperative condition which implies that not only 
the inserted allograft but also patient-related factors contributed to the increased 
late mortality we observed in allograft recipients. 
That patient-related factors play a role is also emphasized in outcome after 
reoperation on the pulmonary autograft procedure. This reoperation is associated 
with low hospital mortality and morbidity rates with good long-term survival. 
These patients were relatively young, with good preoperative condition, a good left 
ventricular function and few symptoms related to aortic regurgitation. 
In conclusion, reoperation after previous implanted aortic valve or aortic root 
can safely be performed and it is obvious that patient-related factors play an 
important role in outcome. Especially in the young adult patient, who has a long 
life-expectancy, with few co-morbidities, desire to avoid anticoagulation use, and a 
possible child wish for females, the pulmonary autograft may provide an adequate 
treatment option despite need for a reoperation later in life and the and complexity 
of the operation. 
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OTHER RELEVANT FACTORS
Other factors that are not related to valve substitutes or patients can infl uence valve 
selection. 
Patient preference also has to be taken into account when selecting a valve substitute. 
Patients may not want to use anticoagulation due to the fact that they live an active 
life, or they prefer a different valve substitute than is recommended. Furthermore, 
valve selection particularly in young adult patients is infl uenced by the treating 
physician as well, bringing in a personal set of experience and expertise. 
Moreover, health care resources can also play a role in valve substitute selection. 
Not all countries have a proper support of professional support regarding INR 
monitoring and this has an effect on which valve substitute is implanted. In these 
countries, biological valve substitutes are the preferred valve substitute due to the 
absent need of anticoagulation treatment.42
CLINICAL RELEVANCE
To what extent can the results of this thesis be useful in clinical practice, i.e. how can 
they help cardiac surgeons or cardiologists who council young adult patients requiring 
aortic valve replacement in tailoring treatment selection? Using the knowledge 
obtained through the studies in this thesis, clinicians will gain improved awareness 
of the fact that patient profi le is a far more powerful factor that determines outcome 
after aortic valve replacement than the prosthetic valve that will be implanted. 
Therefore, better timing of surgery in an early stage of aortic valve disease, may 
for example have a greater impact on patient survival compared with selecting a 
particular valve substitute. On the other hand, improved knowledge of the burden 
of prosthetic valve disease associated with the different valve substitutes –as outlined 
throughout this thesis- may assist the clinician in optimizing valve selection is such a 
way that an optimal quality of life for the patient can be achieved. 
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FINAL CONCLUSIONS
In summary, from the studies in this thesis a number of important insights emerged:
Patient prognosis is mainly determined by patient characteristics and only to a 1. 
lesser extent by the valve type implanted
Several patient factors that are associated with prosthetic valve selection, also 2. 
play a major role in patient survival
Human tissue valves have a comparable durability in young adult patients 3. 
although the mode of failure differs considerably. Given the age-dependency of 
allograft structural valve deterioration in contrast to the autograft, in children 
and young adults the autograft procedure may be a more preferable solution
In endocarditis patients with a long life expectancy and with no extensive 4. 
destruction of cardiac structures aortic valve replacement with a mechanical 
valve may be a preferable solution
Young female patients who want to have children, benefi t from human tissue 5. 
valves as a good valve substitute, at the cost of a reoperation later in life
Reoperative patients have a low mortality rate and especially reoperation after 6. 
a previous autograft procedure shows good patient outcome
RECOMMENDATIONS
In the decision making process of selecting the most suitable valve substitute for 
primary aortic valve placement in adolescents and young adults, patient-related 
factors should play a central role. Clinical decision support tools based on the 
fi ndings in this thesis should be developed, given the complexity of the decision 
making process and the multiple inter-related factors involved. This will require a 
durable collaborative effort of multiple centers in order to gather enough data to 
build and maintain a valid tool that will remain useful for the decennia to come.
Furthermore, it can be considered to either pursue a randomized controlled trial or 
a propensity-matched study of large high quality cohorts of young adult patients 
with either an autograft or mechanical prosthesis, to determine whether the 
survival advantage observed in autograft patients can be assigned to the superior 
haemodynamics of this viable human tissue valve or whether this is due to patient 
selection. Another interesting part to investigate is the quality of life of the patients 
after implantation of a pulmonary autograft or mechanical prosthesis and whether 
would be large differences on various aspects of life, e.g. daily activities, social life or 
work. This may contribute to the decision making process of selecting the optimal 
valve substitute in young adults. 
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Also, further study of the decision making process of surgeons and cardiologists 
with regard to prosthetic valve selection in young adult patients may result in 
identifi cation of other factors that may be important determinants of outcome and 
may allow weighing of the value of the different factors that were already identifi ed 
in this thesis.
Finally, since patient factors play such a central role in survival after aortic valve 
replacement irrespective of the valve substitute used, further study of the timing 
of aortic valve replacement and in particular study of the effect of surgery earlier 
in the natural history of aortic valve disease is warranted. Although aortic valve 
replacement will give a patient prosthetic valve disease for the remainder of life, 
this may very well outweigh the potential damage to the myocardium and resulting 
increased risk of cardiac death in patients who are operated at a later stage of their 
aortic valve disease.
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Chapter 1 comprises the introduction of this thesis. It describes the haemodynamic 
diagnosis of aortic valve disease, the different valve substitutes available and the 
valve substitutes commonly used in young adult patients with their advantages and 
disadvantages. A balanced and objective selection between the valve substitutes 
available and the corresponding advantages and disadvantages has to be made 
in selecting the proper valve substitute. Prognosis after aortic valve replacement 
depends on multiple factors that are associated with the patient and the type of 
valve substitute used. The aim of this thesis was to gain insight in these factors 
predicting outcome after aortic valve replacement with different valve substitutes 
and evaluate if there is a preferred valve substitute in this particular age group. 
This was accomplished by studying different cohorts of young adult patients that 
underwent aortic valve replacement.
Chapter 2 compares the two types of valve substitutes available since optimal 
prosthesis choice in young adults requiring aortic valve replacement remains 
controversial. An evaluation has been made whether patient profi le or the type of 
valve substitute predicts outcome after aortic valve replacement. It appeared that 
patient factors play an important role in selecting a valve substitute and that these 
patient factors determine outcome after aortic valve replacement. Furthermore, this 
chapter briefl y introduces the discussion on which valve substitute can be considered 
in young adult patients weighing the advantages and disadvantages. 
Chapter 3 describes the clinical experience of aortic valve replacement with 
allografts at Erasmus Medical Center in Rotterdam and it questions whether the 
allograft is the preferred valve substitute in young adult patients. All 336 patients 
were prospectively followed over time. With the use of the microsimulation 
model freedom from reoperation for structural failure for allograft was compared 
to biological prostheses. It showed that structural failure rate of the allograft is 
similar to that of a biological prosthesis and that this failure rate is age-dependent. 
Furthermore, in our institution the allograft is preferred in patients with active aortic 
root endocarditis and in patients with a contraindication for anticoagulation use.
Chapter 4 gives insights in the infl uence of the choice of valve substitute on outcome 
after active native aortic valve endocarditis. It describes the combined experience of 
two centers of 138 patients with this disease that underwent aortic valve replacement 
with 106 allografts and 32 mechanical prostheses. Both mechanical prostheses and 
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allografts show comparable outcome and reoperation remains the major problem 
after aortic valve replacement with an allograft. Mechanical prostheses can be a 
proper valve substitute in active native endocarditis, in combination with extensive 
excision of infected tissue, in a specifi c patient population without presence of aortic 
root abscesses.
Chapter 5 compares the outcome after aortic valve replacement with autografts and 
allografts in young adult patient with congenital aortic valve disease. The reason to 
compare these tissue valve substitutes is to asses whether there is a preference for 
one of these valve substitutes in these particular patients. The main conclusion of 
this study was that outcome after surgery with autografts or allografts is satisfactory 
and comparable. Furthermore, for both valve substitutes reoperation remains a 
major concern. 
Chapter 6 is a study of the specifi c patient population of 98 young adult female 
patients in the child bearing age that underwent aortic valve replacement with an 
autograft or an allograft. It was hypothesized that durability of the autograft or 
the allograft is infl uenced by the altered haemodynamic state that exists during 
pregnancy. All female patients were prospectively followed over time and to gather 
information on pregnancy after operation all patients were requested to fi ll in a 
structured questionnaire. This resulted in 23 patients reporting 37 pregnancies. 
During follow-up 18 patients required a reoperation, with no effect of pregnancy 
on the durability of the valve substitute. Furthermore, patient survival is good and 
for the autograft even comparable to the age-matched population, thus tissue valves 
are a good option in young adult female patients who want to become pregnant and 
require aortic valve replacement.
Chapter 7 evaluates a two center experience of 264 patients that underwent the 
Ross procedure. This study discusses different aspects of prognosis and outcome 
after aortic valve replacement with the Ross procedure. Due to the low incidence 
of valve-related complications and a good survival after this operation that is 
comparable to age-matched individuals, patients can live their life without physical 
impairment although there is an increasing reoperation risk.
Chapter 8 consists of a systematic review of reported outcome after the Ross 
procedure, and discusses patient-related factors, surgical-technical considerations 
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and histological aspects of the Ross procedure. This was done in order to improve 
insight into potential determinants of success for this special operation since varying 
results are reported in the literature. After reviewing the considerable experience 
with the Ross procedure worldwide, it can be concluded that it provides children 
and young adults in the fi rst decade after the operation with results that are superior 
to any other valve substitute. On the downside, it also has several limitations that 
become apparent in the second decade after the procedure. Whether these limitations 
may at least in part be addressed by the surgical details and postoperative measures 
discussed in this paper remains to be determined.
Chapter 9 gives an overview of the pulmonary autograft procedure in our own 
institution. It raises the question whether the Ross procedure is still a good treatment 
option of aortic valve disease since in recent years more and more reoperations due 
to autograft failure are observed. Moreover, insights are given in possible factors 
playing a role in autograft failure. In our cohort the Ross procedure has the alleged 
excellent patient survival and particular patient populations benefi t from this 
operation. Careful follow-up of these patients after operation is warranted to gain 
more insight in the mode of autograft failure.
Chapter 10 describes a case report of an asymmetrical dilated autograft root. 
Described is the observation that the aortic wall may become increasingly weak 
after gradually increase of autograft dilatation. This can lead to a limited dissection 
that is prone to a free wall rupture causing a potential lethal complication.
Chapter 11 describes the outcome of aortic root replacement after previous operation 
on the aortic valve, ascending aorta or both and that this can be safely performed. 
Four groups of patients were compared; patients that required replacement of the 
native valve, prosthetic valve, of an allograft or an autograft. Factors were determined 
of the different valve substitute groups, of hospital mortality and of time-related 
events such as late mortality. Although patient-related factors are infl uencing the 
decision which valve is inserted at primary operation, reoperation after pulmonary 
autograft procedure shows the best early and long-term outcome. This result may 
contribute in the decision making in selecting a proper valve substitute in young 
adult patients.
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Chapter 12 includes the general discussion of this thesis in which the aims of the 
thesis are described and insights that emerged from the studies in this thesis are 
discussed. It is also discussed in what way the results can be used in practice, in 
helping clinicians to optimize prosthetic valve selection in young adult patients. Also, 
perspectives and recommendations with regard to future research are presented.
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Hoofdstuk 1 is de introductie van het proefschrift. Het beschrijft de haemodynamische 
diagnose van aortaklep ziekte, de verschillende klepprothesen die beschikbaar 
zijn met hun voordelen en nadelen en welke van deze klepprothesen vaak in 
jongvolwassen patienten worden gebruikt. 
Een gebalanceerde en objectieve afweging tussen de beschikbare klepprothesen met 
bijbehorende voordelen en nadelen zou moeten worden gemaakt wanneer getracht 
wordt de meest geschikte klepprothese te kiezen. De prognose na aortaklepvervanging 
hangt af van verscheiden factoren die van de patient of van de te implanteren 
klepprothese afhankelijk zijn. Het doel van het proefschrift was om inzicht te 
verkrijgen in deze factoren die een voorspellende waarde hebben op uitkomst na 
aortaklepvervanging met de beschikbare klepprothesen in jongvolwassen patienten 
en evalueren of er een voorkeur te bepalen is voor een bepaalde prothese voor 
patienten in dezeleeftijdscategorie. Om dit inzicht te verkrijgen zijn verschillende 
cohorten van jongvolwassen patienten die een aortaklepvervanging ondergingen 
bestudeerd. 
Hoofdstuk 2 vergelijkt de verscheidene soorten klepprothesen die beschikbaar zijn. 
De optimale klepkeuze in jongvolwassen patienten blijft controversieel. Daarnaast is 
bekeken of patient-gerelateerde factoren of het type klepprothese dat geimplanteerd 
wordt bij aortaklepvervanging de uitkomst na de aortaklepoperatie voorspelt. Het 
blijkt uit deze studie dat patient-gerelateerde factoren een belangrijke rol spelen 
in het kiezen van de klepprothese en dat deze factoren ook van invloed zijn op de 
uitkomst na aortaklepvervanging. Daarnaast wordt kort ingegaan op de discussie 
welke klepprothese als beste keuze zou kunnen worden beschouwd in jongvolwassen 
patienten met afweging van de verschillende voordelen en nadelen. 
Hoofdstuk 3 beschrijft de klinische ervaring van aortaklepvervanging met een 
allograft in het Erasmus Medisch Centrum Rotterdam. Daarbij wordt de vraag 
gesteld of de allograft de klep van voorkeur is in jongvolwassen patienten. Alle 
336 patienten in deze studie zijn prospectief gevolgd over tijd. Met gebruikmaking 
van het microsimulatiemodel is vrijheid van reoperatie vanwege structureel falen 
vergeleken tussen de allograft en de biologische klepprothese. Uit de resultaten komt 
naar voren dat de mate van structureel falen van de allograft gelijk is aan die van 
de biologische klep en dat deze mate van falen leeftijdsafhankelijk blijkt. Bovendien 
blijkt dat de allograft in ons centrum voornamelijk gebruikt wordt in patienten die 
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een actieve aortaklep endocarditis hebben en in patienten bij wie het gebruik van 
antistolling gecontraindiceerd is.
Hoofdstuk 4 geeft inzicht in de invloed van klepkeuze op de uitkomst van 
aortaklepvervanging bij patienten met een actieve natieve aortaklependocarditis. 
Het beschrijft de gecombineerde ervaring van twee centra met 138 patienten 
met deze aortaklepziekte, die aortaklepvervanging ondergingen waarbij 106 
allografts en 32 mechanische klepprothesen werden geimplanteerd. Het blijkt uit 
de resultaten dat zowel de allograft als de mechanische klep dezelfde uitkomst na 
operatie hebben. Reoperatie blijft echter het grootste probleem na implantatie van 
een allograft. Mechanische klepprothesen kunnen een goede optie zijn in actieve 
natieve aortaklep endocarditis, echter wel in combinatie met uitgebreide excisie van 
geinfecteerd weefsel en in een specifi eke patientenpopulatie waarbij geen abscessen 
van de aortawortel aanwezig zijn.
Hoofdstuk 5 vergelijkt de uitkomst na aortaklepvervanging met autografts en 
allografts in jongvolwassen patienten met een congenitale aortaklepafwijking. De 
reden om deze kleptypes te vergelijken was om te beoordelen of er een voorkeur 
bestaat voor een van beide kleptypes in deze patientenpopulatie. De belangrijkste 
conclusie van de studie is dat uitkomst na operatie met een allograft of autograft 
uitstekend is en er werden geen duidelijke verschillen waargenomen tussen beide 
kleppen. Daarbij blijkt dat voor beide kleptypen het toenemende aantal reoperaties 
een belangrijke zorg blijft.
Hoofdstuk 6 is een studie van 98 jongvolwassen vrouwelijke patienten in de 
vruchtbare leeftijd die aortaklepvervanging hebben ondergaan met een autograft of 
een allograft en na deze operatie mogelijk zwanger zijn geworden. Het wordt namelijk 
aangenomen dat de duurzaamheid van deze kleppen beinvloedt kan worden door 
de veranderingen in de hemodynamiek die optreden tijdens de zwangerschap. Alle 
vrouwelijke patienten in deze studie zijn prospectief gevolgd over tijd en vragenlijsten 
werden afgenomen om informatie over eventuele zwangerschappen te verkrijgen. 
Uiteindelijk zijn er 37 zwangerschappen in 23 patienten geobjectiveerd. Gedurende 
follow-up ondergingen 18 patienten een reoperatie. Zwangerschap blijkt geen effect 
te hebben op de duurzaamheid van de klep. Daarnaast blijken de patienten een 
goede overleving over tijd te hebbben en voor de autograft is deze overleving zelfs 
vergelijkbaar met leeftijdsgenoten die geen aortaklepvervanging hebben ondergaan. 
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Het kan dus geconcludeerd worden dat weefselkleppen een goede optie zijn wanneer 
er een klepkeuze moet worden gemaakt in jongvolwassen vrouwelijke patienten 
die een aortaklepvervanging moeten ondergaan en na deze operatie zwanger willen 
worden.
Hoofdstuk 7 bespreekt de ervaring van twee centra met 264 patienten die de Ross 
procedure ondergingen. Deze studie richt zich op verschillende aspecten van de 
prognose en uitkomst na aortaklepvervanging met de Ross procedure. Dankzij de 
lage incidentie van klep-gerelateerde complicaties en de goede overleving na deze 
ingreep die vergelijkbaar is met leeftijdsgenoten, kunnen patienten na deze operatie 
een normaal leven leiden zonder fysieke beperkingen, hoewel een reoperatie op 
lange termijn onvermijdelijk lijkt.
Hoofdstuk 8 beschrijft een systematische review van studies over de Ross procedure 
en bespreekt patient-gerelateerde factoren, chirurgisch technische overwegingen en 
histologische aspecten van deze ingreep. Deze review is verricht om beter inzicht te 
krijgen in de varierende resultaten die bereikt worden na de Ross procedure. Na het 
reviewen van de wereldwijd uitgebreide ervaring met de Ross procedure, kunnen 
we concluderen dat het voor kinderen en jongvolwassenen een ingreep betreft met 
superieure resultaten vergeleken met andere kleptypen. Maar de keerzijde is dat 
er verscheidene beperkingen ontstaan in het tweede decennium na deze ingreep. 
Of deze beperkingen deels zijn toe te schrijven aan chirurgische technieken of het 
postoperatieve beleid, zoals besproken in dit artikel, zal verder moeten worden 
onderzocht.
Hoofdstuk 9 geeft een overzicht van de Ross procedure in ons eigen centrum. De 
vraag die wordt gesteld is of de Ross operatie nog steeds een goede behandelingsoptie 
is aangezien er in recente jaren steeds meer studies verschijnen die rapporteren 
over reoperaties vanwege het falen van de autograft. Daarnaast worden inzichten 
gegeven in mogelijke factoren die een rol spelen in het falen van de autograft. In 
onze patientenpopulatie blijkt dat de Ross procedure de verwachte superieure 
patientenoverleving heeft en dat bepaalde patientenpopulaties profi jt hebben van 
deze operatie. Echter, deze patienten moeten nauwkeurig gevolg worden over tijd 
om meer inzicht te krijgen in de manier waarop de klep faalt.
Loes bw.indd   229 31-10-2007   14:41:13
230
Hoofdstuk 10 bestaat uit een case report van een asymmetrisch verwijde autograft 
wortel. Er wordt beschreven dat de aortawand kan verzwakken wanneer de autograft 
geleidelijk toeneemt in diameter. Dit kan leiden tot een beperkte dissectie wat kan 
resulteren in een vrije wandruptuur met een fatale afl oop tot gevolg. 
Hoofdstuk 11 beschrijft de uitkomst van aortawortelvervanging na een 
eerdere aortaklepoperatie, aortachirurgie of een aortaklepoperatie met aorta 
ascendensvervanging. Er werder vier patientengroepen bekeken; patienten waarvan 
de natieve klep vervangen moest worden, waarvan een eerder geimplanteerde 
mechanische danwel een allograft of een autograft aan vervanging toe was. Er is 
gekeken naar welke factoren mogelijk van invloed kunnen zijn van voor de indeling 
in deze vier groepen en welke factoren van invloed kunnen zijn op ziekenhuissterfte 
en late sterfte. Uit deze studie blijkt dat een reoperatie van de aortawortel veilig kan 
worden uitgevoerd. Hoewel patienten-gerelateerde factoren een rol blijken te spelen 
in de keuze welke klep geimplanteerd wordt gedurende de primaire operatie, geeft 
reoperatie na een eerdere Ross procedure de beste resultaten op de vroege en late 
termijn. De resultaten van deze studie zouden kunnen bijdragen in het besliskundige 
proces om de beste klep te kiezen voor de jongvolwassen patient.
Hoofdstuk 12 bevat de discussie van dit proefschrift waarin het doel van het 
proefschrift is beschreven en inzichten die voortvloeien uit dit proefschrift worden 
behandeld. Daarnaast behandelt dit hoofdstuk ook hoe de resultaten van dit 
proefschrift toegepast zouden kunnen worden in de klinische setting, om klinici te 
helpen de klepkeuze in jongvolwassen patienten te optimaliseren. Tenslotte worden 
perspectieven en aanbevelingen gedaan ten aanzien van toekomstig onderzoek en 
wordt afgesloten met een algemene conclusie. 
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Via Londen, Vancouver en Barcelona, naar Lenox en New York om vervolgens weer 
thuis te komen in Rotterdam, het avontuur van promoveren zit erop. In de ruim 
twee jaren dat ik hieraan gewerkt heb, heeft het me niet alleen beter inzicht gegeven 
in de wetenschap, maar ook in mijzelf en in de structuur van een organistatie. 
Promoveren is niet alleen een avontuur, maar ook een voorrecht. Als je dit optimaal 
weet te gebruiken, kun je dus ook nog eens een heleboel van de wereld zien. 
Ik heb met enorm veel plezier gewerkt aan mijn proefschrift, en dit heb ik te danken 
aan heel veel mensen. Nu ben ik mij er van bewust dat ik niet iedereen met naam 
en toenaam kan noemen, dus voor iedereen die ik hier niet genoemd heb, ik ben 
jullie niet vergeten, maar jullie zijn simpelweg met teveel om jullie persoonlijk te 
bedanken. Toch zijn er een aantal mensen in het bijzonder, die een belangrijke 
bijdrage aan mijn promotieonderzoek hebben geleverd, en zonder wie het schrijven 
van mijn proefschrift een stuk onaangenamer en moeizamer zou zijn geweest. Deze 
mensen wil ik graag hieronder bedanken.
Allereerst mijn promotor, Professor Bogers. Zonder u was het niet aan mij om dit 
proefschrift te gaan verdedigen. Mijn dank dat ik alle ruimte heb gekregen om mijn 
promotieonderzoek te kunnen doen op de afdeling Thoraxchirurgie. Ik heb veel 
respect voor uw wetenschappelijke deskundigheid en snelheid waarmee u mijn 
artikelen beoordeelde naast uw drukke werkzaamheden in de kliniek. De discussies 
met u waren altijd zeer aangenaam en heb ik als zeer waardevol ervaren.
Mijn copromotor, Hanneke Takkenberg. Hanneke, mijn ontezeggelijke dank voor 
alles. Ik voel me bevoorrecht dat ik onder jou mocht promoveren. Samenwerken 
met jou is niet alleen zeer prettig, maar ook een bron van onuitputtelijke inspiratie 
en energie. Hoe vaak ik even vast zat met mijn gedachtengang en dat even ‘sparren’ 
met jou mij weer verderhielp. Wat heb ik een lol met je gehad op congressen; toen 
we in Barcelona met de ‘grote man’ zeebanket gingen eten en in New York de avond 
voor mijn praatje nog even een drankje gingen nuttigen. Ik kijk met heel veel plezier 
terug op deze promotietijd en heb dankzij jou het maximale eruit kunnen halen. Ik 
ben er dan ook heel erg trots op dat ik met hulp van jou dit mooie proefschrift tot 
stand heb kunnen brengen. 
Professor Helbing, Professor Steyerberg en Professor van Herwerden, de leden van 
mijn leescommissie. Mijn dank dat u allen bereid bent geweest zitting te nemen 
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mijn promotiecommissie en de wetenschappelijke waarde van het proefschrift heeft 
willen beoordelen.
Dear Professor Yacoub, I am grateful that you were willing to be an opponent at my 
thesis defense. Working with you was a great pleasure and your scientifi c knowledge 
is enormously inspiring and motivating. 
Marijke Rozema, Angeliek Venema, Liz van der Velden, Ria Hussaarts en Els 
Berenschot, de onderzoeksgroep. Dank voor alle leuke, mooie, emotionele, 
opbeurende en dierbare momenten. Ik zal de gezellige koffi edrinkuurtjes -al dan 
niet met iets lekkers erbij- gaan missen, maar zodra ik de kans krijg kom ik zeker 
een “bakkie doen”. Ik hoop van harte dat de traditie van de onderzoeksuitjes in ere 
wordt gehouden en wil er graag deel van uit blijven maken!
Martijn van Geldorp en Menno van Gameren, collegae promovendi. Het was me 
een genoegen met jullie samen te werken. Ik ben benieuwd naar jullie eindresultaat. 
Haal het maximale uit de tijd die jullie nog rest en zie jullie waarschijnlijk snel weer 
terug in de kliniek.
Jos Bekkers en Lex Maat, mijn kamergenoten. Ik heb me zeer gewaardeerd door 
jullie gevoeld en heb met veel plezier bij jullie op de kamer aan mijn proefschrift 
gewerkt. Met een glimlach denk ik terug aan al de discussies die we gevoerd hebben, 
de door jullie vertelde anecdotes, de bekertjes koffi e-met-melk-en-suiker of zwart 
die ik gehaald heb, en de vaderlijke bezorgdheid of ik echt wel zeker wist of ik de 
Thoraxchirurgie wel in wilde gaan. Heren, bedankt voor deze mooie tijd. 
Ard Struijs, collega en intensivist. De talloze gesprekken die we hebben gevoerd 
waren een welkome afl eiding tussen het turen naar mijn beeldscherm en de data-
analyses door. Als ik het even niet meer zag zitten wist je altijd een verhelderende 
kijk op de zaak te geven waardoor ik een stuk gemotiveerder weer verder kon. 
Bedankt voor al deze waardevolle momenten en ik hoop dat ik nog veel van je kan 
blijven leren.
Alle medewerkers van het Thoraxsecretariaat die bijgedragen hebben aan de 
plezierige werkomgeving. Dames, bedankt. Ik weet nu denk ik wel hoe ik een fax 
moet versturen!
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Sue Edwards, dear Sue, thank you for showing me around in Harefi eld and introducing 
me in the world of the human tissue valves, the medical records department and the 
real life of the British.
Karin Vedders, hoe mooi is de omslag van mijn boekje geworden. Zonder jouw 
hulp was het resultaat van mijn proefschrift lang niet zo bijzonder geweest als dat 
het nu is.
Rianne Spoor, je bent niet alleen mijn goede vriendinnetje, maar ook mijn paranimf. 
Bedankt dat je me met je relativeringsvermogen vaak hebt geholpen en vind het erg 
bijzonder dat je me wil bijstaan tijdens mijn verdediging.
Tenslotte wil ik nog bedanken;
Mijn grote broer Tim, ondanks dat je een paar duizend kilometer verderop woont, 
altijd kan ik een beroep op je doen. Bedankt dat je meegedacht hebt in het proces 
van stellingen bedenken. Ik heb vaak moeten lachen om de gevatte mailtjes die je me 
wist voor te schotelen. Bedankt dat je er bent.
Dagmar, je bent een topmeid, ik ben blij dat mijn broer jou als wederhelft heeft 
gevonden. Dank voor het introduceren in de wereld van de chattonies.
Mijn grote kleine broertje Joost, je bent een goud waard. Bedankt voor alles wat je 
voor me gedaan hebt en dat je altijd voor me klaar staat. Door de kennis die ik van 
jou geleerd heb, heb ik menig collega verder kunnen helpen. Ik ben blij met jou.
Lieve papa en mama, bedankt voor jullie onvoorwaardelijke steun in alles. Zonder 
jullie vertrouwen weet ik niet of ik wel tot zover gekomen zou zijn. Ik ben er trots op 
dat jullie mijn ouders zijn en pap, je taak als paranimf zal je zeker goed staan!
Op naar het volgende avontuur!
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